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2Abstract
The  mitogenic  and  anti-apoptotic  effects  of  insulin-like  growth  factor-1 
(IGF-I)  are  regulated  by  a  family  of  insulin-like  growth  factor  binding 
proteins  (IGFBPs),  particularly  IGFBP-3.  In  vitro  studies  have 
demonstrated the importance of the IGF-I axis in regulating the growth of 
breast cancer cells.  Little is known,  however, about the IGF-independent 
role  of  IGFBP-3  in  breast  cancer  and  the  mechanisms  regulating  its 
production.
We  investigated  the  expression  of  IGFBP-3  in  malignant  and  paired 
adjacent normal (n=53), and healthy normal (n=17) breast tissue samples 
using RT-PCR,  immunohistochemistry and ELISA. We compared  IGFBP- 
3  expression  with  other  members  of  the  IGF-I  axis,  other  known 
tumorigenic  genes  and  clinicopathological  parameters.  We  also 
developed  a  novel  tissue  explant  system  using  fresh  normal  and 
malignant  breast  tissue,  with  which  we  examined  the  in  vitro  effects  of 
IGFBP-3  alone  and  in  combination  with  known  apoptotic  agent, 
doxorubicin (n=6), on tissue viability and apoptosis.
Results  demonstrated  universal  high  level  of  expression  of  IGFBP-3 
mRNA  in  all  types  of breast tissue.  There was  no  difference  in  level  of 
expression between any of the three groups of breast tissue (approaching 
those  seen  in  the  liver  where  it  is  predominantly  produced).  96%  of 
samples also expressed  IGFBP-3 protein.  High  levels of IGFBP-3 mRNA 
were associated with the presence of high grade ductal carcinoma-in-situ 
(p<0.0001),  the  pre-invasive  stage  in  breast  cancer.  A  significant 
correlation  was  also  found  between  IGFBP-3  negative/weakly  positive 
tumours and lymph node negativity (p<0.05),
3thereby  supporting  an  association  between  IGFBP-3  and  the 
development  of  invasive  disease.  There  was,  however,  no  significant 
correlation  between  IGFBP-3  expression  and  other  clinicopathological 
parameters.
The  in  vitro tissue  explant  system  demonstrated  that  IGFBP-3  had  little 
effect  by  itself  on  apoptosis.  However,  when  used  in  combination  with 
doxorubicin,  a  marked  enhancement  of  apoptosis  was  seen  in  breast 
tumours.  In  contrast,  less  apoptosis  was  seen  in  normal  breast  tissue 
suggesting a protective effect. These divergent effects suggest a potential 
novel chemotherapeutic approach in the treatment of breast cancer.
These findings suggest that IGFBP-3 may play a role in tumorigenesis.  It 
may therefore be possible in future, that IGFBP-3 levels could be used  in 
cancer risk assessment and prevention or infact, as markers of response 
to cancer treatments.
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141. Introduction
1.1  The GH-IGF-I axis
The  growth  hormone-IGF-l  axis  has  been  increasingly  implicated  in  the 
development  of cancer.  It  has  been  known  for  some  time  that  patients 
with acromegaly who have increased levels of growth hormone (GH) and 
IGF-I,  are  at  increased  risk  of  colon  cancer  and  also  have  increased 
mortality due to  other malignant  and  vascular diseases  (1;2).  IGF-I  was 
discovered  more  than  40  years  ago  and  is  known  to  be  a  mediator  of 
growth  hormone  (GH)  activity.  GH  is  essential  for  linear  growth  and 
development and circulating levels decline progressively with age.  Serum 
IGF-I  levels  similarly  decline  with  age  and  largely  reflect  GH  secretion 
and therefore have been used clinically as a marker of GH status.
IGF-I  is  present  at  high  levels  throughout  the  body.  It  circulates  at 
concentrations  approximately  1000  times  higher  than  most  peptide 
hormones.  GH  is  considered  to  be  the  predominant  regulator  of 
circulating  IGF-I,  however, there are other factors that contribute to IGF-I 
concentrations  in  serum  and  tissue.  Age,  sex  and  nutritional  status  all 
affect  IGF-I  levels  (3).  Other  factors  include  insulin-like  growth  factor 
binding protein-3 (IGFBP-3) which binds approximately 85% of IGF-I and 
maintains  its  high  serum  concentration  by  slowing  it’s  clearance.  Other 
binding  proteins  bind  approximately  15%  of  IGF-I  and  the  rest  of  IGF-I 
circulates free (4).  IGF-I binding to the IGF-IR may prevent apoptosis and 
the  presence  of  IGF-IR  on  some  tumours  can  implicate  a  more 
aggressive  prognosis  (5;6).  At  a  tissue  level,  IGF-I  is  an  important 
regulator of cell survival, growth and metabolism.
15Insulin-like  growth  factor  binding  protein-3  (IGFBP-3)  is  a  40-44kDa 
glycoprotein  of  hepatic  origin  and  is  responsible  for  carrying 
approximately 90% of circulating IGF in the serum.  Unlike IGF-I,  IGFBP-3 
levels  are  relatively stable  and  are  less  susceptible to  nutritional  effects 
(7).  It exists as a  150-kDa ternary complex consisting  of IGF-I,  IGFBP-3 
and  a  bound  acid  labile  subunit  (ALS).  The  large  size  of  this  ternary 
complex  prevents  it  from  crossing  the  capillary  barrier  (8)  and  also 
prolongs  its  half-life  from  10  minutes  in  the  unbound  state,  to 
approximately  12  hours.  IGFBP-3  may  therefore  inhibit  the  mitogenic 
actions  of  IGF-I  by  binding  to  it with  such  affinity that  it  prevents  IGF-I 
from binding to its own receptor (Fig. 1).  It may also enhance its effects by 
increasing  its  bioavailability  at  the  target  site  (9-11).  Within  the  last 
decade  it  has  become  clear  that  IGFBP-3  could  inhibit  cell  growth  and 
induce  apoptosis  by  IGF-  independent  mechanisms.  Little  is  known, 
however,  about the  IGF-independent  role of  IGFBP-3  in  cancer and  the 
mechanisms regulating its production.
16Figure  1.  Summary of growth  hormone- IGF axis demonstrating the 
production  of IGF-I and  IGFBP-3 from the liver and the formation  of 
the ternary complex
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GHR = growth hormone receptor
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IGF-I = insulin-like growth factor-1
IGFBP-3 = insulin-like growth factor binding protein-3
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17IGFBP-3 is one of a family of six high affinity IGF-binding proteins present 
in  the  circulation  (IGFBP-1  -   6)  (12)  which  modulate  the  interactions 
between  IGFs  I  and  II  and  their  receptors.  There  are  also  several  low 
affinity  binding  proteins  that  have  recently  been  named  IGFBP-related 
proteins  (IGFBP-rPs).  IGFBPs  have  been  shown  to  be  produced  in 
almost  all  tissues  to  varying  degrees,  however,  IGFBP-3,  the  most 
abundant IGFBP, is produced predominantly from the liver (13).
IGFBPs were originally described as passive circulating transport proteins 
for IGFs. However they are also implicated in a complex variety of cellular 
functions,  and  exert  actions  also  at  a  tissue  level,  depending  on  their 
primary structure  and  their  post-translational  modifications.  IGFBPs  also 
have  important  IGF  independent endocrine and  paracrine effects as well 
as their well documented effects on  IGF-I  (14-16).  Previous studies have 
also  implicated  the  role  of  IGFBPs  in  cell  motility,  adhesion(12;17), 
survival, apoptosis and the cell cycle (18-20).
IGFBPs  are  known  to  interact with  several  signalling  pathways  such  as 
PI3-kinase pathway (21), the type II transforming growth factor-P (22) and 
the  retinoid-X  receptor  (23).  They  may  also  have  a  unique  signalling 
pathway of their own.
IGFBP-3 is the main circulating binding protein in serum and circulates as 
a  large ternary complex (150kDa).  It controls the bioavailibity of IGF-I  by 
prolonging  its  half-life.  Recent  studies  have  shown  that  IGFBP-5  is  also 
capable  of forming  a  ternary  complex  with  IGF-I  or  II  and  the  ALS  (24) 
which is slightly smaller in size (130kDa).  It is therefore possible for IGF-I 
to be transported around the circulation in the absence of IGFBP-3. Small 
amounts  of  IGF-I  bind  to  IGF  binding  proteins  as  a  binary complex  and 
less than 1% travel free in the circulation (8).
18The main function of IGFBP-3 was thought to be as a ‘reservoir’ for IGF-I. 
In  serum,  the  IGF/BP-3  ternary  complex  is  present  in  ten-fold 
concentrations greater than  all other binding  proteins (25).  IGFBP-3  also 
has  a  higher  affinity  for  IGF-I  than  all  the  other  binding  proteins  and 
similarly,  IGF-I  is  thought  to  bind  with  higher  affinity  to  IGFBP-3  than  it 
does to IGF-IR (26).
The ALS component of the ternary complex also has an  important role in 
modulating  IGF-I  and  IGFBPs.  (27).  The  normal  half-life  of free  IGF-I  is 
approximately  10  minutes  and  that  of  IGFBP-3  is  30-90  minutes.  The 
half-life of the ternary complex,  however,  is  12  hours. Therefore it serves 
to greatly prolong the half-life of IGF-I  (28).  IGFBP proteases (IGFBP-Pr) 
also  play  an  important  role  in  modulating  levels  of  IGF-I  as  they  cleave 
IGFBPs.  Free IGF-I is then released and able to exert its effects at a local 
level.
1.1.1  IGF dependent effects
It  is  well  known  that  IGF-I  binds to  IGFBP-3  with  greater affinity  than  it 
does  to  its  own  receptor  and  this  therefore  enables  it  to  tightly  control 
tissue activity (29).  IGFBP-3 may be either inhibitory or stimulatory to IGF 
actions  (30;31).  The  high  affinity  with  which  IGFBP-3  binds  to  IGF-I  is 
thought to have an  inhibitory effect on the action of IGF-I, by preventing it 
from  interacting with the  IGFI-R (9-11).  One study investigating this  used 
IGF-I  analog  des-IGF-l  which  binds  and  activates  IGF-IR  but  does  not 
bind  BP-3.  In  the  human  HL-60  promyeloid  cell  line,  BP-3  inhibited  the 
proliferative  effects  of  IGF-I  and  -II  but  did  not  inhibit  the  proliferative 
effects of des-IGF-l. The anti-proliferative effects of BP-s,  therefore,  may 
be dependent on the binding and sequestration of IGF-I (32). Conversely, 
IGFBP-3 may also enhance the action of IGF-I by providing a reservoir of 
IGF-I and increasing the amount of IGF-I at a local tissue level that once
19free,  is able to exert its effects.  In the breast,  IGFBP-3 is thought to have 
a  predominantly inhibitory effect.  Interestingly,  it has also been shown to 
induce apoptosis by sequestering IGF-I in MCF-7 cells (33).
1.1.2  IGF independent effects
It is becoming  increasingly clear that as well as modulating the activity of 
IGF-I,  IGFBP-3  exerts  its  own  effects.  The  IGF-I  independent  pro- 
apoptotic  effects  of  IGFBP-3  were  first  demonstrated  in  1993  by 
Rosenfeld  et al when  it was  observed that  IGFBP-3  inhibited the growth 
of Hs578T breast cancer cells which do not respond to  IGF-I  (34).  Rajah 
et al also  observed  in  1997  that when  IGFBP-3  was  added  to  an  IGF-I 
negative mouse fibroblast cell line, a significant increase in apoptosis was 
observed  (18).  Valentinis  et  al  used  fibroblasts  from  IGF-IR  knockout 
mice which demonstrated growth inhibition when transfected with a vector 
containing  the  IGFBP-3  gene  (35).  This  growth  inhibitory  effect  of  BP-3 
was therefore mediated by an IGF-independent pathway.
Studies  performed  by  Perks  et  al  looked  at  the  apoptotic  effects  of 
IGFBP-3 on Hs578T cells and found that when used on its own,  IGFBP-3 
had minimal effects,  however, when used with a ceramide analogue (C2), 
apoptosis  was  significantly  accentuated  (36;37).  Furthermore,  where 
IGFBP-3  significantly  accentuated  this  apoptosis,  IGFBP-4  and  -5 
reduced C2-induced apoptosis and  IGFBP-1, -2 and -6 had no significant 
effect  at  all.  This  suggests  that  the  IGFBP  family  exerts  its  apoptotic 
effects through differing apoptotic signalling pathways.
Other  studies  looking  at  the  IGFBP-3  enhancement  of  C2-induced 
apoptosis  in  Hs578T cells  have  also  suggested  a  possible  link with  cell 
association  and  binding  protein  proteolysis  (38),  an  effect which  may  be 
reversed  when  treated  with  IGF-I.  As  well  as  ceramide  analogue,  C2, 
IGFBP-3 has also been shown to significantly accentuate the apoptosis
20caused by DNA-damaging stimuli such as ionizing and  UV irradiation and 
chemotherapeutic drugs such as paclitaxel (39-42).
Some  studies  have  demonstrated  that  IGFBP-3  is  capable  of  inducing 
apoptosis on its own as well as potentiating the apoptotic effects of other 
DNA  damaging  agents  such  as  UV  radiation  and  cytotoxics  (39-41). 
Further  transfection  of  IGFBP-3  into  radiation  resistant  T47D  breast 
cancer cells restored the sensitivity to ionising radiation. This is one of the 
only studies demonstrating  an  independent apoptotic effect of IGFBP-3 ;  
mostly IGFBP-3 has been shown to enhance the apoptotic effect of other 
agents.  Cell  culture  studies  are,  however,  difficult  to  assess  as  some 
degree  of  apoptosis  always  occurs  and  in  general,  IGFBP-3  shows  a 
more  marked  effect  when  used  in  combination  with  other  apoptotic 
agents.
A study  performed  in  1995  reported  that  IGFBP-3  gene  expression  was 
induced  by  tumour  suppressor  gene  p53  (43).  In  colon  cancer  cells, 
IGFBP-3  was  shown  to  be  a  mediator  of  p53-dependent  apoptosis 
(41 ;43)  and  similarly  in  an  oesophageal  cancer cell  line,  apoptosis  after 
prior  irradiation  demonstrated  an  increase  in  p53  which  was  further 
enhanced  by addition  of exogenous  IGFBP-3  (41).  Butt et al transfected 
IGFBP-3  into  wild-type  (MCF-7)  and  mutant  (T47D)  breast  cancer  cells 
resulting  in  apoptosis,  thereby  suggesting  that  apoptosis  may  occur 
independently of functional p53 (22;40). Apoptosis seen  in breast cancer 
cells over expressing  IGFBP-3 has been shown to be associated with an 
increase in Bad and  Bax, which are pro-apoptotic, and a decrease in  Bcl- 
2  and  Bcl-xL,  which  are  anti-apoptotic  (40).  This  suggests that  IGFBP-3 
may cause apoptosis using this apoptotic signalling pathway.  Similarly in 
studies  looking  at  apoptosis  in  a  prostate  cancer  cell  line  (PC-3), 
apoptosis  induced  by  IGFBP-3 was  inhibited  by a  caspase  inhibitory8). 
Caspases are a family of cysteine aspartic acid-specific proteases which 
play a central role in the apoptotic pathway (44).
21The  mechanisms  underlying  these  IGF  independent  effects  have  yet  to 
be elucidated. Unfortunately, a specific IGFBP-3 receptor has not been 
fully  discovered  (34;45).Oh  et al suggested  that  a  cell  surface  IGFBP-3 
receptor  may  exist  in  1993.  In  this  study,  the  inhibitory  effects  of 
oestrogen  receptor  negative  Hs578T  breast cancer cells were  shown  to 
be dose dependent and diminished by co-incubation with IGFs, but not by 
analogs with  reduced affinity for BP-3 (46). A putative receptor has been 
cloned and initial data shows direct activation of caspase 8 in response to 
BP-3  binding.  Over  expression  of  this  receptor  has  been  shown  to 
increase  cell  surface  association  of  IGFBP-3  and  apoptosis,  however, 
further work is needed to fully assess the mechanism of action (23).
1.2  IGFBP structure
The  IGFBP  genes  share  a  common  structural  relationship whereby four 
conserved exons are located within genes ranging from 5kb (IGFBP-1) to 
greater than 30kb (IGFBP-2 and IGFBP-5) (47).
All six binding proteins are well conserved and have been shown to share 
an  overall  protein  sequence  homology  of 50%  within  a  species  (48;49). 
The most highly conserved  regions  include the  N-terminal  ligand-binding 
domain  and  the  C-terminal  region  which  is  thought  to  be  involved  in 
protein and  extracellular matrix (ECM)  interactions.  There are also many 
conserved  cysteine  residues  within  these  regions.  These  residues  are 
thought to  be  important in forming the  high  affinity  bonds with  IGF-I  and 
IGFBPs  that  lack them  have  a  reduced  ability to  bind  IGF-I  and  II  (50). 
Previous  studies  have  shown  that  IGFBPs  from  fish,  reptiles  and  birds 
are able to specifically bind 125l-labeled mammalian IGF-I (51;52), thereby 
providing  evidence  that  IGFBPs  were  present  in  early  vertebrate 
evolution despite the fact that no  IGFBP genes have been  cloned  in this 
group.
22The  structural  differences  between  the  IGFBPs  may  account  for  their 
differential  actions  (29).  The  RGD  sequence  (arginine-glycine-aspartic 
acid)  is  present  in  IGFBP-1  and  -2  and  is  thought  to  facilitate  the 
association  of IGFBP-1  with  cell surface by the fibronectin  receptor (12). 
All  IGFBPs contain  heparin  binding  sites which enable the attachment to 
cell surface/ECM (53).  IGFBP-3 and -5 demonstrate the highest affinity of 
heparin  binding  sites  and  also  possess  nuclear  localisation  sequences 
(54);  structurally,  they are the  most similar.  IGFBP-3  is  known  to  be  N- 
glycosylated (55) and  IGFBP-5 is known to be O-glycosylated  (56) which 
are  associated  with  cell  and  matrix  association,  although  studies  have 
shown  that  glycosylation  of  IGFBP-3  has  no  significant  effect  on  IGF-I 
(57)  or  ALS  binding  (58).  The  significance  of  these  post-translation 
modifications is not fully understood.  However, they may contribute to the 
prolonged half life of IGFBP-3 in the circulation.
1.2.1  IGFBP proteases
IGFBP  proteases  were  first  described  in  the  circulation  of  pregnant 
women (59-61).  IGFBP proteases have been shown to cleave IGFBP-2 to 
6 with the production of fragments that have a greatly reduced affinity for 
IGF-I.  This  cleavage  therefore  means  that  more  IGF-I  is  made  freely 
available  to  exert  its  effects  via  the  IGF-IR.  Since  then,  an  increase  in 
protease  activity  has  been  reported  in  several  pathophysiological 
conditions,  such as diabetes and  severe illness,  leading to the possibility 
that  they  may  be  autocrine/paracrine  growth  regulators  (62-64).  An 
increased  protease  activity  has  also  been  reported  in  advanced  breast 
cancer and other advanced malignancies (65;66).  It was proposed that an 
increased  protease activity may be implicated  in breast tumorigenesis by 
facilitating the release of IGF-I at a tissue level (67).
23Proteases  implicated  in  the  specific  cleavage  of  IGFBP-3  include 
prostate-specific antigen  (PSA),  cathepsin  D and  plasmin. All  have been 
demonstrated  in  breast cancers.  PSA,  usually found  in seminal fluid,  has 
recently  been  reported  to  be  synthesized  by  the  breast  (68-70). 
Measurement  of  PSA  levels  and  IGFBP-3  has  been  found  to  have 
significant  prognostic  implications  in  screening  for  prostate  cancer  (71). 
Reports,  however,  have been conflicting with high  levels of PSA reported 
in  benign  disease  and  lower  levels  in  advanced  cancer  (68).  It  has  also 
been  reported  in  a  study  of  200  breast  tumour  cytosols,  that  no 
correlation exists between PSA and IGFBP-3 levels (expression) (70).
Plasmin  has  also  been  reported  to  be  a  prognostic  marker  in  breast 
cancer (72).  It is thought to proteolyse  IGFBP-3 into fragments which are 
able  to  inhibit  the  mitogenic  effects  of  IGF-I  despite  having  a  reduced 
affinity  for  IGF-I  (73).  This  is  further  support  for  IGFBP-3  independent 
effects  since  it  suggests  that  IGFBP-3  fragments  are  independently 
bioactive.
High  levels  of  cathepsin  D  have  been  significantly  correlated  with  the 
development of metastases in  breast cancer in one study that measured 
levels  in the cytosol of breast tumours  (74;75).  It has also been  reported 
that  oestrogen  enhances  the  secretion  of  cathepsin  D  in  oestrogen 
receptor postitive and not negative breast cancer cells (76;77).
A  high  level  of  proteolytic  activity  is  generally  thought  to  result  in  an 
increased risk of tumourigenesis since IGF-I is cleaved from IGFBP-3 and 
free  to  exert  its  effects.  There  is  some  evidence,  however,  that  the 
fragments  produced  by  IGFBP-3  cleavage  may  also  exert  anti­
proliferative  effects  on  breast  cancer  cells.  The  exact  role  of  IGFBP 
proteases, therefore, have yet to be fully elucidated.
241.2.2  IGFBP-related proteins (IGFBP-rP)
IGFBP-rPs  are  a  group  of  newly  identified  proteins  which  share  some 
homology with the amino-terminal end of IGFBPs (78). There appears to 
be some structural differences in the carboxy-terminal end of IGFBP-rPs, 
thereby accounting for the reduced affinity for which they bind  IGF-I.  Due 
to this  reduced  affinity binding,  their role  in the  bioactivity of IGF-I  is  not 
thought to be physiological.  IGFBP-rP-1  does in fact bind insulin with high 
affinity (79), thereby suggesting an IGF independent function.
IGFBP-rP1  has  been  found  to  be  over  expressed  in  normal  breast 
epithelial cells and down regulated in breast tumours (80). Similarly it has 
been found to be down regulated  in prostate cancer and  is thought to be 
a potential tumour suppressor protein for prostate cancer (81).
1.3  GH-IGF-I axis and breast cancer
There  are  various  stages  at  which  IGF-I  and  IGFBP-3  are  thought  to 
contribute to the development of cancer.  IGF-I  may directly influence the 
initial  stages  of  malignant  transformation  by  enhancing  cell  survival, 
migration  and  proliferation.  Similarly,  it  may  interfere  with  the  normal 
mechanisms of cell cycle arrest and  apoptosis.  It may also play a part in 
the  development  of  local  invasion  and  metastases  and  later  on,  in  the 
development  of  resistance  to  therapeutic  agents.  In  addition  to  these 
direct effects,  IGF-I  may indirectly promote tumourigenesis  by interacting 
with  oncogenes,  tumour  suppressor  genes,  other  hormones,  such  as 
oestrogen  in breast cancer and  IGF binding proteins,  particularly IGFBP-
3.  It  also  induces  vascular endothelial  growth  factor  (VEGF)  which  has 
well known angiogenic effects.
25IGFBP-3  may  indirectly  influence  tumorigenesis  by  binding  IGF-I  and 
thereby inhibiting the mitogenic effects of IGF-I.  It may also directly effect 
tumourigenesis  by it’s own  anti-proliferative  and  pro-apoptotic effects.  In 
this  way,  IGFBP-3  is  thought  to  play  a  cancer  protective  role.  Normal 
tissue  homeostasis  is  dependent  on  the  tight  control  of  cellular 
proliferation and  apoptosis. Any abnormality in this  regulation  may result 
in  an  increase  in  cell  number  or  survival  of  cells  which  have  acquired 
mutations.  The  mechanisms  by  which  BP-3  may  alter  cancer 
susceptibility, however, remains undetermined.
IGF-I  is  a  potent  mitogen  and  has  marked  anti-apoptotic  effects  on 
normal  and  malignant  breast  cancer  cells(12;82).  In  mice  the 
development of the breast requires IGF-I action (83;84). Transgenic mice 
that  over  express  genes  encoding  GH  or  IGF-I  receptor  (IGF-IR)  also 
have  an  increased  incidence  of  mammary  gland  epithelial  hyperplasia 
and an increased risk of breast cancers (85;86).  IGF-I exerts its effects on 
cellular  proliferation  and  apoptosis  via  the  IGF-IR  which  is  a  trans­
membrane tyrosine kinase receptor and over expressed in  breast cancer 
tissue  (87).  A  negative  feedback  loop  exists  whereby  free  IGF-I 
suppresses  the  secretion  of  GH  from  the  pituitary  (88).  IGF-I  also 
regulates  the  expression  of  several  genes  associated  with  breast 
tumourigenesis;  c-myc,  VEGF,  progesterone  receptor  (PgR)  and 
cathepsin  D  (89).  In  the  absence  of  IGF-I  action,  several  known 
oncogenes  are  unable  to  produce  malignant  transformation,  however, 
with  re-expression  of  the  IGF-IR,  the  malignant  potential  of  these 
oncogenes is restored (90-95).
1.3.1  Epidemiological studies
Epidemiological studies on  IGFBP-3 and breast cancer are controversial. 
Some studies have shown a link between a high serum IGF-I and a low
26serum IGFBP-3 with an increased risk of developing breast cancer in pre- 
and  post-menopausal  women  (96-98).  A  few  studies,  however,  have 
failed  to  demonstrate  an  association  (96;99;100).  Recent  studies  have 
shown that high serum  levels  of IGF-I  and  low IGFBP-3 were present in 
women with stage I and II breast cancer (101). A high ratio IGF-l/IGFBP-3 
ratio was therefore associated with an increased risk of developing breast 
cancer.  Another  study  reported  a  link  between  a  high  serum  IGF-I  and 
low IGFBP-3 with an increased  risk of pre-menopausal ductal carcinoma 
in situ (102).  It has been thought that it is not the absolute serum  level of 
IGF-I  or  BP-3  that  is  important,  more  the  molar  ratio  between  them. 
Therefore  having  a  high  IGF-  I  to  a  low  BP-3  ratio  would  imply  an 
increased  risk of developing breast cancer and conversely a low IGF-I to 
a high BP3 would protect against cancer.
A recent prospective population study has provided evidence that a  high 
serum  IGF-I  to  a  low  BP-3  ratio  is  associated  with  a  high  risk  of 
developing  breast  cancer  in  pre-menopausal  women  (96).  Other 
epidemiological studies have shown a similar link with colon, prostate and 
lung  cancer  (103-105).  These  studies  demonstrate  that  serum  IGF-I  is 
positively  associated  with  risk  while  IGFBP-3  is  negatively  associated. 
The overall  increase  in  relative  risk  (2-4 fold)  appears to  be  small when 
compared  to  the  increase  in  risk  associated  genetic  mutations  such  as 
BRCA1/2,  however,  such  mutations  are  rare.  It  seems  therefore  that  a 
high  IGF-l/BP-3  ratio is  likely to  be  more  common  in the  population  and 
so the overall increase in cancer risk may be significant.
Interestingly,  a  recent meta-analysis  of 20  studies  compared  uppermost
t
and  lowermost centiles  of IGFBP-3  serum  levels  and  reported  that  high 
serum  levels of IGFBP-3 are associated with a significant increase in the 
risk of pre-menopausal  breast cancer (98).  This  study also showed  that 
increasing IGF-I concentrations were associated with an increased risk of 
pre-menopausal  breast  cancer.  No  protective  effects  of  higher 
concentrations of BP-3 were detected. Another recent study looking at
27the  IGF  axis  and  breast  cancer  in  Chinese  women  similarly  found  that 
IGFBP-3  and  IGF-I  levels  were  higher  in  women  with  breast  cancer 
versus controls (106). The adjusted odds ratio was 3.01  for women in the 
highest  IGFBP-3  tertile  when  compared  to  those  in  the  lowest  tertile, 
thereby supporting the previous meta-analysis’ findings of an association 
between  breast  cancer  and  a  high  BP-3.  In  some  culture  conditions, 
IGFBP-3  has  been  shown  to  have  anti-apoptotic  effects  (19; 107), 
possibly  reflecting  an  acquired  resistance  to  its  usual  growth  inhibitory 
effects  and  may  account  for  the  unexpected  positive  associations 
between BP-3 and breast cancer in the above two studies.
In  studies  looking  at  other  cancers,  a  positive  correlation  was  seen 
between high IGF-l/low BP-3 and subsequent risk of developing prostate, 
colorectal  and  lung  cancer  (108-110).  The  meta-analysis  performed  by 
Renehan  et a/,  however,  reported  that  IGF-I  levels  in  the  upper versus 
lower tertile were associated with an increased risk of prostate, colorectal 
cancer  and  pre-menopausal  breast  cancer  only.  They  reported  that  no 
inverse associations with  IGFBP-3 were detected,  except for lung cancer 
(98).
These studies provide evidence for an association between IGFBP-3 and 
breast  cancer  risk  but  do  not  establish  causality.  It  remains  to  be 
determined  what  the  biological  significance  is  for  different  levels  of 
IGFBP-3 and what controls local expression resulting in tumourigenesis.
1.3.2  In Vitro and animal studies
IGFBP-3  has  multiple,  complex  actions  in  different  tissues.  It  has  been 
shown  to  inhibit  or  potentiate  the  actions  of  IGF-I  in  different  culture 
systems  (111; 112).  A study looking  at a  prostate  cancer cell  line  (PC-3) 
demonstrated  a  growth-stimulatory  effect  that  was  thought  to  be 
dependent on the active proteolysis of IGFBP-3 via prostate specific
28antigen (PSA, a known IGFBP-3 protease) (113). Two other studies have 
shown  anti-apoptotic  effects  (107; 110).  Most  studies,  however,  have 
demonstrated that IGFBP-3 has an inhibitory effect on  breast cancer cell 
growth.  Oh  et al demonstrated that IGFBP-3 inhibited  growth of Hs578T 
cells independent of IGF-I (34). Gill et al also demonstrated similar effects 
in  this  cell  line  and  also  showed  that  with  the  use  of  known  apoptotic 
ceramide  analogue,  C2,  apoptosis  could  be  further  accentuated  (36). 
Similarly,  IGFBP-3  has  been  shown  to  enhance  the  apoptotic  effect  of 
known  cytotoxic,  paclitaxel  which  is  a  drug  that  works  via  TNFa  and 
ceramide generation (114).
IGFBP-3  markedly  inhibits  growth  of  breast  cancer  cell  line  MCF-10A 
(115) and also in the MCF-7 cell line (33).  In a study looking at the effects 
of IGFBP-3 in T47D cells, growth inhibitory effects were initially observed, 
however,  after  several  passages  cells  became  resistant  to  these 
inhibitory effects and proliferation was seen (19).  It was proposed that the 
development  of  resistance  to  IGFBP-3’s  inhibitory  effects  may  play  an 
important role in the progression of breast cancer.  Interestingly,  IGFBP-1, 
2, 4,  5 and 6  have not been shown to have any growth  inhibitory effects 
on breast cancer cell line, Hs578T (37).
Previous  in  vitro studies  have  shown  a  link  between  IGFBP  expression 
and oestrogen  receptor status in  breast cancer cells.  IGFBP-3 and  1   are 
found  in  oestrogen  receptor  negative  cell  lines  and  IGFBP-2  is 
predominantly  found  in  oestrogen  receptor  positive  cells  (116-118). 
Estradiol  has  been  shown  to decrease  production  of IGFBP-3  in  MCF-7 
cells (33) and other studies have confirmed a marked increase in IGFBP- 
3 mRNA in oestrogen receptor negative tumours (119-121).
Early  animal  studies  showed  that  IGFBP-3  inhibited  DNA  synthesis  in 
chick  embryo  fibroblasts  when  stimulated  by  serum,  fibroblast  growth 
factor and TGFp (122; 123). Further studies with mouse fibroblasts
29showed that  IGFBP-3  had  a growth  inhibitory effect  in  serum-containing 
media, an effect which was not reversed by insulin (124). This lead to the 
idea  that  the  growth  inhibitory  effect  of  IGFBP-3  was  IGF-independent. 
Fibroblasts  from  IGF-IR  knockout  mice  were  then  transfected  with 
IGFBP-3  resulting  in  growth  inhibition  and  it was  thought  that  IGFBP-3 
may  be  acting  by  blocking  a  different  receptor  (35).  Lee  et  al  stably 
transfected  non-small  cell  lung  cancer  (NSCLC)  cell  line  NCI-H23  with 
IGFBP-3  cDNA  and  demonstrated  that  xenotransplantation  into  nude 
mice  resulted  in  minimal  tumour  growth  (125).  In  another  study, 
adenoviral  IGFBP-3  construct  was  injected  into  H12999  NSCLC 
xenografts and a massive destruction of tumours was observed (126).
One study implanted  prostate cancer xenografts into SCID mice and the 
animals were subsequently treated with  IGFBP-3 and  retinoid-X-receptor 
(RXR)  ligands  (23).  When  used  alone,  no  effect  was  seen  on  tumour 
growth,  however,  in combination  a  marked  reduction  in tumour size was 
observed. A similar reduction in tumour size was reported when  IGFBP-3 
was given to SCID mice implanted with colon cancer (127).
Other knockout  mice  studies for all  members  of the  IGFBP family  have 
only  demonstrated  minor  changes  in  phenotype  suggesting  that  there 
may  be  compensatory  changes  in  other  members  of the  IGFBP  family. 
Mice  overexpressing  IGFBP-3  resulted  in  selective  organomegaly  and 
mammary  gland-targeted  expression  of  IGFBP-3  resulted  in  an  altered 
involution  after  pregnancy  (128).  These  findings  demonstrate  that  local 
action of IGF-I may be altered and that there may be an IGF independent 
effect locally on tissue growth and development.
1.3.3  The IGF axis and oestrogen signalling
The IGF-axis and oestrogen appear to have a profound synergistic effect 
on breast cancer cells. Previous mice studies have shown that the
30mammary gland  needs IGF-I and oestrogen  in order to develop fully and 
without  IGF-I,  full  development  does  not  occur  (83;84).  In  vitro  studies 
have  confirmed  that  co-treatment  of  MCF-7  cells  with  IGF-I  and 
oestrogen  results  in  proliferation  and  this  effect  is  blocked  by anti-IGF-l 
antibodies  (129).  Other  studies  have  shown  that  in  the  absence  of 
oestrogen,  IGF-I  still  activates  oestrogen  receptor-mediated  gene 
transcription  and  that the  synergistic effect  of  both  IGF-I  and  oestrogen 
results  in  an  enhanced  transcription  of  oestrogen  receptor  regulated 
genes (130).
Oestrogen  is  also  known to  act at several  points within  the  IGF-I  signal 
transduction pathways. When IGF-I binds to IGFI-R, auto phosphorylation 
of  the  receptor  (3  subunits  occurs  with  a  resultant  increase  in  receptor 
tyrosine  kinase  activity  (129).  This  leads  to  phosphorylation  of  IRS-I 
(insulin-receptor substrate  protein-1)  and  activation  of other downstream 
signalling  pathways  involved  in  mediating  mitogenic  responses  such  as 
phosphatidylinositol  3-phosphate  kinase  (PI-3K)  and  C-Jun  N-terminal 
kinase  (131-133).  Similarly,  oestrogen  activates  several  components  of 
the MAP kinase pathway (134)and  also acts synergistically with  IGF-I  to 
enhance Akt protein synthesis and activity (135).
This  increase  in  Akt  protein  synthesis  and  activity  results  in  the 
phosphorylation  of  BAD,  an  apoptosis  inducing  member  of  the  Bcl-2 
protein  family.  The  result  is  that  BAD  is  sequestered  and  so  unable  to 
bind and inactivate anti-apoptotic Bcl-2 and Bcl-XI thereby resulting in the 
suppression of apoptosis.  One study has shown that breast cancer cells 
are  protected  from  chemotherapy  induced  apoptosis  by  IGF-I  and  that 
this effect is mediated by PI-3K (136).
In the clinical treatment of breast cancer,  Tamoxifen  is used to block the 
effects  of  oestrogen.  Studies  have  shown  that  as  well  as  blocking 
oestrogen,  it also suppresses serum  IGF-I  levels,  probably as a  result of 
suppression of  GH secretion (137;138).  In vitro studies have shown that 
Tamoxifen also blocks IGF-I mediated proliferation of breast cancer cells.
31In addition to these effects, Tamoxifen has also been reported to increase 
IGFBP-3  levels  and  thereby  reduce  the  amount  of  bioactive  IGF-I 
available (139).
In  breast  cancer  tissue  studies,  estradiol  has  been  shown  to  increase 
mRNA expression of IGF-I four to six fold  in normal breast tissue (83).  It 
has  also  been  shown  to  up  regulate  expression  of  IGFI-R  mRNA 
expression in oestrogen  receptor (ER) positive breast cancer cells (140). 
Estradiol further  increases  IGF-I  bioactivity  by down  regulating  IGFBP-3 
synthesis and  increasing synthesis of cathespin  D,  an  IGFBP-3 protease 
which acts to degrade IGFBP-3 (141).
In  contrast  to  these  effects,  progestin  appears  to  inhibit  oestrogen 
stimulated  growth  in  ER-positive  breast  cancer  cells  (142)  and 
progesterone  agonists  in  fact  down  regulate  IGFI-R  mRNA  in 
progesterone  receptor  (PR)  positive  breast  cancer  cells.  A  down 
regulation of IGFBP production was also seen in this study (143).
1.4  Expression in breast tissue
Most  studies  looking  at  the  role  of the  IGF  axis  in  breast  cancer  have 
concentrated on in vitro studies using breast cancer cell lines. There has, 
however, become increasing in vivo evidence of a role for the IGF system 
in breast cancer tissues.
Interestingly,  IGF-I  mRNA  has  been  detected  in  normal  and  malignant 
breast  tissue  (144),  whereas  it  does  not  appear  to  be  expressed  from 
several  breast  cancer cell  lines  (145).  Another study  has  demonstrated 
that stromal fibroblasts rather than epithelial cells are the main source of 
the local protein, supporting the role of IGF-I acting in a paracrine manner 
(146).  IGF-I mRNA expression has also been found to correlate positively 
with degree of tumour differentiation (147) and negatively with vascular
32invasion  (148).  Both  IGF-I  and  IGF-IR  mRNA  have  both  been  found  to 
correlate  positively with  oestrogen  (ER)  and  progesterone  (PgR)  status 
(149) and  since a  strong  ER/PgR  status  is associated  with  an  improved 
prognosis, they may carry some additional prognostic information (150).
Several  IGFBPs  have  been  found  to  be  expressed  by  various  breast 
cancer  cell  lines,  however,  it  does  appear  to  correlate  with  hormone 
receptor  status  (151).Cell  lines  MDA-330,  MDA-231  and  Hs578T  are 
hormone  receptor  negative  and  express  higher  levels  of  IGFBP-3, 
whereas  hormone  receptor  positive  cells  MCF-7,  T-47-D  and  BT-20 
express  higher  levels  of  IGFBP-2  and  -4  (117).  These  cell  line  studies, 
however,  may  not  truely  reflect  physiologically  relevant  conditions. 
Similarly,  IGFBPs  appear to  be  over expressed  in  breast  cancer tissue 
when  compared  to  normal  breast  tissue  and  their  expression  differs 
according  to  hormone  receptor  status  as  it  does  in  breast  cancer  cell 
lines.  IGFBP-3  mRNA  therefore  appears  to  be  higher  in  hormone 
receptor negative breast tumours  (152).  Tumour levels of IGFBP-3  have 
also  been  positively  correlated  with  tumour  size  (153). IGFBP  1-5  have 
been detected in in vivo breast cancer specimens,  however, whether it is 
produced  by  the  actual  tumour  cells  themselves  or  the  surrounding 
stroma  has  never  been  documented  (120).  These  few  in  vivo  studies, 
however,  have  small  sample  sizes  and  therefore  definitive  IGFBP 
expression in breast tissue has yet to be elucidated.
1.5  Local versus endocrine effects
The  biological  significance  of  locally  produced  versus  systemically 
delivered  IGF-I  and  BP-3  is yet to  be elucidated.  It  is thought that there 
may be several mechanisms by which IGF-I enhances the mitogenicity of 
breast cancer cells.  Firstly,  IGF-I  may stimulate the proliferation of breast 
cancer cells in an endocrine fashion (128) and secondly, the surrounding 
stroma  may  produce  IGF-I  which  may  produce  mitogenic  effects  in  a 
paracrine or autocrine fashion (145).
33A study involving IGF-I knockout mice with a reduction of plasma IGF-I by 
25%,  did  not  demonstrate  any  phenotypical  differences  from  normals 
(154).  It  is  possible,  therefore,  that  paracrine  and  autocrine  IGF-I 
production  may  be  all  that  is  required  to  sustain  normal  growth  and 
development.  In  situ  hybridisation  studies  have  reported  that  IGF-I  is 
located predominantly in stromal tissue, whilst IGF-I I is expressed by both 
stromal  cells  and  breast  cancer cells  (144; 155; 156).  This  suggests that 
IGF-I  may  be  working  in  a  paracrine  fashion  and  similarly,  IGF-I I  has 
been  found  to  be  over  expressed  in  stromal  cells  surrounding  breast 
cancers  (157;158).  A  definite  conclusion  regarding  its  expression  and 
localisation remains to be determined.
1.5.1  Circulating levels of IGF-I and IGFBP-3
IGF-I and  IGFBP-3 are produced  primarily in the  liver and are thought to 
have a common,  growth hormone regulatory mechanism. The production 
of IGF-I,  IGFBP-3  and  ALS  is  directly affected  by  GH.  Previous  studies 
have  shown  that  reduced  levels  are  seen  in  growth  hormone-deficient 
states  and  more  is  seen  in  growth  hormone-excess  (159-161).  Studies 
have  shown,  however,  that  IGF-I  and  ALS  are  produced  by  the 
hepatocyte  and  IGFBP-3  are  produced  in the  non-parenchymal  Kuppfer 
cells  (162).  It  has  been  suggested,  therefore,  that  the  main  site  of  GH 
regulation  of the ternary  IGF-binding  complex  is at the  level  of ALS and 
IGF-I  synthesis and  so changes  in  IGFBP-3  levels may be secondary to 
changes in IGF-I regulation or clearance.
Serum  IGFBP-3  levels  rise  throughout  early  childhood,  peaking  in 
puberty,  then  gradually  decline  with  age.  They  are  generally  higher  in 
girls  and  are also  positively correlated  with  height and  BMI  (Body  Mass 
Index).  Serum  IGF-I  levels  show  a  similar  increase  from  childhood  to 
puberty  but  much  larger  than  that  seen  with  IGFBP-3.  Levels  then 
gradually decline with age and no difference is seen according to sex or
34BMI  (163; 164).  Significant  differences  in  IGFBP-3  levels  exist  between 
early  and  late  puberty  and  so  there  is  a  large  reference  range  for 
interpretation  of  population  IGFBP-3  and  IGF-I  levels.  The  sharper 
increase in serum  IGF-I seen during puberty means that the molar IGF-I: 
IGFBP-3  ratio  is  increased.  This  suggests  a  possible  differential 
regulation  of IGF-I  and  IGFBP-3  in  puberty and  so the  increasing  IGF-I: 
IGFBP-3 ratio may reflect biologically active, free IGF-I (163).
Previous  studies  have  demonstrated  that  there  is  a  positive  correlation 
between serum  IGF-I and  IGFBP-3 levels despite the paradox that IGF-I 
is  positively  correlated  with  cancer  risk  and  IGFBP-3  is  negatively 
correlated.  This  suggests that there  may  be  a  biological  significance  of 
individuals  within  the  broad  normal  ranges  between  acromegaly 
(hypersecretion  of  growth  hormone,  IGF-I  and  IGFBP-3)  and  growth 
hormone deficiency.  In contrast, other studies have shown that advanced 
cancers are associated with  low levels of IGF-I which  is thought to be as 
a  result of cachexia and  malnourishment.  IGFBP-3 protease activity has 
also  been  shown  to  increase  in  advanced  cancer  states  (65; 165).  The 
increase in cancer risk seen in  individuals with high  IGF-l/IGFBP-3 ratios 
may be due to differences in cell cycle kinetics and hence may impact on 
many extra divisions  in  epithelial  cell  populations  in the  long term  (166). 
The  need  for  further  prospective  studies  in  this  area  of  research  is 
therefore clear.
Anti-oestrogen  Tamoxifen  has  been  shown  in  several  studies to  reduce 
serum  IGF-I  (66; 167-170).  One study,  however,  showed that levels were 
unchanged  (139)  and  another  showed  an  increase  in  IGF-I  with 
Tamoxifen treatment (171).  Levels of IGFBP-3 in response to Tamoxifen, 
however,  seem  to  be  contradicting.  Three  studies  report  unchanged 
levels (165;167;171)whilst others have found  increased  levels (139; 172). 
The  effects  of  Tamoxifen  are  thought  to  be  mediated  by  several 
pathways;  inhibition  of  protein  kinase  C  (173),  stimulation  of  TGF-p 
(174)as well as anti-angiogenic effects (175; 176). A recent study has
35demonstrated  that  Tamoxifen  reduced  serum  IGF-I  levels  and  risk  of 
recurrence (177), therefore,  it may be possible that its effects on the GH- 
IGF axis are partly responsible for its beneficial effects in the treatment of 
breast cancer.
1.6  Modulation by other growth regulators
Recently  it  has  been  shown  that the  IGF-independent  growth  inhibitory 
effects  of  IGFBP-3  may  involve  interaction  with  other  growth  factor 
systems.  For  example,  transforming  growth  factor-p  (TGF-P)  has  been 
shown  to  have  marked  anti-proliferative  effects  on  breast  cancer  cells 
which is also associated with an increased expression of IGFBP-3 mRNA 
and  protein  (178).  Other  studies  have  also  shown  that  TGF-P  induces 
expression  of  IGFBP-3  and  that  its  growth  inhibitory  effects  may  be 
inhibited  by  antisense  oligoncleotides  to  IGFBP-3  (179; 180).  A  positive 
correlation  has  also  been  reported  between  IGFBP-3  and  TGF-P1  in 
breast cyst fluid  in  women  who  also  have  a  reduced  risk  of developing 
breast cancer (181).  One study has  proposed  that the TGF-pv receptor 
may be a putative IGFBP-3 binding site (45).
Many studies looking at breast cancer cell lines have shown correlations 
between  IGFBP-3  mRNA,  protein  expression  and  the  growth  inhibitory 
effects of TGFp,  anti-oestrogens  (182),  retinoic acid  (183) and vitamin  D 
analogs  (184; 185).  Other  studies  have  shown  that  other  growth 
modulators  such  as  anti-oestrogens,  vitamin  D  and  TNFa  are  able  to 
induce  production  of TGF-P  in  breast  cancers  (186-188).  It  is  possible, 
therefore, that TGF-P exerts its anti-proliferative effects on breast cancer 
cells via IGFBP-3.
361.7  Nuclear actions of IGFBP-3
IGFBP-3 has been localised to the nucleus of certain cells and contains a 
nuclear  localisation  sequence  which  may  facilitate  nuclear  transport. 
(54; 189; 190).  The  nuclear  role  of  IGFBP-3  is  unclear,  however,  the 
cellular  effects  involve  modulation  of gene  transcription.  The  retinoid  X 
receptor (RXR) plays a key role in regulating gene transcription mediated 
by  the  following  factors;  thyroid  receptors,  peroximase  proliferators 
activating  receptors and the vitamin  D receptor (191-194).  The  RXR can 
form  a  heterodimer with these  nuclear transcription factors,  for example 
the vitamin D receptor (VDR), which then bind to specific DNA sequences 
(vitamin  D  response  elements,  VDREs)  which  are  located  within  the 
promoter region of responding genes (195).
Retinoic acid has been shown to inhibit the growth of breast cancer cells 
as well  as  up  regulate  IGFBP-3,  4  and  6  mRNA (196).  It has also  been 
recently  reported  that  retinoid  X-receptor  may  be  a  binding  protein  for 
IGFBP-3  and  that  it forms  a  complex with  IGFBP-3 which  is then  taken 
into the nucleus after treatment with retinoic acid (23).  In this study it was 
observed  that  the  pro-apoptotic  effects  of  IGFBP-3  requires  an  intact 
RXR  signalling  pathway  as  RXR  knockout  cells  were  unresponsive  to 
IGFBP-3  induced  apoptosis.  This  implies  that  the  IGF-independent 
actions  of  IGFBP-3  mat  be  mediated  through  direct  effects  on  gene 
expression.
There have also been many studies investigating the effects of vitamin D 
analogues on  breast cancer cells.  In  vitro studies  have shown  that they 
inhibit  proliferation  and  in  vivo  studies  have  shown  that  they  cause 
regression  of  breast  tumours  (197-199).  One  study  reported  a  link 
between  the  anti-proliferative  effects  of  vitamin  D  with  an  increase  in 
IGFBP-3 protein (184). Vitamin D has also been previously shown to
37increase p53 protein expression, another possible mechanism by which it 
mediates its anti-proliferative effects (43).
In  vitro  studies  have  shown  that  anti-oestrogens  have  anti-proliferative 
effects on MCF-7 breast cancer cells with an  increase in  IGFBP-3 and  5 
mRNA  and  protein  levels  (182;200).  It  appears,  therefore  that  retinoic 
acid  and  vitaman  D  may  exert  their  antiproliferative  effects  on  breast 
cancer cells via up regulation of IGFBP-3.
The main ligand for the vitamin D receptor (VDR) is 1,25(OH)2D, which is 
converted  from  its  precursor  25(OH)D  by  25-hydroxyvitamin  D-1-a 
hydroxylase (laOHase).  Binding of 1,25(OH)2D to the VDR results  in  its 
translocation  to  the  nucleus  where  it  acts  as  a  transcription  factor.  In 
addition  to  this,  enzyme  24  hydroxylase  (240hase)  is  responsible  for 
breaking down active vitamin D. Extra-renal sites of laOHase expression 
have  been described  but its  in  vivo expression  in the human  breast has 
not been investigated.
1.8  Aims of study
There is increasing evidence that  IGFBP-3  is expressed  in  breast tissue 
and  may  influence  the  development  of  breast  cancers  in  women. 
Epidemiological studies have shown that IGFBP-3 levels may have a role 
in  breast cancer risk and  prevention,  however, further work is  needed to 
elucidate  its  expression  in  breast  tissue  and  also  its  potential  IGF- 
independent,  growth  inhibitory effects.  The conflicting  evidence obtained 
from  previous  work  suggests  the  need  to  clarify  the  expression  and 
effects of IGFBP-3 in breast tissue.
38The aims of this study were;
1.  To determine  and  compare  the  expression  of  IGFBP-3  mRNA  in  the 
following groups;
1 . Paired samples of normal and malignant breast tissue.
ii.  Normal  breast  tissue  from  women  undergoing  surgery  for  benign 
disease such as fibroadenoma/hamatoma.
iii.  Paired normal and malignant tissue from women with recurrent breast 
cancer.
2.  To  confirm  mRNA  expression  at  a  protein  level  using 
immunohistochemistry.
3. To correlate the local IGFBP-3 expression with the expression of;
i.Other members of the growth hormone/IGF-l axis (IGF-I and IGF-IR)
ii.The  vitamin  D  axis  (vitamin  D  receptor,  1-a  hydroxylase  and  24- 
hydroxylase).
iii. Other  genes  associated  in  breast  tumourigenesis:  COX-2  (cyclo- 
oxygenase 2), VEGF (vascular endothelial growth factor).
4.  To  determine  whether  such  expression  correlates  with  the  clinical 
behaviour  of  breast  cancer:  including  clinico-pathological  features 
(tumour  size,  grade,  histological  type,  lymph  node  status,  presence  of 
vascular  invasion,  presence  of  ductal  carcinoma  in  situ  (DCIS)  and 
hormonal status) and survival (follow-up of 20 months by end of study).
5.  To  investigate  the  serum  IGF-I  and  IGFBP-3  levels  in  women  with 
breast cancer and determine their IGF-l/BP-3 ratios.
396.  To determine the physiologically relevant IGF-I  independent effects of 
IGFBP-3  on  apoptosis  using  an  in  vitro  model  of primary  breast tissue 
culture.
402. Methods
2.1 Materials
2.1.1 Major
Tissue Homogeniser Ultraturrax T8 -  GMBH & Co, Germany.
Rneasy RNA extraction kit, Qiagen Ltd, Crawley, West Sussex,UK.
RNA 6000  Nano  Labchip  kit  (RNA  quantification),  Agilent  Technologies 
UK Ltd, Cheshire,UK.
Ribogreen  (RNA  quantification),  Molecular  Probes,  Amsterdam,  The 
Netherlands.
Wallac Victor2  1420  Multilablel  Counter (plate  reader),  Perkin  Elmer  Life 
Sciences, Cambridge,UK.
Mx4000™  RT-PCR  multiplex quantitative  PCR  system,  Stratagene,  The 
Netherlands.
Brilliant™  plus  single  step  quantitative  RT-PCR  core  reagent  kit, 
Stratagene, The Netherlands.
Primers  and  probes  designed  by  Primer  Express  software,  ABI  Perkin 
Elmer, Warrington,UK.
ABC kit, Vector Labarotories, USA.
NuaireTM  DH  Autoflow  automatic  C02  Incubator,  Triple  Red  Lab 
Technology Ltd, Oxfordshire, UK.
41Balance, Sartorius 1800, Sartorius Ltd, Sussex, UK.
MTS  proliferation  assay,  Cell  Titer  96  AQueous  One  Solution  Assay, 
Promega, Southampton,UK.
LDH cytotoxicity detection kit, Roche Molecular Biochemicals, NJ, UK. 
Caspase-3 protease assay, Apotarget, California, USA. 
Immunofluorescence, TSA™, Perkin Elmer, USA.
2.1.2  Minor
RNA later, Ambion (Europe) Ltd, Huntingdon, UK.
Cryogenic 2ml vials, Corning Inc, NY,USA.
Scalpels blade no. 10, Fisher Scientific UK, Loughborough, UK.
Pipette tips, Starlab, Helsinki, Finland.
24 well and 96 well microplates, Abgene UK.
Microcentrifuge tubes, Starlab, Helsinki, Finland.
Depex mounting medium, Gerr, Canada.
Ethanol (96%), VWR International Ltd, Lutterworth, UK.
Amphotericin (0.25pg/ml), Invitrogen Ltd, Paisley, UK.
Penicillin (10mg/ml), Invitrogen Ltd, Paisley, UK.
42Streptomycin (10mg/ml), Invitrogen Ltd, Paisley, UK.
Polyclonal rabbit anti-IGFBP-3 antibody, Upstate, USA. 
Dulbecco’s Modified Eagle Medium, GibcoBRL, Paisley, UK. 
Bovine serum albumin, Sigma Poole.
Human IGFBP-3, Gropep, Australia.
IGFBP-3 ELISA, Diagnostic Systems Labarotories, Texas, USA. 
Doxorubicin, Sigma, Poole.
Human anti-caspase-3 antibody, R&D systems, USA.
432.2  Ethics
Local Ethical Committee Approval was obtained and consent forms were 
designed  specifically  for this  study  (appendix A).  Full  informed  consent 
was obtained prior to collection of all samples and a copy of this form was 
filed  in  the  patient’s  notes,  in  the  Research  Department,  given  to  the 
patient and also given to the Pathology Department.
2.3  Tissue collection
2.3.1 Tumour specimens
Mastectomy (with  breast cancer)  and  segmental  mastectomy specimens 
were  collected  from  53  women  at  the  time  of  surgery.  A  further  10 
specimens were collected from women with  recurrent breast cancer that 
had  developed  resistance  to  Tamoxifen.  All  specimens  contained 
tumours  that  were  clinically  palpable  (greater  than  1cm  in  size). 
Specimens were  placed  on  ice  and  transported  swiftly to the  Pathology 
department.  Samples of breast tumour tissue  and  normal  breast tissue, 
as  far  away  from  the  tumour  site  as  possible  (approximately  8-10cm), 
were  harvested  and  placed  immediately  into  ‘RNA  later’(Ambion,  UK). 
The  samples  were  then  snap  frozen  in  liquid  nitrogen  and  stored  at  - 
80°C.
2.3.2 Normal breast tissue specimens
These samples were collected from 17 woman undergoing breast surgery 
for  benign  disease  or  breast  reduction  surgery.  All  patients  were  age 
matched  as far as  possible to  the  patients within  the tumour  bank.  Full 
informed consent was obtained for all specimens. At the time of surgery,
44samples of normal breast tissue were harvested from the tissue removed 
at  operation  and  placed  into  ‘RNA  later’  and  then  snap  frozen  in  liquid 
nitrogen. These samples were also stored at -80°C.
2.4  RNA extraction
Successful extraction of RNA requires disruption of the tissues,  inhibition 
of the  activity  of  RNases  (enzymes  that degrade  RNA)  and  removal  of 
any contaminating genomic DNA or proteins.
All tissue samples were stabilised  in  ‘RNA later’  prior to archival storage 
at  -80°C.  Use  of  this  reagent  allows  immediate  stabilisation  of  RNA 
thereby  preventing  any  changes  in  gene-expression  pattern  that  may 
occur with  RNA  degradation.  All  eppendorfs  used  had  been  previously 
autoclaved.
Tissue  samples  of  approximately  20-30mg  were  subsequently  excised 
after removal  from  ‘RNA  later1 .  Due  to  poor yield  of  RNA from  adjacent 
normal  breast  tissue,  sample  size  of  these  samples  was  increased  to 
50mg.
Qiagen  ‘Rneasy’  kit  was  used  to  extract  RNA.  This  technique  allows 
isolation  of  RNA  molecules  longer than  200  nucleotides.  This  therefore 
provides mostly mRNA as most RNAs less than 200 nucleotides long are 
excluded.  Lysis  buffer  RLT,  containing  guanidine  thiocyanate  and  B- 
mercaptoethanol,  was  used.  This  buffer  is  effective  in  inactivating 
RNases  to  allow  isolation  of  intact  RNA.  Tissue  disruption  was  first 
achieved using a tissue homogeniser and then using mortar and pestle.
452.4.1  Tissue homogenization
500|jl of buffer RLT was added to 30mg of frozen tumour or 700|jl RLT to 
50mg  of frozen  adjacent  normal.  This  increase  in  buffer for the  normal 
tissue  is  needed  as  normal  breast  tissue  is  difficult  to  lyse  and  more 
buffer  is  needed  to  complete  homogenization  and  to  prevent  the 
subsequent minicolumns from clogging.
A  rotor  ‘Ultra-turrax’  homogenizer  was  used  to  disrupt  the  tissues  for 
approximately 15-20 seconds at speed setting 4. Care was taken to avoid 
over-heating  and  foaming.  The  rotor  homogenizer  disrupts  the  tissues 
using  turbulence  and  mechanical  shearing.  The  sample  was  then  snap 
frozen using liquid nitrogen. Some difficulties were experienced using the 
tissue homogeniser and  normal breast tissue as the normal tissue had a 
high fibrous tissue and fat content.  This  lead to unsatisfactory disruption 
of the  tissues  prior to  extraction.  The  different technique  of mortar  and 
pestle grinding was then employed for normal samples.
2.4.2  Mortar and pestle
Using  this  technique,  each  frozen  sample  was  placed  into  a  mortar 
containing  liquid  nitrogen.  The  sample was then  ground  to fine  powder 
using  a  pestle  and  the  powder  then  scraped  into  a  chilled  eppendorf 
using a  round  bottomed  scalpel blade.  500pl or 700pl of buffer RLT was 
then added  accordingly and the mixture shaken vigorously prior to  snap 
freezing in liquid nitrogen.
For  subsequent  mRNA  extraction,  all  samples  were  defrosted  for  5 
minutes  in  a  water  bath  at  55  -  65°C.  They  were  then  placed  in  the 
centrifuge  for  5  minutes  at  13,000  rpm.  The  supernatant  was  carefully 
transferred into a new eppendorf, discarding any unhomogenized tissue.
46An equal volume of 70% ethanol was then added to the supernatant.  For 
example,  500pl  to  the  tumour  samples  and  700pl  to  the  normals.  The 
samples  were  then  mixed  by  vortexing.  700pl  of  the  mix  was  then 
pipetted  into the RNeasy mini column which was placed  into a collection 
tube.  The  column  and  tube  were  then  centrifuged  at  9000  rpm  for  1  
minute.  The  mini  column  contains  a  silica-gel-based  membrane  which 
allows  binding  of total  RNA whilst  contaminants  may  be washed  away. 
The protocol then states that the follow through  may then  be discarded. 
After several extractions with poor yield of RNA,  it was discovered that it 
was beneficial to pipette the follow through back into the mini column and 
re-centrifuge for a further minute before discarding.
This  process  was  then  repeated  for  the  remaining  buffer/ethanol  mix. 
350pl  of  buffer  RWI  (ethanol  containing)  was  then  added  to  the  mini 
column and the column left to stand for 15minutes with  its lid open. After 
15 minutes, the column was placed  into the centrifuge at 9000 rpm for 1  
minute. At this  point a  DNase step was performed.  This step  is optional 
but  used  for  the  purposes  of  this  study  as  Taqman  PCR  analysis  is 
sensitive to even small amounts of DNA.
2.4.3  DNase Step
A mixture of 10pl DNase I stock solution and 70pl buffer RDD was made 
up,  for each  sample.  This  was then  mixed  gently  by  inverting  the  tube. 
80pl was then pipetted directly onto the membrane within the mini column 
and  left, with  lids open, for  15 minutes. After 15 minutes,  a further 350pl 
of  buffer  RWI  was  pipetted  into  the  mini  column  and  the  column  then 
centrifuged at 8000 rpm for 1   minute. At this point the follow through was 
discarded and the mini column placed in a new collection tube.
500pl of RPE was then added to the mini column and centrifuged at 9000 
rpm  for  1   minute.  The follow  through  was  then  discarded  and  a  further 
500pl RPE added, centrifuged at 9000rpm for 3 minutes and discarded.
47The  mini  column  was  then  centrifuged  at  10  000  rpm  for  3  minutes  in 
order to dry out the membrane and then transferred  into a new collection 
tube.
80pl  of  RNase  free  water was  then  added  directly  onto  the  membrane 
and  left to stand for 2 minutes. The mini column was then centrifuged at 
10 000 rpm for 3 minutes. A further 65pl  of RNase free water was then 
added and the mixture left to stand for 5 minutes.  The column was then 
centrifuged at 13 000 rpm for 4 minutes.  145pl of follow through was then 
collected  into  two  new  eppendorfs;  10pl  in  one  eppendorf  for  RNA 
quantification and the remaining  135pi into another for archival storage at 
-80°C.
2.5  RNA analysis
There  are  many  different  methods  of  analysing  and  quantifying  RNA. 
Usually,  the  quality  is  checked  by  gel  electrophoresis  whereby  two 
distinct  bands form;  28S  and  18S.  The  ratio  of 28S:18S  should  be  2:1 
thereby confirming that the  RNA has not undergone significant digestion 
by RNases.  If the RNA has degraded, the ratio will be reversed. With this 
method  of  quality  control,  it  is  the  ribosomal  (rRNA)  and  not  the 
messenger  RNA that  is  checked  as  it  is  the  rRNA which  produces  the 
strong bands. Messenger RNA only produces a faint smear on a gel.
Initially,  the  Ribogreen  RNA  quantification  kit  was  used  to  quantify  the 
RNA.  It  is  a  fluorescent  nucleic  acid  stain  that  is  able  to  accurately 
measure  RNA  up  to  as  little  as  5  ng/ml  RNA.Those  samples  mostly 
included normal breast tissue which, due to its high fat content, tended to 
produce  low yields  of mRNA.  Breast tumour tissue,  however,  produced 
much  higher quantities  of mRNA  and  so for these  samples,  the Agilent 
bioanalyzer was used.
482.5.1 Ribogreen RNA Quantification Kit
The  Ribogreen  method  of  RNA  quantification  is  a  sensitive  fluorescent 
nucleic  acid  stain  that  may  be  used  in  conjunction  with  a  fluorescence 
microplate  reader.  The  Ribogreen  reagent  is  an  unsymmetrical  cyanine 
dye  which  demonstrates  a  >1000  fold  increase  in  fluorescence  when 
bound  to  RNA.  Free  nucleotides  and  contaminating  proteins  do  not 
interfere with the measurement.  It is essential that all samples have had 
DNA removed as it also binds to the Ribogreen reagent.
Samples to be quantified were removed from -80°C storage and  kept on 
ice.  Clean  disposable  gloves  were  used  throughout  to  minimise 
contamination  from  RNases.  TE  assay  buffer  was  provided  at  20x 
strength required. It comprised  10mM Tris-HCL and  1mM EDTA at pH 7.5 
and was diluted to 1/20 using nuclease-free water (2ml TE was added to 
38ml water).  Nuclease-free water was prepared  by treatment of distilled, 
de-ionized  water  with  0.1%  diethyl  pyrocarbonate  (DEPC)  followed  by 
incubation for 2-3 hours at 37°C and then autoclaved for 15 minutes. This 
sterilizes the water and eliminates the DEPC.
2.5.1.1  Tumours
400pl of TE was  pipetted  into an  autoclaved  eppendorf.  One eppendorf 
for each  sample  to  be  analysed.  2pl  of tumour  RNA was then  pipetted 
into the TE buffer.
492.5.1.2  Normal tissue
300|jl  of TE  was  used  for each  sample  of  normal  tissue.  5pl  of  normal 
RNA was then pipetted into the TE buffer.
The  Ribogreen  reagent was then  made  into a  1  in  200 solution with TE 
buffer and protected from light. This involved pippetting 50pl of Ribogreen 
into  9.95ml  TE  buffer  and  mixing  by  pipetting.  200pl  of  the  Ribogreen 
solution  was  then  added  to  each  of the  above  tumour or  normal  tissue 
samples.  100pl of this mix was then pipetted into three consecutive wells 
within a 96 well plate and incubated for 2-5minutes.
2.5.1.3  Standard curve
A  standard  curve  was  then  prepared  to  display  the  linear  correlation 
between  RNA  concentration  and  fluorescence.  Ribosomal  RNA  was 
provided at 100pg/ml and diluted to 2pg/ml using 10pl of standard RNA in 
490pl TE buffer.
50The following solutions were then prepared:
| Vol of 2pg/ml |  Vol |  1:200 |  Concentration
|  RNAftil) |   of TE (pi) |  Ribogreen of  RNA
*   j  '   j  ~
I  agent
j  ! (ng/ml)
160 I 40 | 200 800
120 |  80 |  200 600
100 |  100 | 200 500
80 |  120 | 200 400
60 |  140 j  200 300
40 |   160 | 200 200
20 |  180 | 200 100
10 |  190 | 200 50
0 |   200 | 200 O(blank)
At each concentration,  100pl of solution was pipetted  into 3 consecutive 
wells  within  the  above  mentioned  96  well  plate  and  incubated  for  2-5 
minutes.
The 96 well plate containing the sample RNA and the standard curve was 
then  placed  in  a  fluorescence  microplate  reader and  measured  at 450- 
520 nm. The instrument’s gain was set so that the sample containing the 
highest  RNA  concentration  yielded  a  fluorescence  intensity  near to  the 
maximum.  This  ensured  that  all  sample  readings  remained  in  the 
detection range.
First,  the average of all three fluorescence values was calculated  for all 
samples.  Then  the  fluorescence  value  of  the  blank  reagent  was 
subtracted from each of these values. For the standard curve graph, this
51value was then plotted as a scatter graph against the RNA concentrations 
(Fig 2). From the plots on the graph a trend line was then added and from 
this the y-intercept value was calculated.
Figure  2.  Representative  standard  curve  of  sample  RNA  from  a 
breast cancer (each value is the mean of three fluorescence values) 
quantified using the Ribogreen assay. Y intercept value is 14.3 and 
R value >0.99.
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522.5.1.4 Calculation of RNA from standard curve
The mean of three fluorescence values were calculated  per sample.  The 
fluorescence  value  of the  blank  reagent  was  then  subtracted  from  this 
value.  This  value  was then  used  to  calculate  the  concentration  of  RNA 
according  to  the  dilution  factor  used  in  making  up  the  RNA/TE  and 
ribogreen solutions;
2.5.1.4.1 Tumour
[Fluorescence/y-intercept]  x  [400/2]  x [400/200]  =  concentration  of RNA 
ng/ml.
2.5.1.4.2 Normal
[Fluorescence/y-intercept]  x  [300/5]  x  [400/200]  =  concentration  of  RNA 
ng/ml.
2.5.2. Agilent Bioanalyzer
The  RNA 6000  Nano LabChip  Kit simultaneously measures quantity and 
quality of messenger or total  RNA (Fig  3).  It comprises a  lab chip and  a 
bioanalyzer attached  to  a  PC.  Each  sample  is  injected  into  a  well  and 
then  moves  sequentially  from  its  well  to  a  central  separation 
microchannel, where it is separated electrophoretically. As the fragments 
move down the central separation channel, they separate by size and are 
detected by fluorescence and recorded by the bioanalyzer machine.
53Firstly,  samples were taken from  -80°C  storage  and  placed  on  ice.  The 
protocol recommends that all RNA samples should be heat denatured at 
70°C for 2 min,  however,  due to poor yield  of RNA this practice was  not 
continued.
The  Bioanalyzers electrodes were  cleaned  prior to  each  chip.  This was 
performed  using  350pl  RNase Zap followed  by  350pl  RNase-free water 
pipetted into an electrode cleaner and then into the bioanalyzer.
The gel was  prepared  by  pipetting  550pl  of RNA 6000  Nano gel  matrix 
into the top receptacle of a spin filter. The spin filter was then centrifuged 
at 4000  rpm for  10  minutes.  65pl  of filtered gel was then  pipetted  into a 
new,  autoclaved eppendorf.  1  pi of 6000  Nano dye concentrate was then 
added  to  the  65pl  of  filtered  gel  and  the  eppendorf  vortexed.  Proper 
mixing was inspected visually. The eppendorf was then centrifuged for 10 
minutes at 14 000 rpm.
The  chip  priming  station  base  plate  was  placed  in  position  ‘C’  and  an 
RNA  Nanochip  placed within  it.  9pl of the gel dye  mix was  pipetted  into 
the bottom of the well marked  ‘G.’ Care was taken to avoid bubbles. The 
plunger was then advanced to the 1ml level, the chip priming station was 
closed and the plunger held in place by the syringe clip. This remained in 
position for 30 seconds. After 30 seconds, the plunger was released and 
the  plunger  allowed  to  resume  its  usual  position.  After  5  seconds,  the 
plunger was  slowly  pulled  back  if  it  hadn’t  already  resumed  its  normal 
position. The priming station was then opened and 9pl of gel dye mix was 
pipetted into the two wells above the one marked ‘G.’
54Figure  3.  RNA  Nano  Labchip  in  chip  priming  station.  Each  chip 
analyzes  12  samples  simultaneously.  G  represents  the  well 
containing the gel-dye mix and # represents the well containing the 
ladder.
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• • • • 
• • • •
• • • •G
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Labchip
5pl of RNA 6000 Nano Marker was pipetted  into the well marker ‘ladder’ 
and then into each of the 12 wells consecutively.
552.5.2.1  Loading the ladder and samples
3pl  of RNA 6000  ladder was  pipetted  into an  autoclaved  eppendorf and 
denatured  at  70°C  for  2  minutes.  1pl  was  then  pipetted  into  the  well 
marked ‘ladder.’
1  pi of each of the samples to be analysed was then pipetted into each of 
the  sample  wells  labelled  1  to  12.  The  chip  was  then  placed  into  the 
vortex mixer and vortexed for 1  minute at set point (2400 rpm).
After  vortexing,  the  chip  was  then  placed  into  the  Agilent  2100 
Bioanalyzer.  The  lid  was  closed.  The  software  instructions  on  the 
accompanying  PC  were  then  followed;  the  correct  assay  selected,  the 
sample  wells  labelled  and  the  ‘start’  button  clicked  to  commence  the 
assay.  All  RNA  concentrations  were  then  collected  from  the  PC  at  the 
end of the assay.
562.7. Real time reverse transcriptase polymerase chain 
reaction (RT-PCR)
RT-PCR  is  a  sensitive,  in  vitro  method  used  to  detect  messenger  RNA 
(mRNA).  It  is  used  to  measure the  abundance  of specific  RNA or  DNA 
sequences  in  clinical  samples  and  may  also  be  used  to  screen  for 
mutations and single nucleotide polymorphisms.  The Taqman assay has 
been used to quantify transcription from individual cells (201) and paraffin 
embedded tissue (202).  It has wide ranging clinical applications and  has 
been  used  to  screen  serum  for  genetic  diseases  (203),  detect  the 
presence of viral and bacterial pathogens (204-207) and has been useful 
in the detection of erb-B2 transcription in breast cancer (208).
The technique  relies on  having  unique,  known  sequences of DNA either 
side  of  the  segment  to  be  amplified.  Short  DNA  oligonucleotides 
complementary to the flanking sequences are required and are known as 
primers.  DNA  may  be  heated  in  order to denature the  double  helix  and 
become  single  strands.  Upon  cooling,  double  stranded  DNA  reforms.  If 
an  excess  of  oligonucleotide  primers  complementary  to  the  sequences 
flanking the segment of interest are added, they will preferentially anneal 
to  the  segment  and  with  the  addition  of a  DNA  polymerase  enzyme,  a 
second strand complementary to this segment will be produced. The DNA 
polymerase of the thermophile algae Thermus aquaticus (Taq.)  is stable 
at  the  temperatures  required  to  cause  dissociation  of  double  stranded 
DNA  (209).  Use  of Taq  polymerase  allows  a  rapidly  repeating  cycle  of 
denaturation,  primer annealing  and  sequence  extension  to  occur and  is 
known  as  a  polymerase  chain  reaction  (PCR).  It  is  a  process  that was 
first  reported  in  1985  (210)  and  has  since  been  modified  to  incorporate 
Taq polymerase and an automated thermocycler (211).
57The  PCR  reaction amplifies  DNA.  mRNA  may be  reverse transcribed  in 
order to form complementary DNA (cDNA)  using a reverse transcriptase 
(RT) enzyme.  RT enzymes were originally derived from  retroviruses and 
are  now  manufactured  from  cloned  viral  genes.  Using  this  technique,  it 
possible to rapidly detect very small amounts of mRNA.
The first step in the assay is the enzymatic conversion of RNA to a single­
stranded cDNA template.  This is followed  by exponential amplification  in 
a  PCR  reaction  (Fig  4).  Dedicated  RNA  and  DNA  dependent  DNA 
polymerases may be used in single or separate reactions. This allows for 
the customisation of individual RT-PCR assays. Seperation of the RT and 
PCR steps allows a stable library of cDNA to be generated which may be 
stored  for  long  periods,  alternatively  a  single  polymerase which  acts  as 
both  an  RNA  and  DNA-dependent  DNA  polymerase  may  be  used  in  a 
single reaction thereby minimising error and risk of contamination.
2.7.1  Reverse transcription
Two  commonly  used  reverse  transcriptases  (RTs)  are  avian 
myeloblastosis  virus  reverse  transcriptase  (AMV-RT)  and  Moloney 
murine  leukaemia  virus  reverse  transcriptase  (MMLV-RT).  RNA 
transcripts  may  have  significant  secondary  structure  that  affects  the 
ability  of  the  RNA-dependent  DNA  polymerase  (RT)  to  generate 
transcripts  (212) and  may also affect  RT-PCR quantification. AMV-RT  is 
the  more  robust  RT,  retains  significant  polymerisation  up  to  55°C  and 
may  also  eliminate  any  problems  associated  with  RNA  secondary 
structure.  MMLV-RT,  however,  has  significantly  less  RNAse  H  activity 
which can interfere with the synthesis of long amplicons (213;214).
The  RT  step  may  be  primed  by  specific  primers,  random  hexamers  or 
oligo-dT primers. Use of random hexamers and oligo-dT primers can
58maximise the number of mRNA molecules that may be analysed from  a 
very  small  sample  of  RNA.  mRNA  specific  primers  were  used  for  the 
purposes  of  this  research,  however,  since  they  decrease  background 
priming  and  use  of  random  hexamers  can  overestimate  mRNA  copy 
numbers up to 19-fold (215).
59Figure  4.  PCR  reaction.  The  graph  demonstrates  product 
accumulation  during  the  exponential  and  plateau  phases  of  the 
reaction (log scale).
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602.7.2 The Polymerase Chain Reaction
A variety of thermostable DNA-dependent polymerases are available and 
differ  in  their  processivity,  thermal  stability,  fidelity  and  ability  to  read 
modified  triphosphates  such  as  deoxyuridine  and  deoxyinosine  in  the 
template strand (216;217).
The  most commonly  used  enzyme,  Taq  DNA  polymerase was  used  for 
the purpose of this research.  It has an oligonucleotide which is labelled at 
one end (5') with a fluorescent group and a quencher at its 3' end (Fig 5). 
It has a 5’-3’ nuclease activity but lacks a 3’-5’ proofreading exonuclease 
activity.
The labelled oligonucleotide and  primers were added to the  PCR assay. 
When  the  fluorescent  and  quenching  groups  are  close  together,  the 
emissions from the  reporter dye are absorbed  by the quencher dye and 
so the fluorescent emission is low. As the DNA is amplified, an increasing 
amount of oligonucleotide probe hybridises to the denatured DNA. During 
the extension phase of the  PCR cycle,  the 5-3' exonuclease activity of 
polymerase  cleaves the fluorophore from  the  probe.  As  the fluorophore 
moves  away  from  the  quencher,  there  is  an  increase  in  fluorescence. 
This is measured in proportion to the amount of DNA synthesized during 
the  PCR.  The  Stratagene  Mx4000,  as  used  in  this  study,  contains 
photomultiplier tubes in order to detect the fluorescence.
2.7.3 One-enzyme RT-PCR
The one enzyme system  is  useful where target  RNA contains extensive 
secondary  structure.  It  utilises  Thermus  thermophilus  (Tth)  polymerase 
which  is  a  DNA  polymerase  with  intrinsic  RT  but  no  Rnase  H  activity 
(218). This technique is particularly useful in reducing
61the  amount  of  hands-on  time  in  the  experimental  set  up  and  therefore 
minimises the  potential  contamination  of reaction  mixtures.  A study  has 
also  shown  that  RT-PCR  reactions  using  Tth  polymerase  may  be  more 
robust and  resistant to inhibitors  (219).  The drawbacks of this technique 
are that it is not as sensitive as the two-enzyme technique (220;221),the 
presence  of  Mn2+  ions  reduces  the  fidelity  of  nucleotide  incorporation
(222), Tth polymerase lacks a 3’-5’ exonuclease proofreading activity and 
first strand  synthesis  must  be  initiated  from  specific  rather than  random 
primers.
62Figure  5.  Polymerase  chain  reaction  using  Taqman  technology.  I: 
oligo  labelled  with  fluorescent  group,  II:  polymerase  cleaves  the 
fluorophore  from  probe,  III:  probe  fluoresces  as  DNA  polymerase 
seperates fluorophore from quencher.
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632.7.4 Instrument
The Mx4000™ real-time multiplex quantitative PCR system was used for 
this  study  as  it  accurately  quantifies  mRNA.  It  has  a  high  specification 
and  is easy to use.  It is a fluorescence based  kinetic technique that uses 
a  halogen  lamp  in  order  to  excite  fluorescence.  It  also  contains  an 
integrated  personal  computer  that  operates  independently  from  the 
instrument’s  embedded  microprocessor  which  is  useful  in  protecting 
against loss of data.
All  PCR  was  performed  using  the  MX4000  Multiplex  QPCR  System. 
Samples  were  prepared  in  a  96  well  microplate,  which  consisted  of  12 
strips  of  8  wells.  The  strips  were  then  placed  in  the  thermal  cycler. 
Amplification  and  detection  occur  in  the  same  tube  thereby  minimising 
handling of samples (‘one step’ technique). The wells are cone shaped to 
improve  temperature  conductivity.  The  light  source  of the  Mx4000  is  a 
quartz,  tungsten  halogen  lamp.  It excites  a wide variety of fluorophores. 
Light from the halogen  lamp  is directed  into the 4 fibre optic illumination 
paths.
Target  sequences were  amplified  and  detected  in  the  same  instrument 
and  the  rate  of  accumulation  of  amplified  DNA  was  measured  by  the 
machine  over  the  course  of  the  PCR  assay.  The  greater  the 
concentration  of  target  sequences,  the  fewer  the  number  of  cycles 
required  to  achieve  a  yield  of  amplified  product.  The  concentration  of 
target sequences may be expressed  as the fractional  cycle  number (Ct) 
required  to  achieve  a threshold  of amplification.  Ct may then  be  plotted 
against the log of the copy number to give a standard curve.  This graph 
may then be used to quantify target sequences in unknown samples.
Fluorescence emission is collected from each of the QPCR samples as a 
result of light from the fibre optic illumination paths. The emission is
64collected  by  fibre  optics,  filtered  spectrally  and  detected  by  4 
photomultiplier  tubes  (PMT).  Each  PMT  has  an  individual  gain  that 
automatically adjusts to the specific signal of a given dye.
The emission data is collected every few seconds and the data analysed 
by a software package on a nearby connected computer.
2.7.5  Optimisation
2.7.5.1  One step RT-PCR
The Brilliant™ plus single-step quantitative RT-PCR core reagent kit was 
used  for  all  RT-PCR  assays.  The  single-step  technique  is  useful  for 
performing cDNA synthesis and PCR amplification in one tube and using 
one  buffer.  This  permits  the  RT  reaction  to  be  carried  out at  increased 
temperatures using primers and significantly higher melting temperatures, 
while  reducing  both  hands  on  time  and  the  likelihood  of  introducing 
contaminants into reaction mixtures.
The kit also includes Stratascript™ reverse transcriptase which is a novel 
Moloney  murine  leukaemia  virus  reverse  transcriptase  (MMLV-RT) 
without any RNase H activity. This mutant of MMLV-RT is able to produce 
larger  yields  of  full  length  cDNA  transcripts  than  wild  type  MMLV-RT 
which  has  substantial  RNase  H  activity.  RNase  H  has  a  highly 
undesirable  degradative  activity  which  can  affect  the  reverse 
transcriptase function.
Surestart™  Taq  DNA  polymerase  is  used  as  part  of  the  single-step 
technique.  It  is  a  modification  of Taq2000™  DNA  polymerase  with  hot 
start  capability.  Surestart™  Taq  is  able  to  reduce  background  and 
increase amplification of desired PCR products.
65The main drawback of this technique is that it may not be as sensitive as 
the two-enzyme technique (220;221).
2.7.5.2  Primers and probes
The  probes  used  in  this  study  included  IGFBP-3,  IGF-I,  VEGF  189 
(isoform associated with liver metastases),  COX-2, VDR,  1-a-OHase and 
24  OHase.  They  were  newly  designed  using  Primer  Express  software 
and are shown in Table 1.
Taqman  probes  are  linear  with  the  fluorophore  at  the  5'  end  and  the 
quencher  either  at  the  3'  end  or  internal.  If  the  probe  is  intact,  no 
fluorescence is emitted from the fluorophore. During the annealing phase, 
the primers and probe hybridise with the target. The DNA polymerase 
then  displaces  the  probe  and  the  5'  nuclease  activity  of  the  DNA 
polymerase  separates  the  fluorophore  from  the  quencher.  During  each 
PCR  cycle,  fluorescence  may then  be  detected  as  it  accumulates.  The 
probes should  have a melting temperature of 7-10°C  higher than that of 
the  primers.  The  ideal  concentration  should  be  determined  empirically, 
ideally being the lowest concentration which  results in the lowest Ct with 
an adequate fluorescence.
Probe  concentration  is  usually  in  the  100nM  range  and  they  must 
compete for  binding  to  their target  with  the  amplification  primers  which 
are  present  in  greater  concentrations.  As  amplification  primers  are 
extended  as  soon  as  they  bind  to  their targets,  the  hybridisation  target 
sequence  is rapidly masked with newly synthesized  DNA. Therefore,  the 
melting  temperature  (Tm )  of  the  probe  must  be  significantly  greater 
(approximately  10°C) than that of primers,  to ensure that they  hybridise 
before the primers.  Most probes used here were approximately 30 bases 
in  length  with  a  G/C  content of approximately  50%.  This  ensures  good 
specificity and a Tm  high enough to be useful under PCR conditions.
66Primers  should  bind  to  separate  exons  to  avoid  false  positive  results 
arising  from  amplification  of  contaminating  genomic  DNA.  RNAse-free 
DNAse  was  used  in  the  purification  of  RNA  preparations  as  the 
intron/extron  boundaries  were  unknown.  Primer  selection  is  based  on 
estimated  melting  temperatures  (Tm ),  the  desire for small  amplicon  size 
and location of the probe. They must be designed to exact specifications 
and  the  Taqman  technology  provides  its  own  primer  and  probe  design 
programme known as Primer Express.
The  optimal  concentration  of upstream  and  downstream  primers  is  also 
the  lowest concentration which  results in the lowest Ct with an adequate 
fluorescence.  When  used  with  Taqman  probe,  the  primer  concentration 
may  be  varied  between  50  to  300  nM  and  should  be  determined 
empirically.  Too  great  a  primer  concentration  may  result  in  mispriming 
and accumulation of non-specific product. Too low a primer concentration 
is less problematic for real-time assays as target copy numbers will have 
been calculated well before the primer supply is used up.
The  optimal  length  for  single  stranded  primers  is  approximately  15-20 
bases,  the  G/C  content should  be between 20-70% and  their Tm  should 
not differ by more than  1-2°C.  The minimum Tm  should  be 58°C and the 
maximum  should  be  60°C.  PCR  primers  were  designed  with  similar 
annealing temperatures for all targets to be amplified.
67Table  1.  Table  of  primer  and  probe  sequences.  Forward  (F)  and 
reverse (R) primers and Taqman probes (P) used in RT-PCR.
Target  Primer/  Sequence (5’ -  3’)
gene  ' Taqman
__________ probe  ___________________________________________
IGFBP-3  F  -AGA ACA GAT ACC CAG AAC TTC TTC-
R  -CGC CCT CCG ACT GCT G-
P  TTT TAT TTC AAC AAG CCC ACA GGG TAT-
  GGC
IGF-I  F  -CTT CAG TTC GTG TGT GGA GAC AG-
R  -CGC CCT CCG ACT GCT G-
P  -TTT TAT TTC AAC AAG CCC ACA GGG-
TAT GGC-
VEGF  F  -TGT GAA TGC AGACCA AAG AAA GA-
189  R  -CGT TTT TGC CCC TTT CCC-
P  -AGA GCA AGA CAA GAA AAT CCC TGT-
GGG C-
COX-2  F    -GAA TCA TTC ACC AGG CAA ATT G-
R  -TTT CTG TAC TGC GGG TGG AAC-
P  -TTC CTA CCA CCA GCA ACC CTG CCA-
VDR  F  ;   -ATC TGC ATC GTC TCC CCA  GAT-
R  -AGC GGA TGT ACG TCT GCA GTG-
P  -TGA TTG AGG CCA TCC AGG ACC GC-
laOHase  F  -GCT ATT GGC GGG AGT GGA C-
R  -GCC GGG AGA GCT CAT ACA GA-
P  -CCC AAG AGA GCG TGT TGG ACA CCG-
24 OHase  F  -TCC TTT GGG TAA AGC ATA TTC ACC-
R  -GCC TGT CTG AAA GAA TCT ATG AGG-
P  -AAC TGT TGC CTT GTC AAG AGT CCG
682.7.5.3 Magnesium chloride
Magnesium  chloride concentration  requires  strict control  as  it can  affect 
the  specificity  of  the  PCR  primers  and  probe  hybridisation.  The  ideal 
concentration  is  that  which  results  in  the  lowest  Ct  and  the  highest 
fluorescence  at  a  given  target  concentration.  The  MgCfe  concentration 
may  be  titrated  from  2-6mM  with  increments  of  0.5  mM;  in  this  case, 
MgCb concentration was 3mM.
In  addition,  MgCI2  can  increase  the  melting  temperature  (Tm )  of double 
stranded  DNA  and  forms  soluble  complexes  with  dNTPs  which  can 
produce  the  actual  substrate  that  the  polymerase  recognises.  High 
concentrations of dNTPs therefore interfere with  polymerase activity and 
affect primer annealing by reducing free MgCfe.
2.7.5.4 Internal reference dye
A passive reference dye was used to provide a stable baseline to which 
the samples were normalised. The dye provided was diluted to 1:200 and 
a fresh solution made up for each assay.
2.7.5.5 Threshold cycle (Ct)
With  every  PCR  assay,  fluorescence  values  are  recorded  during  each 
cycle  and  represent the  amount of product amplified  to that  point  in  the 
amplification  reaction.  The  greater the  RNA template  at the  start of the 
reaction, the fewer the number of cycles taken to reach the point in which 
the  fluorescent  signal  is  statistically  higher  than  the  background  value
(223).  This  point  is  referred  to  as  the  Ct and  always  occurs  during  the 
exponential phase of amplification.
69The  reporter  signal  is  normalised  to  the  fluorescence  of  an  internal 
reference dye to  allow for corrections  in  fluorescent fluctuations  caused 
by  changes  in  concentration  or  volume,  and  a  Ct  value  is  reported  for 
each sample. This value may then be translated into a quantitative result 
by constructing a standard curve.
2.7 6 PCR Reaction and conditions
The Brilliant™ plus single-step quantitative RT-PCR core reagent kit was 
taken from storage at -80°C and defrosted on ice. The reference dye was 
diluted  to  a  solution  of  1:200  with  DEPC  water.  Each  experimental 
reaction was made up to a volume of 25pl per sample. Each reaction was 
performed in duplicate, therefore the final volume per sample was 50pl.
The following  reagents  were then  pipetted,  in  order,  into  an  autoclaved 
eppendorf (a master mix for all samples was made up at the beginning of 
an experiment to reduce pipetting error);
2.5pl of 10x core RT-PCR buffer
1.5pl of 50nM magnesium chloride
2pl of dNTP mix
1.2pl of IGFBP-3 primer
0.25pl of Stratascript reverse transcriptase
0.25pl of SureStart Taq DNA polymerase
0.38pl of diluted reference dye
0.4pl of IGFBP-3 probe
10.5pl of nuclease-free DEPC water (to make solution up to 25pl).
This  solution  was  then  placed  in  the  centrifuge  at  10,000rpm  for  5 
minutes.  46pl  of  the  mix  was  then  pipetted  into  each  individual 
microcentrifuge tube and 4pl of experimental RNA was added. For each
70assay,  2  positive  controls  (liver  RNA),  2  negative  controls  (water)  and 
approximately 6 amplicons (serially diluted) were run in parallel.
Each  one was then  mixed  by pipetting  up  and  down  and  the  pipette tip 
was discarded each time. The microcentrifuge tubes were then placed  in 
the  centrifuge  for  5  minutes  at  300  rpm.  25pl  of  each  experimental 
reaction  was  then  aliquotted  into  duplicate  microcentrifuge  tubes.  The 
optic  caps  were  then  carefully  and  firmly  positioned  onto  the 
microcentrifuge tubes. The tubes were then placed  into the centrifuge for 
a further 5 minutes at 300 rpm.
Taking  care  not to  disturb the  samples,  the  microcentrifuge tubes  were 
then  transfered  into  the thermal  plate.  The  reaction  and  thermal  profile 
were then set up using the software package on the connecting  PC. The 
thermal profile used for each PCR reaction is shown below (Fig 6).
The  data  was  collected  at each  ‘END’  point.  Using  the  software,  it was 
possible  to  determine  the  Ct  values  for  each  sample  (performed  in 
duplicate).
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Figure 6. Thermal reaction conditions for each PCR reaction. Stages 
1 and 2 = RT, stage 3 = PCR (45 cycles).
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722.7.7 Quantification
Quantification  of  mRNA  may  be  performed  by  quantitative  or  semi- 
quantitative  methods  (224).  Commonly,  semi-quantitative  methods  are 
employed by sampling the RT-PCR reaction mixture and dot-blot analysis 
(225)  which  are  not precise  and  laborious.  Quantitative techniques  may 
be competitive or non-competitive (226;227).
Non-competitive RT-PCR involves the co-amplification of the target with a 
second  RNA  molecule  under  reagent  concentrations  and  conditions  so 
that there is no competition  between target and standard  (228).  In these 
circumstances, quantification may be unreliable as the efficiencies of the 
RT and  PCR steps may vary.  Competitive quantification involves spiking 
into  the  RNA  samples  before  RT  of  known  amounts  of  RT-PCR 
amplifiable  competitors  that  should  be  synthetic  RNA  molecules.  The 
internal  standard  shares  the  same  primer  recognition  and  internal 
sequences  as  the  primary  target  and  so  competes  for  reagents.  Both 
should be amplified with the same efficiency as they are virtually identical 
and their amplicons may be distinguished  by the addition of a  restriction 
enzyme site to the standard (229) or by varying its size (230). A series of 
PCR tubes containing the target are spiked with serial dilutions of known 
copy numbers (107,  106,  105 etc) of the internal standard. The higher the 
concentration of the internal standard, the more likely the primers will bind 
and amplify it rather than the target. Gel electrophoresis may therefore be 
performed  and  a  comparison  can  be  made of ethidium  bromide  stained 
standard and target amplicons to allow target quantification  (231).  There 
is  still,  however,  approximately  10%  error and  this  method  may  still  not 
result  in  absolute  quantification  as differences  in  amplification  efficiency 
between target and competitor will remain undetected.
732.7.7.1 Normalisation
It  is  well  established  that  an  appropriate  standard  is  used  within  each 
PCR  experimental  assay.  The  accepted  method  is  to  amplify  a  cellular 
RNA  at  the  same  time  as  the  target,  which  serves  as  an  internal 
reference against which  other RNA may be normalised  (232).  The  ideal 
standard should be expressed at a constant level among different tissues, 
at all  stages of development and  should  be  unaffected  by experimental 
treatment (233). The problems with this method is that errors easily occur 
in the amount of starting  material  between samples.  There may also  be 
differences in the amount of RNA obtained from different tissue types e.g 
normal  and  malignant  tissue,  and  differences  also  exist when  samples 
have  been  taken  from  different  patients.  Therefore,  obtaining  an  ideal 
standard that accommodates these differences is an important part of the 
assay.
Three  commonly  used  RNAs  to  normalise  gene  expression  include  the 
mRNAs specifying the housekeeping genes glyceraldehyde-3-phosphate- 
dehydrogenase (GAPDH),  p-actin  and  ribosomal  RNAs  (rRNA).  GAPDH 
is  ubiquitously expressed  by  most tissues  and  its  expression  has  been 
shown  to  be  constant  at  different  times  throughout  experimental 
manipulation  (234;235).  Evidence  does  suggest,  however,  that  GAPDH 
concentrations vary greatly amongst  individuals  (236),  during  pregnancy 
(237), with developmental stage (238;239) and during the cell cycle (240). 
It has also been shown to be up regulated  in tumours and this variation, 
therefore, suggests that its use as a normal control may be inappropriate.
P-actin  is also moderately expressed  in  most cell types.  It is traditionally 
used  as an  internal  standard  in  PCR assays.  Several  studies,  however, 
have shown that transcription  levels may vary widely in  breast epithelial 
cell culture studies (241).  rRNAs constitute 85-90% of total cellular RNA 
are generated by a distinct polymerase (242) and their levels are less
74likely to vary under conditions that affect the expression of mRNAs (243). 
rRNA transcription can,  however,  be affected  by biological factors, drugs 
and  may  vary  amongst  individuals  (241).  It  is  also  expressed  at  much 
higher  levels  than  target  mRNAs  and  cannot  be  used  for  normalisation 
when  targets  have  been  enriched  for  mRNA  as  it  is  lost  during  mRNA 
purification.
There are obviously inherent problems associated with normalising to an 
internal  standard  and  with  comparing  copy  numbers  between  samples 
obtained from different individuals or tissues.  In this study, we normalised 
copy  numbers  relative  to  total  RNA  concentration.  Little  is  known, 
however,  about the total  RNA content per cell of different tissues in vivo 
or  how  this  may  vary  between  individuals  and  between  normal  and 
malignant  tissue.  Bustin  et  al  addressed  some  of  these  issues  by 
obtaining  blood  from  healthy  patients  and  counting  and  purifying 
nucleated  blood  cells.  RNA  content  was  quantitated  and  little  variation 
was  observed  in  amount  of  total  RNA  per  cell  thereby  confirming  the 
validity of this technique in comparing results between individuals (244).
RNA  concentration  was  determined  accurately  using  the  Agilent 
Bioanalyzer  and  also  confirmed  using  Ribogreen  quantitation  as 
described earlier.  Copy numbers of target genes were then  recorded  as 
copy number per pg total  RNA.  The drawbacks of this approach  include 
the fact that total  RNA may be  increased  in  highly proliferating cells and 
so  this  may  affect  the  accuracy  of  comparing  absolute  copy  numbers 
between  normal  and  malignant  tissue  (233).  In  order  to  compare  our 
normalisation  technique  with  the  standard  housekeeping  gene  method, 
GAPDH  mRNA  expression  was  measured  on  all  samples  according  to 
the PCR protocol.
752.7.7.2 Generation of standard curves
Standard  curves  were  constructed  with  each  experimental  reaction  in 
order to determine the absolute quantification of mRNA transcription. This 
method  allows  the  copy  number  per  cell  to  be  determined.  A  standard 
curve  was  constructed  for  each  amplicon  thereby  ensuring  accurate 
reverse transcription and  PCR amplification profiles(233). The amplicons 
were diluted serially as follows;  1010,  109,  108,  107,  106,  105,  104,  103,  102 
and  101   using  TE  buffer.  These samples were then  run  alongside each 
RT-PCR  assay  and  the  Ct  values  obtained  were  used  to  construct  an 
absolute  standard  curve  .  A  linear  graph  was  obtained  from  three 
independent  serial  dilutions  of  amplicon  and  assaying  each  dilution  in 
duplicate,  together with  positive  and  negative  controls.  This  allows  the 
copy  number per cell  to  be  determined  from  absorbance.  The  dilutions 
were  made  over  the  range  of  copy  numbers  expected  from  the  target 
mRNA  expected  in  the  experimental  samples  in  order  to  maximise 
accuracy.
The  construction  of a  standard  curve  for each  target  amplicon  allows  a 
quantitative  method  for  detecting  differences  in  gene  expression. 
Differences may be detected in amplification efficiency and sensitivity.
762.8  Immunohistochemistry
2.8.1  Introduction to immunohistochemistry
Immunohistochemistry  allows  the  identification  and  localisation  of 
proteins  on  tissue  sections  using  antibodies  linked  to  enzymes  that 
produce colour changes  in  indicator dyes.  This  involves the binding  of a 
primary  antibody  to  the  antigen  and  secondly,  the  detection  and 
visualisation of the bound antibody by one of a variety of enzyme based 
chromogenic  systems.  The  type  of  chromogenic  substrate  depends  on 
the  type  of  enzyme  used  e.g  aminoethyl  carbazole  (AEC)  and 
diaminobenzidine (DAB) may be used with horseradish  peroxidase.  DAB 
substrate  has  high  sensitivity  and  produces  an  insoluble,  permanent 
brown precipitate which has a high contrast in photographs. Amplification 
of the staining may be achieved by using antibodies and enzymes which 
combine through  binding  proteins such  as the  avidin  biotin  system.  This 
system  essentially  involves three  steps;  primary  antibody,  biotin-labeled 
secondary  antibody  and  avidin-biotin-peroxidase  complex.  A  lattice-like 
complex  is  therefore  produced  which  is  attracted  to  the  sites  of  biotin- 
labeled antibody to give sensitive staining (245).
2.8.2 Tissues and its preparation
2.8.2.1  Tumour bank
Immunohistochemistry against IGFBP-3 (Table 2) was performed on 3pm 
sections  of  paraffin  embedded  blocks  of  24  paired  samples  of  breast 
tumour and adjacent normal tissue which had previously undergone RNA
77analysis. The avidin biotin complex (ABC) immunohistochemistry method 
was used (246).
Table  2.  Optimal  dilution  for  primary  BP-3  antibody  used  for 
immunohistochemistry.
Human tissue
Antibody against Type F P
IGFBP-3 Pab - 1:200
F = frozen tissue 
P = paraffin embedded tissue 
- = not tested
Pab = Polyclonal rabbit antibody (purified IgG from rabbit antiserum, does 
not recognise IGFBPs 1,2,4,5 or 6) (247,248).
782.8.3 Protocol for DAB staining
Tissues  were  prepared  using  standard  fixation  and  paraffin  embedding 
techniques  courtesy  of  the  Pathology  Department,  St  Bartholomew’s 
Hospital.  Paraffin sections were then dewaxed and  rehydrated according 
to the following standard  procedures.  For each specimen,  one slide was 
stained  as  per protocol and  one was  used  as a  negative control and  so 
was treated with just horse serum  and  no antibody.  Sections of paraffin 
embedded human liver were used as a positive control.
2.8.3.1 Standard dewaxing procedure
The slides were placed  into a metal  rack. The rack was then placed  in a 
glass  jar  containing  xylene  for  5min.  The  rack  was  then  placed  into 
another container of xylene  for a further 5  min.  The  samples were then 
rinsed  in  100%  absolute  alcohol  for  3  min,  then  in  separate  containers 
100% alcohol 3 min, 90% alcohol for 3 min, 70%, 3 min. The slides were 
not allowed to dry between any of the steps.
100ml  of  10x  citrate  buffer was  added  to  900ml  of distilled  water.  This 
solution  was  poured  into  a  microwaveable  container.  The  pH  was  then 
measured  and  HCI or NaOH was then added  as necessary to make the 
solution have a pH of 6.
2.8.3.2 Antigen retrieval
After  the  dewaxing  procedure,  slides  were  placed  into  a  glass  jar 
containing 3% H2O2 in methanol (270ml methanol and 30ml H2O2) for 10 
minutes.  In  a  microwavable  container  100ml  citrate  buffer  (pH  6.0)  was 
heated in the microwave for 12 minutes. Slides were transferred into a
79plastic  rack,  rinsed  in water then  placed  into the  hot citrate  buffer.  The 
microwavable container was then closed and heated in the microwave for 
a further 10 minutes.
After  4  minutes  in  the  microwave,  the  container  was  removed  and  the 
plastic rack of slides were placed under running water. Water was poured 
into a metal tray.  Each slide was taken from the rack, excess water was 
drained off by blotting with paper and taking care not to disturb the tissue 
section.  The  margins  of the  tissue  section  were  then  marked  using  an 
Immedge  pen,  to  aid  viewing  of  the  small  section.  The  slide  was  then 
placed on the tray and the tissue section covered  in horse serum, taking 
care to use enough volume to completely cover the section. The tray was 
then left for 5 minutes at room temperature.
2.8.3.3  Primary antibody incubation
The anti-IGFBP-3 antibody was then made up into a solution of 1   in 200 
using  phosphate  buffer saline  (PBS):  1pl  antibody plus 200pl  PBS.  The 
horse serum was drained from all slides except the negative controls. The 
remaining  samples were then  covered  fully  in  antibody solution  and  the 
lid placed on the metal tray to provide a humidified atmosphere. The tray 
was then placed in the incubator at 42°C for 11 /4 hours.
2.8.3A Secondary antibody incubation
The secondary antibody solution was made up of 2.35ml of PBS,  150pl of 
horse  serum  and  50pl  of  biotinylated  secondary  antibody.  The  solution 
was then vortexed.
The tray was then  removed  from  the  incubator.  The  slides were  placed 
back  into  the  rack  and  then  into  a  glass jar  containing  PBS  for  2  x  5 
minutes to wash off excess antibody. The slides were then placed back
80onto the metal tray, the edges dried and each tissue section was covered 
fully with the secondary antibody solution.  The  lid  was then  placed  onto 
the tray and incubated at room temperature for 30 minutes.
2.8.3.5  Tertiary antibody incubation
The tertiary complex consisted  of HRP- avidin  and  biotin complex which 
binds to the secondary antibody. The solution was vortexed and prepared 
at least 30 min before use.
The slides were then removed from the tray and washed twice in PBS for 
5 min at a time.  Excess PBS was blotted off the slide using tissue paper, 
taking care to avoid tissue section. The slides were then placed  back on 
the  metal tray  and  each  tissue  section  was  covered  in  tertiary  solution. 
The tray was incubated at room temperature for 20 min.
After  incubation  with  the  tertiary  complex,  the  slides  were  placed  back 
into a rack and washed twice in PBS for 5 min. The slides were removed 
and a  liquid  DAB applied to each tissue section for 5 min. As soon as a 
brown colour develops, slides were washed in water.
Each slide was then counterstained by rinsing in Gills haematoxylin for 30 
sec followed by 1  % acid-alcohol for 1   sec. Slides were then rinsed under 
running  water for 2  min,  70%  alcohol  2  min,  90%  alcohol  2  min,  100% 
absolute alcohol for 2 min, in another absolute alcohol for 2 min, in xylene 
for 2 min and finally in another xylene for 2 min.
A coverslip was then quickly applied to each tissue section  using  Depex 
mounting  medium  and  the  slides  were  left  overnight  and  viewed  under 
the microscope the following day.
Sections of liver were used as a positive control in each run. The sections 
of normal breast and cancer were randomly mixed prior to staining.
81Specificity  was  confirmed  by  complete  absence  of  staining  by  pre­
incubation  of the  antibody with  IGFBP-3  ligand  (Gropep,  Australia)  (Fig
7).
Figure  7.  IGFBP-3  blocking  peptide  confirming  specificity  using 
sections of liver (1  in 200 dilution).
Negative control  Positive control  Blocking peptide
822.8.4 Quantification of Immunohistochemical Staining
Sections  of  normal  and  malignant  breast  tissue  were  randomly  mixed 
prior to staining. Assessment was performed in a blinded manner on two 
separate occasions by a single investigator.  In order to quantify IGFBP-3 
protein expression,  a scoring system based on the  proportion of positive 
cells and  intensity of staining was employed.  This was scored as follows 
and a separate score determined for stromal and epithelial staining:
Proportion of positive staining cells:
No. Cells Score
<5% 1
5-50% 2
>50% 3
Intensity of staining of positive cells:
Intensity Score
0 1   (none)
+ 2 (weak)
++ 3 (moderate)
+++ 4 (strong)
The two scores were added together to give a  score out of 7.  Separate 
scores were calculated for epithelial and stromal staining. A score of 1-3 
was  classified  as  negative  and  a  score  of 4-7  was  positive.  These  two 
scores  were  combined  together  to  give  a  total  score  out  of  14:  1-6 
=negative  and  7-14  =  positive  with  a  subgroup  of  10-14  =  strongly 
positive.  The procedure was  repeated again without viewing the first set 
of results.
832.9  Serum IGF-I and IGFBP-3
2.9.1  Sample collection
5ml of blood was venesected from each patient undergoing breast cancer 
surgery  involved  in the  study.  Blood  was taken from  36  patients on  the 
day prior to  breast surgery  (pre-operative)  and  from  35  patients  up to 6 
months  after  surgery  (post-operative).  Of  the  post-operative  group, 
patients  were  classified  into  those  taking  Tamoxifen  (T)  and  those  not 
taking Tamoxifen (NT).
The  blood  was  collected  aseptically  into  glass  tubes  containing  no 
additives  and  care  was  taken  to  avoid  needlestick  injury.  All  samples 
were  centrifuged  at  10,000rpm  for  15  minutes  at  room  temperature. 
Serum was separated from red cells by pipetting and collected in a fresh, 
round bottomed eppendorf. These samples were frozen at -80°C.
2.9.2 Serum IGF-I
This  was  measured  on  all  samples  by  an  in-house  radioimmunoassay, 
courtesy  of  the  Growth  Factor  Lab,  St  Bartholomew’s  Hospital  (249). 
Total  IGF-I  was  measured  after the  samples  were  separated  from  their 
binding proteins by acetone extraction.
2.9.3 Serum IGFBP-3
Serum  IGFBP-3  was  measured  using  active  IGFBP-3  Enzyme-Linked 
Immunosorbent  Assay  Kit.  All  samples  and  reagents  were  brought  to 
room temperature before the assay.
84Serum  samples were thoroughly mixed  prior to use and diluted to  1:100 
in  the  standard  dilutent  containing  Ong/ml  IGFBP-3  (in  a  protein  based 
buffer). Wells to be used were then marked on the microtitration strips, all 
samples were performed in duplicate. 25pl of each standard (2, 5, 20,  50 
and  100 ng/ml IGFBP-3),  control (samples of high and  low concentration 
IGFBP-3) and the unknown diluted samples were pipetted into each well. 
50pl  of assay buffer was then  added  to each well.  The wells were then 
placed in a microplate shaker at approximately 700 rpm, for 2hours (room 
temperature).  Each well was then  aspirated  and  washed five times with 
wash  solution.  The  microplate  was  then  inverted  and  blotted  dry  on 
absorbent material.
The  conjugate  solution  was  then  prepared  by  diluting  the  antibody- 
enzyme conjugate concentrate at a  ratio of 1:50  using the assay buffer. 
100pl  of this solution was then  added  to each well.  The  microplate was 
then shaken again at 700 rpm for 1   hour at room temperature.  Each well 
was then washed and aspirated a further five times followed  by inverting 
the plate and blotting dry.
100pl  of  tetramethylbenzidine  (TMB)  solution  was  then  added  to  each 
well  and  the  plate  then  re-shaken  at  700  rpm  for  10  minutes  at  room 
temperature.  100pl  of  stopping  solution  (0.2M  sulfuric  acid)  was  then 
added  to  each  well.  The  microplate  was  then  placed  in  a  microplate 
reader  and  absorbance  measured  at  450nm  (background  absorbance 
was set to 600nm).
852.10  In Vitro Tissue explant culture
2.10.1 Tissue collection
Fresh breast tissue samples were obtained from 6 breast cancer patients 
undergoing  surgery.  As  before,  full  informed  consent  was  obtained 
(Appendix A). All cancers were clinically palpable (>1-2cm in size).
2.10.2 Tissue processing
Each breast specimen was transported from surgery to the Department of 
Pathology  immediately  after removal  from  the  body.  The  specimen  was 
orientated,  inked and a sample of tumour (T) and adjacent normal tissue 
(AN)  excised  by the  Pathologist.  AN was  macroscopically  normal tissue 
taken  as  far  away  from  the  T  as  possible.  Care  was  taken  when 
dissecting  normal  tissue  to  obtain  glandular tissue  and  avoid  fat.  Each 
sample was then  placed  into  seperate  sterile  cryogenic vials  containing 
serum free DMEM and transported quickly to the laboratory.
2.10.2.1  Preparation of the medium
The stock solution used for all experiments contained ; 500ml Dulbecco's 
Modified  Eagle's  Medium  (DMEM),  1g  of bovine  serum  albumin,  5ml  of 
penicillin/streptomycin  mix  (10mg/ml)  and  0.5ml  of  amphotericin 
(0.25pg/ml). All were added to the medium via a sterile filter and stored at 
-4°C.
86In order to carry out this culture technique, large tumours were necessary 
to  provide  enough  tissue.  The  size  of  the  specimen  therefore  was  a 
limiting factor.
2.10.2.2 Preparation of IGFBP-3
The  optimum  concentration  of  IGFBP-3  for  apoptotic  effects  was 
recommended at 200ng/ml.  IGFBP-3 was prepared from 15pg lyophilized 
form. It was diluted in 75pl of 1mM hydrogen chloride (HCL) to make 75pl 
of 200pg/ml BP-3. This was aliquoted into 12pl vials to avoid freeze thaw 
cycles and stored at -80°C.
2.10.2.3 Preparation of Doxorubicin
For physiologically relevant cytotoxic effects in cell culture conditions, the 
recommended concentration of doxorubicin was 0.3pM.  Doxorubicin was 
prepared from lyophilized form (MW=580).  1.16mg was carefully weighed 
and  mixed thoroughly with  20ml  medium to make a  lO^M  solution.  This 
solution  was  then  aliquoted  into  1.2ml  vials  and  stored  at  -80°C.  For 
experimental  use,  one vial was thawed and vortexed.  1ml was added to 
9ml of medium and vortexed to make a 10'5M solution.  1ml of this solution 
was then added to a further 9ml of medium and vortexed to make a 10^M 
solution.  150pl  of this  solution  was  then  added  to  350ul  of  medium  in 
order to make a 0.3pM solution,
872.10.3 Culture protocol
All  experiments  were  carried  out  in  a  class  2  containment  hood.  The 
tissue was  dissected  into  1-2mg  pieces  using  sterile  scalpels  and  petri 
dishes.  Each  piece  was  washed  in  a  separate  petri  dish  containing 
medium  prior  to  incubation  in  a  24  well  plate  at  37°C  5%  CO2  in  the 
following conditions;  medium,  200ng  IGFBP-3,  0.3mM doxorubicin and  a 
combination of 200ng IGFBP-3 and 0.3mM doxorubicin. The total volume 
in  each  well  was  500pl.  Doxorubicin  is  a  cytotoxic  agent  used  in  the 
treatment  of  breast  cancer.  It  causes  apoptosis  by  interfering  with 
microtubule formation. Explants were removed after 5 min, 24, 48 and 72 
hours of incubation. The explants were immediately snap frozen  in  liquid 
nitrogen  and  stored  at  -80°C.  The  viability  of  the  explant  system  was 
assessed  by measuring  LDH  release and  performing  MTS assay on the 
medium at each time point.
2.10.4  Assessment of tissue explant system viability
2.10.4.1  MTS Cell proliferation assay
The  MTS  Cell  Proliferation  Assay  was  used  to  assess  viability  of  the 
tissue explant technique.  Cell viability can be reflected by the integrity of 
the mitochondria. When the MTS reagent (a tetrazolium salt) is applied to 
living  cells,  it  is  converted  to  a  colour  compound  (formazan)  with  the 
emission of light at 490nm. The assay is based upon the reduction of the 
tetrazolium  salt [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)- 
2-(4-sulfophenyl)-2H-tetrazolium]  (MTS).  NADPH/NADH  produced  by 
dehydrogenase enzymes in metabolically active cells bioreduce the MTS 
tetrazolium  compound.  This  bioreduction  results  in  a  coloured  product, 
soluble in tissue culture medium. Absorbance readings of medium and
88the MTS dye were taken to determine the number of metabolically active 
cells in the breast tissue samples.
2.10.4.1  1 Protocol
A  solution  of  5  mg/ml  MTS  dissolved  in  PBS  was  made  up  and  filter 
sterilised.  100pl  of MTS dye was added  to the tissue after incubation  in 
500pl  media.  All  experiments were carried  out in  duplicate,  in  a  24 well 
plate.  The  plate  was  then  incubated  in  a  CO2  incubator  at  37°C  for  4 
hours.  After  4  hours,  100pl  of  the  media/dye  mix  was  taken  from  the 
sample  and  control  wells  and  an  absorbance  reading  at  490nM 
wavelength was performed.
2.10.4.1.2 Controls
For each time frame, there was a corresponding well with medium only + 
explant  and  dye.  This  positive  control  was  subjected  to  the  same 
conditions as the other, experimental wells and was assayed with MTS in 
the same way.
Triton-X  results  in  maximum  disruption  of plasma  membranes  and  was 
used as a negative contol.  To make up a solution of 2% Triton,  200pl of 
triton  100 was  added  to  9.8ml  medium  and  mixed  thoroughly.  500pl  of 
this  solution  was  then  added  to  a  well  containing  an  explant  and 
incubated as protocol.
2.10.4.1.3 Variability of the MTS assay
In  order to  look at the  effect of the  different tissue weights  on  the  MTS 
absorbance,  normal  and  malignant  breast  tissue  was  dissected  into 
approximately 20 explants of visibly different sizes. These explants were
89placed  into  a  24 well  plate.  MTS  dye  and  medium  were added  to each 
sample well including 2 control wells. After 4 hours of incubation at 37°C 
5%  CO2,  the  plate  was  removed  from  incubation.  The  tissue  samples 
were  removed,  blotted  dry  using  absorbant  paper  and  weighed.  The 
absorbances  were  read  and  MTS  values  adjusted  according  to  their 
weights.
2.10.4.2  LDH Cytoxicity detection
The  lactate dehydrogenase  (LDH)  assay  is  another colorimetric method 
which was used to evaluate cell death. It is based on the measurement of 
cytoplasmic enzyme  activity that  is  released  by  damaged  cells  into  cell 
culture medium  upon damage to cellular plasma membranes.  In contrast 
to  the  MTS  assay  which  measures  metabolic  activity,  this  assay 
quantitates cell death and  lysis.  The amount of enzyme activity detected 
in the culture medium correlates to the proportion of lysed  or dead cells 
(250).
A two  step  enzymatic  reaction  occurs when  LDH  containing  tissue  free 
media  is incubated with the reaction mixture provided  in the kit.  The first 
reaction  involves  reduction  of  NAD+  to  NADH/H+  by  LDH  catalysed 
conversion of lactate to pyruvate.  In the second step,  a catalyst from the 
reaction  mixture transfers  H/H+ from  NADH/H+ to tertrazolium  salt  INT. 
This transfer results  in the  reduction  of INT (yellow) to formazoan  (red). 
The amount of red colour produced, therefore, correlates with the amount 
of  formazoan  formed  and  hence  the  amount  of  dead  /membrane 
damaged  cells  in  the  medium.  Absorbance  may  then  be  read 
spectrophotometrically.
This assay was performed on the culture medium for all six experiments.
902.10.4.2.1 Protocol
100|jl of assay medium was added into duplicate wells of a 96 well plate. 
The  reaction  mixture was  prepared  immediately  prior to  the  assay:  mix 
250pl of bottle  1   (catalyst) with  11.25ml  of bottle 2  (INT dye solution).  It 
was mixed thoroughly.  100pl of reaction mixture was then added to each 
well  and  incubated for 30min  at 20-25°C.  The  plate was protected  from 
light during this time. The 96 well plate was then placed into a microplate 
reader and the absorbance was read at 490nm.
2.10.4.2.2 Controls
A  negative  control  of  medium  only  was  used  for  each  time  frame.  A 
positive  control  of 2%  Triton  was  also  used  for each  time frame.  Triton 
was used to ensure maximum LDH release for the purposes of a positive 
control.
2.10.4.2.3 Variability of the LDH assay
In order to assess the  inter-assay variability of the LDH  assay,  duplicate 
sets of samples were used, where tissue availability allowed. Also,  intra- 
assay variability was assessed by assaying each well 12 times.
2.10.5  Assessment of apoptosis
2.10.5.1  Introduction to apoptosis
Apoptosis is a mode of cell death used by multicellular organisms to
91eradicate cells in diverse physiological and  pathological settings (251).  It 
is  a  normal  component  of  the  development  and  health  of  multicellular 
organisms  (otherwise  known  as  programmed  cell  death).  It  is 
characterised  by  cell  shrinkage,  chromatin  compaction,  plasma 
membrane  blebbing  and  collapse  of the  cell  into  small  intact fragments 
known  as apoptotic bodies that are  removed  by  phagocytes  (252).  This 
occurs  in  response  to  a  variety  of  stimuli  and  does  so  in  a  controlled, 
regulated fashion. It is therefore distinct from cell death which occurs as a 
result  of  necrosis  whereby  uncontrolled  cell  death  occurs  and  leads  to 
lysis of cells, inflammatory responses and potentially serious sequelae.
2.10.5.2  Caspases
Caspases are a family of proteins that are typically activated  in the early 
stages  of apoptosis.  They  are  a  group  of  cysteine  proteases  that  exist 
within  the  cell  as  inactive  precursors  (or  zymogens).  So  far  14 
mammalian caspases have been identified, some of which are involved in 
the regulation of apoptosis, the rest are involved in the processing of pro- 
inflammatory  cytokines  (253;254).  They  may  be  cleaved  to  form  active 
enzymes  following  the  induction  of  apoptosis.  Once  activated,  they 
breakdown  key  cellular  substrates  which  are  necessary  for  normal 
cellular  function  including  structural  proteins  in  the  cytoskeleton  and 
nuclear  proteins  such  as  DNA  repair enzymes.  They  may  also  activate 
DNases which cleave the DNA in the nucleus. As a result, morphological 
changes occur.
Apoptosis  may  be  induced  by  activation  of  death  receptors.  Death 
receptors  are  cell  surface  receptors  that  transmit  apoptosis  signals 
initiated by specific ligands. They play an important role in apoptosis and 
can  activate  caspases  within  seconds  of  ligand  binding  and  so  this 
mechanism  is  very  rapid.  They  belong  to  the  tumour  necrosis  factor 
(TNF)  gene  superfamily and  generally  can  have  several functions  other 
than initiating apoptosis. Death receptors include Fas, TNF receptor-1
92and  TRAIL  (TNF-related  apoptosis  inducing  ligand)  receptors  DR4  and 
DR5.  Other  mechanisms  of  inducing  apoptosis  include  cellular  stress 
such as cytotoxic drugs, DNA damage and cytotoxic T lymphocytes which 
promote  apoptosis  by  delivering  a  serine  protease  (granzyme  B)  which 
has a similar substrate specificity to caspases (Fig 8).
Induction  of apoptosis via death  receptors  results  in the  activation  of an 
initiator caspase such as caspase 8 or caspase 10. These caspases can 
then activate other caspases in a cascade. This cascade eventually leads 
to  the  activation  of  the  effector  caspases,  such  as  caspase  3  and 
caspase 6.  These caspases are  responsible for the cleavage of the key 
cellular proteins that leads to the typical morphological changes observed 
in  cells  undergoing  apoptosis.  Molecules  that  regulate  caspases 
activation therefore play an important role in regulating cell survival.
93Figure 8. Induction of apoptosis via the death  receptor, granzyme B 
(via mitochondria) and cell injury.
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942.10.5.2.1 Caspase-3
Caspase-3,  otherwise  known  as  CPP32  or apopain,  is  a  key effector of 
the  caspase  family.  It  exists  intra-cellularly  as  an  inactive  pro-enzyme 
called  pro-caspase-3.  Pro-caspase-3  is  then  cleaved  into  active  17  and 
12 kDa subunits by upstream proteases such as caspase-6 and 8 during 
apoptosis. The increased expression of caspase-3 results in apoptosis.
The following  Caspase-3  Protease Assay was  used  to  measure  in  vitro 
caspases-3  proteolytic activity  in  the cell  lysate.  The assay  involves the 
quantification  of  caspases  that  recognise  the  amino  acid  sequence, 
DEVD.  Substrate  DEVD-pNA  is  made  up  of chromophore,  p-nitroanilide 
(pNA)  and  DEVD  which  is  a  synthetic  tetrapeptide  and  an  upstream 
amino  acid  sequence  of  the  caspase-3  cleavage  site  in 
PARP(Polymerase).  When  the  substrate  is  cleaved  by  caspase-3,  free 
pNA light absorbance can  be quantified  using a fluorescence microplate 
reader at 405nm.
2.10.5.3  Caspase-3 protease assay
The frozen explants from the above six experiments were removed from 
-80°C  storage  and  placed  into  liquid  nitrogen.  Each  explant  was  then 
taken  out  of  liquid  nitrogen  and  homogenised  in  turn.  Homogenisation 
was  performed  using  a  mortar,  pestle  and  liquid  nitrogen  to  grind  the 
samples into a fine powder.  The powder from each was then  placed  into 
separate  sterile  eppendorfs.150pl  of  chilled  cell  lysis  buffer  was  then 
added  (this  contained  tris  buffered  saline).  The  sample  was  then 
incubated  on  ice  for  10  minutes.  After  10  minutes,  the  samples  were 
centrifuged  for  1   minute  at  10,000rpm.  The  cell  lysate  was  then 
transferred to a 96 well plate. In a separate glass container, 50pl of 2 x
95reaction buffer per sample was aliquoted. To this,  10pl of 1.0M DTT was 
added for every 1ml of 2 x reaction buffer used,  immediately before use. 
50pl of this solution was then added to each sample.  5pl of 4mM  DEVD- 
pNA substrate  was then added to each well and the plate was incubated 
in the dark at 37°C for 2 hours.
After  2  hours,  the  plate  was  transferred  to  a  fluorescence  microplate 
reader  and  the  kinetics  of  the  proteolytic  cleavage  of  substrates  was 
monitored using an excitation wavelength of 405nm.
2.10.6 Validation of caspase-3 assay
In  order  to  validate  the  apoptotic  findings  of  the  caspase-3  protease 
assay,  tissue  explants  were  stained  with  anti-caspase-3  antibody  and 
immunofluorescence.
2.10.6.1  Anti-caspase 3 immunohistochemistry
Anti-caspase  3  immunohistochemistry  was  performed  on  two  of  the 
above  tumour  explant  experiments.  Explants  incubated  for  24  and  48 
were placed into 2ml of 4% paraformaldehyde fixative and stored at -4°C. 
Tissues  were  then  embedded  in  paraffin  and  sectioned  according  to 
standard  protocols  (approximately  8-10  sections  per  explant).  The 
standard  procedure  for  dewaxing  and  rehydration  of  tissue  slides  was 
used,  as  described  earlier.  Each  slide  was  stained  with  human  anti- 
caspase-3  antibody  at  a  dilution  of  1   in  100,  using  the  previously 
described  protocol.  The  slides  were  randomly  mixed  prior  to  staining. 
Assessment  of  number  of  apoptotic  cells  was  performed  in  a  blind 
manner  on  two  separate  occasions  by  a  single  investigator.  The  mean 
number of apoptotic cells was  calculated  for all the  slides  prepared  per 
explant.
962.10.6.2 Immunofluorescence
Immunofluorescence utilises the same protocol for immunohistochemistry 
as used before, however, detection of antigens involves fluorescence with 
fluorescent labeled antibodies. Tyramide Signal Amplification was used in 
combination  with  DAB  for  the  anti-caspase  3  antibody  staining  on  the 
tissue explant frozen sections from 2 experiments. TSA uses horseradish 
peroxidase  to  catalyze  the  deposition  of a  fluorophore-labeled  tyramide 
amplification  reagent  onto  tissue  sections  that  have  been  previously 
blocked  with  proteins.  The  reaction  takes  less  than  10  minutes  and 
results  in  the  deposition  of  numerous  fluorophore  labels  immediately 
adjacent  to  the  immobilised  horseradish  peroxidase  enzyme.  The 
fluorophores  were  then  detected  by  fluorescence  visualization 
techniques.
2.10.6.2.1  Protocol for Immunofluorescence
The  protocol  for  immunofluorescence  follows  all  the  same  steps  as  for 
DAB staining  until the liquid  DAB is added to each  slide. A solution was 
made  up  of  450pl  of  amplification  diluent  and  9pl  of  fluorescein.  This 
solution  was  then  added  to  cover each  tissue  section.  The  slides  were 
then left in the dark for 5 minutes and washed in PBS. Using fluorescence 
microscopy,  the  slides  were  then  assessed  for  development  of 
fluorescence  and  once  ready,  placed  in  PBS  for  5  minutes.  All  slides 
were mounted using ‘immunomount’.
973 Statistical Evaluations
All  statistical  calculations  were  carried  out  using  Stats  Direct  (Ashwell, 
Herts, UK). P values <0.05 were considered significant.
3.1 RT-PCR data
All RT-PCR data was expressed as a copy number per pg total RNA. The 
median value was calculated for AN, T,  NN, RN and  RT for each marker. 
The  differences  in  median  copy  number  between  tissue  types  for each 
marker were then  calculated  using  non-parametric tests  (Mann Whitney 
U).
In order to determine any correlation  between  markers,  Spearman  Rank 
correlation was used.  In order to assess any correlation between IGFBP- 
3  mRNA  expression  and  clinico-pathological  variables,  samples  were 
divided  according  to  each  variable  i.e.  ER  positive,  ER  negative,  lymph 
node  positive  and  lymph  node  negative.  The  difference  in  median  copy 
numbers for each variable was then calculated using non-parametric test, 
Mann Whitney U.
3.2 BP-3 protein expression
The  differences  in  staining  between  the  normal  breast  tissue  versus 
tumour and stromal versus epithelial staining were evaluated using a two 
sided Fisher exact test or a chi-square test as appropriate. These findings 
were  also  correlated  to  the  following  clinicopathological  parameters; 
tumour size (greater or less than 2cm), tumour histology, nodal status,
98vascular  invasion  and  oestrogen  receptor  status  using  Spearman  rank 
correlation.
3.3 Serum IGF-I and BP-3 levels
In order to calculate differences in serum IGF-I and BP-3 levels in pre and 
post-operative  breast  cancer  patients,  Mann  Whitney  U  non-parametric 
tests were  used.  For determining  the  IGF-I  BP-3  ratios for each  patient, 
each value was first corrected for age and then ratios were obtained and 
compared again using Mann Whitney U.
3.4 Tissue explant culture
For  MTS,  LDH  and  caspase-3  assays  absorbance  readings  were 
recorded  and  mean  values  and  standard  errors  of  the  mean  were 
calculated. The differences were then compared using Mann Whitney U.
3.5 Anti-caspase 3 immunhistochemistry
For each sample, sections were randomly mixed and number of apoptotic 
cells  were  counted  in  a  blinded  manner  by  a  single  observer.  Mean 
values  for each  sample were then  calculated  and  differences  assessed 
using Mann Whitney U.
994. Results
4.1  Results of RNA Quantification
4.1.1  Ribogreen standard curve results
Fig  9A  demonstrates  the  fluorescence  values  for four  normal  and  four 
malignant  breast  samples  analysed  using  the  Ribogreen  method.  Each 
value is a mean of three values. The RNA concentration for each sample 
was then  calculated  using  the y-intercept value from the standard  curve 
(Fig  9B)  and  the dilution factor as previously mentioned.  The  Ribogreen 
method is particularly useful for detecting smaller concentrations of RNA. 
For  example,  it  can  be  seen  that  normal  breast  tissue  produces 
approximately  3-4  times  less  RNA than  breast tumours.  This  technique 
was therefore used to detect the smaller quantities of RNA extracted from 
normal  breast tissue.  Unfortunately,  unlike  the  Agilent  Bioanalyzer,  this 
technique only provides information on quantity and not quality of RNA.
4.1.2 Results of Agilent Bioanalyzer
For  each  lab  chip  analysed,  the  well  marked  ladder  should  produce  7 
clear peaks  in  order to confirm that the  gel  has worked  (Fig  10).  Fig  11 
shows  an  electropherogram  and  an  autoradiograph  of  extracted  RNA 
from  a  breast  sample  using  the  Agilent  Bioanalyzer.  The 
electropherogram  shows  three  peaks.  The  first  peak  is  a  marker  that 
enables  comparison  between  samples.  The  following  two  peaks 
represent the  two  ribosomal  peaks.  The  ratio  of these  peaks  should  be 
approximately 2:1  (28S:18S).This ratio in conjunction with a smooth
100baseline  represents good  quality  RNA.  RNA degradation  is  seen with  a 
decreasing  ratio of ribosomal bands,  additional peaks and a decrease  in 
the RNA signal or shorter fragments. The height of the peaks should also 
compare  well  with  the  marker  peak  thereby  indicating  a  good 
concentration of RNA.  The Agilent software is then able to calculate the 
ratio of the sample peaks to the marker peak thereby providing the RNA 
concentration for each sample.
101Figure 9 A and B. RNA quantified using Ribogreen(A). The standard 
curve(B)  shows  that  increasing  fluorescence  correlates  well  with 
increasing RNA concentration.
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Figure 10.  Representative electropherogram (A) and autoradiograph 
(B) of a single RNA sample.  The ladder demonstrates 6  RNA peaks 
and 1  marker peak. The marker allows comparison with other chips.
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103Figure 11. Electropherogram (A) and autoradiograph (B) of extracted 
RNA  demonstrating  high  quality  and  quantity  of  total  RNA.  Two 
ribosomal peaks are seen with a ration of 2:1.
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1044.2 Results from RT-PCR
4.2.1  Results from generation of standard curve from amplicons
A  linear graph  was  constructed  for each  amplicon,  the  high  and  low  Ct 
values were discarded to correct for pipetting  errors  and  the average of 
the  remaining  values  was  calculated.  The  Ct  value  is  inversely 
proportional to the  log  of the initial copy number (255).  Standard  curves 
were constructed  by plotting the Ct values with 95% confidence  intervals 
against the  logarithm of the  initial  copy numbers.  The copy numbers for 
each  of the  experimental  samples  were  then  calculated  after  real-time 
amplification from the linear regression of that standard curve.
Fig (12) demonstrates the amplification plot of IGFBP-3 amplicon.  Serial 
dilutions  of  the  BP-3  amplicon  were  diluted  as  previously  described. 
Fluorescence values were recorded for each  known concentration and  a 
standard  curve  (Fig  B)  was  constructed  of  Ct  values  against  log  copy 
number.  Fig  A  demonstrates  smooth  exponential  amplification  of  the 
amplicon. The run was repeated if successful amplification did not occur.
105Figure  12.  Amplification  plot of BP-3 amplicon  (A) and  construction 
of  standard  curve  (B).  Serial  dilutions  result  in  different 
fluorescence  values.  The  smaller  the  Ct  value,  the  higher  the 
concentration of DNA.
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experiments, each sample was performed in duplicate.
y=-3.3443x+47.337
R 2  = 0.9973
25
20
Ct
12 6 8 10 4
Log copy number
1064.2.2 Results from individual markers
4.2.2.1  IGFBP-3
All  samples  expressed  IGFBP-3  mRNA.  A  high  universal  expression  of 
IGFBP-3 mRNA was detected  in all of the following groups;  normal (AN) 
(median  1.61  x  108) and  malignant breast tissue  (T)  (median  1.6 x  108), 
normal tissue from healthy volunteers (NN)  (median 2.6 x  108),  recurrent 
breast cancers (RT) (median 1.2 x 108) and normal breast tissue adjacent 
to  recurrent  breast  cancers  (RN)  (median  1.20  x  10s).  The  level  of 
expression was similar to that seen in the liver (approximately 1.0 x 101°). 
No significant difference was detected  between any of the above groups 
(Fig 13).
4.2.2.2 IGF-I
A significant down regulation of IGF-I mRNA was seen in breast tumours 
when  compared to adjacent  normal  breast tissue,  (5.28 x  106 vs  1.18  x 
107,  p=0.003)  (Fig  14).  Interestingly,  5  tumours  (9%)  and  3  adjacent 
normal  (6%)  samples  did  not  express  IGF-I  at  all  indicating  an  IGF-I 
negative sub-group of breast tissue. Also,  23%  of recurrent tumours did 
not  express  IGF-I  and  a  significant  down  regulation  was  seen  when 
compared  to  primary  tumours  (1.4  x  106  vs  5.28  x  106,  p=0.0001).  No 
significant difference was seen in IGF-I expression between normal tissue 
from  healthy  patients  and  those with  cancer (2.34  x  107  vs  1.18 x  107, 
p=0.08),  however,  a significant down  regulation  of IGF-I  expression was 
seen  in  tumours  compared  to  normal  tissue from  healthy  patients  (5.28 
x106 vs 2.34 x 107, p=0.001).
1074.2.2.3 VEGF
All samples expressed VEGF mRNA.  No statistical differences in level of 
expression  can  be  seen  amongst  the  groups  of  breast  tissue  (Fig  15). 
There  was  also  a  large  variation  in  expression  seen  in  primary  breast 
tumours.
4.2.2.4 COX-2
All samples expressed COX-2 mRNA (Fig  16). A significant up regulation 
was seen in the normal tissue adjacent to cancer (AN) when compared to 
breast  tumours  (T)  (median  copy  number  3.14  x  107  vs  1.15  x  107, 
p=0.0001)  and  normal  tissue  from  healthy  patients  (p=0.004).  No 
difference in expression was seen between recurrent tumours (RT) (2.37 
x  107,  range  4.72  x  106 -  8.1  x  107),  their adjacent  normal  tissue  (RN) 
(1.28 x  107,  range  1.36 x  106 -  5.1  x  107)and  also with  primary tumours 
(T).
4.2.2.5 1  alpha hydroxylase
Median  laOHase  mRNA  levels  were  significantly  lower  in  the  AN 
samples  (1.7  x  107;  range  1.04  x  105 -   1.57  x  108)  compared  with  NN 
samples  (5.2  x  107;  range  4.59  x  106  -   2.52  x  108;  p<0.01)  (Fig  17). 
Median mRNA copy number in T samples (2.8 x 107;  range  1.75 x 106 -  
3.38  x  108)  was  higher than  in  paired  AN  samples  (p<0.04)  with  higher 
levels  (>3 fold) detected  in  11/30 tumours,  and  lower levels  in  4 tumour 
samples.
1084.2.2.6 Vitamin D receptor
Median VDR mRNA levels were significantly higher in tumours (3.3 x 106;  
range  7.12  x  104 -  8.7  x  107)  compared  to  both AN  (1.65  x  106;  range 
5.21  x  105 -  8.45 x  106;  p=0.002)  and  NN  samples  (median  1.55 x  106; 
range 4.83 x 105 -  7.19 x 106;  p=0.01) (Fig  18). There was no difference 
between AN and NN samples.
4.2.2.7 24 hydroxylase
Median  240Hase  mRNA  levels  were  significantly  higher  in  healthy 
normal  breast  tissue  (NN)  (1.0  x  108,  range  1.1  x  107  -   6.1  x  108) 
compared to both AN  (9.7 x  106,  range 2.6 x  105 -  2.9 x  108,  p=0.0001) 
and  tumours  (1.3 x  107,  range  3.4 x  105 -  5.3 x  108,  p=0.002)  (Fig  19). 
There  also  appeared  to  be  a  down  regulation  of  240hase  in  recurrent 
breast cancers (RT, RN).
109Figure  13. The expression  of IGFBP-3  mRNA in  breast tumours (T), 
adjacent  non-cancerous  tissue  (AN),  normal  tissue  from  healthy 
patients  (NN),  and  recurrent  normal  (RN)  and  recurrent  malignant 
(RT)  tissue.  Values  are  the  mean  and  standard  error  of  the  mean 
(SEM).
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110Figure  14.  The  mRNA  expression  of  IGF-I  demonstrating  down 
regulation in tumours (T) compared to adjacent normal tissue (AN). 
Values are expressed as mean + SEM.
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111Figure  15.  VEGF  mRNA  expression  showing  similar  levels  of 
expression  in  all  types  of  breast  tissue.  Values  are  expressed  as 
mean + SEM.
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112Figure  16.  Expression  of COX-2 mRNA. An  up regulation  is seen  in 
adjacent normal  tissue  (AN) when  compared to  breast tumours  (T) 
and  normal tissue from  healthy patients (NN). Values are expressed 
as mean + SEM.
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113Figure 17. Expression of laOHase mRNA. A down regulation can be 
seen  in  T  and  AN  when  compared  to  normal  tissue  from  healthy 
patients (NN). Values are expressed as mean + SEM.
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114Figure 18. Expression of VDR mRNA. A significant up regulation can 
be seen in T when compared to AN and NN. Values are expressed as 
mean + SEM.
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115Figure  19.  Expression  of  24  OHase  mRNA.  A  significant  down 
regulation  is  seen  in  AN  and  T  when  compared  to  NN.  Values  are 
expressed as mean + SEM (n=24).
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1164.2.3. Results from correlation with clinico-pathological features
The  breast  tumour  samples  were  divided  into  two  groups;  those 
expressing  high  (>  1.0  x  108,  n=35)  and  low  levels  of  IGFBP-3  (<1.0  x 
108, n=18) mRNA for further analysis. A statistically significant increase in 
ductal  carcinoma  in  situ  (DCIS),  known  precursor  for  invasive  breast 
cancer,  was  found  in  the  high  group  when  compared  to  the  low  group 
(p<0.0001, Mann Whitney U). On further analysis, there was also found to 
be  a  statistically  significant  increase  in  the  presence  of extensive  high 
grade  DCIS  between the two groups  (p<0.0008,  Mann Whitney  U).  The 
presence  of  extensive,  high  grade  DCIS  is  thought  to  predict  for  a 
substantially  increased  risk  of  axillary  node  involvement  and  systemic 
disease with a tendency for poor tumour markers (256).
No  correlation  was  found  between  IGFBP-3  mRNA  expression  and  the 
following  clinico-pathological  parameters:  tumour  size,  tumour  grade, 
histological  type,  ER/PgR  status,  lymph  node  status  and  presence  of 
vascular invasion.
4.2.4.  Results  of correlation  of  BP-3  with  other  tumour  associated 
genes.
A positive correlation was detected between IGF-I and IGFBP-3 mRNA in 
breast  tumours  (Spearman  rank,  R=0.38,  p=0.01).No  significant 
correlation  was  detected  between  IGFBP-3  and  IGF-I  mRNA  in  normal 
breast tissue.  Similarly,  no  significant correlation  was  detected  between 
IGFBP-3 mRNA and tumour associated genes; VEGF and COX-2 (Table
1173). A positive correlation was detected, however, between IGFBP-3 levels 
in normal breast tissue and housekeeping gene, GAPDH (R=0.4, p=0.02, 
Spearman  Rank  correlation).  No  such  correlation  was  seen  with  breast 
tumours,  thereby  confirming  its  variable  expression  in  normal  and 
cancerous tissue. Within the breast cancers,  GAPDH expression  ranged 
from 5.28 x 107 to 5.88 x 1010 and therefore supports the evidence that it 
is not a reliable internal reference for normalisation of PCR assays.
A  positive  correlation  was  detected  between  IGFBP-3  and  1  alpha 
hydroxylase  mRNA  expression  in  breast  tumours  (R=0.4,  p=0.01, 
Spearman Rank Correlation).  No other correlation was detected between 
IGFBP-3  and  other  members  of the  vitamin  D  axis;  vitamin  D  receptor 
(VDR)  and  24  hydroxylase,  the  enzyme  responsible for  breaking  down 
active vitamin D.
118Table 3.  Correlations  between  IGFBP-3  mRNA from  breast tumours 
with  other  markers.  A  positive  correlation  is  seen  with  IGF-I  and 
laOHase.
Marker Correlation  coefficient
(R)
P value
IGF-I 0.37 0.01
VEGF 0.2 0.19
COX-2 -0.11 0.23
GAPDH -0.05 0.7
1-alpha hydroxylase 0.4 0.01
Vitamin 
D receptor
0.2 0.2
24 hydroxylase 0.04 0.85
4.2.5.  BP-3 expression and survival
By the time of writing, 4 deaths had occurred as a result of breast cancer 
out of the cohort of 53 women  (mean follow up of 20 months). All four of 
these  tumours  expressed  high  levels  of  IGFBP-3  mRNA  and  their 
tumours were associated with  extensive  high grade  DCIS,  however,  this 
did not reach statistical significance.
1194.3.  Results from Immunohistochemistry
4.3.1.  Results of DAB staining
Immunohistochemical  analysis  of  IGFBP-3  in  normal  and  malignant 
breast tissue demonstrated positive immunoreactivity in 96% samples (46 
out  of  48)  (Table  4).  Two  samples  consisting  of  one  tumour  and  one 
normal sample were  negative  (4%).  24 samples (50%) were classed  as 
strongly  positive  and  22  (46%)  were  weakly  positive.  No  difference  in 
immunostaining was seen  between  normal  and  malignant breast tissue. 
No  statistically  significant  correlation  was  seen  between  protein 
expression and IGFBP-3 mRNA (R= -0.2, p=0.17).
Table 4. Immunostaining of IGFBP-3 in normal (N) and malignant (T) 
breast  tissue  demonstrating  that  96%  of  samples  stained  positive 
for BP-3 and 50% of these samples were strongly positive.
N T Total
Negative (1-6) 1   (4%) 1   (4%) 2 (4%)
Positive (7-9) 9 (38%) 13 (54%) 22 (46%)
Strongly  positive 
(10-14)
14 (58%) 10 (42%) 24 (50%)
Total 24 24 48
1204.3.1.1 Stromal vs epithelial staining
There was an increase in stromal versus epithelial staining in normal and 
tumours  (Fig  20,  21  and  22).  In  the  normal  breast  samples,  67%  of 
samples (16 out of 24) stained positively in the epithelium whereas 100% 
stained  positively in the  stroma  (p<0.0001)  (Table  5).  Similarly in  breast 
tumours, 46% of samples stained positively in the epithelium as opposed 
to 100% stromal staining (p<0.0001) (Table 6). Overall, there appeared to 
be  a  similar  pattern  of  staining  for  both  normal  and  tumour  sections, 
although  more  tumours than  normals  stained  negative  in the epithelium 
(54% vs 33%).
121Figure  20.  IGFBP-3  peptide  is  detected  in  the  stroma  of  a  breast 
tumour expressing BP-3 mRNA.
Negative control  Positive staining, stromal
Figure  21.  IGFBP-3  staining  of  normal  breast tissue  demonstrating 
stromal versus epithelial expression.
Negative control Normal breast tissue
122Figure  22.  IGFBP-3  protein  expression  in  a  breast  tumour 
demonstrating  strong  epithelial  and  stromal  staining. 
Immunofluorescence confirms findings.
DAB staining Immunofluorescence
123Table  5.  Epithelial  staining  scores  for  IGFBP-3  in  normal  and 
malignant  breast  tissue.  Approximately  half  of  all  samples  are 
negative  for  IGFBP-3,  more  so  in  tumours  when  compared  to 
normals (54% vs 33%).
N T Total
Negative(1-3) 8(33%) 13(54%) 21(44%)
Positive(4-7) 16(67%) 11(46%) 27(56%)
Total 24 24 48
Table  6.  Stromal  staining  scores  for  IGFBP-3  in  normal  and 
malignant breast tissue. All samples stain positively for BP-3 in both 
normals and tumours.
I  N T Total
Negative(1-3) I o 0 0
Positive(4-7) | 24(100%) 24(100%) 24(100%)
Total I  24 24 48
1244.3.2. Correlation with Clinicopathological Parameters
A  statistically  significant  correlation  was  detected  between  IGFBP-3 
negative tumours and lymph node negativity (p=0.05, Fisher’s Exact test). 
No  significant  correlation  was  observed,  however,  between  IGFBP-3 
protein  expression  and  tumour  size  (greater  or  less  than  2cm),  tumour 
histology, vascular invasion, oestrogen receptor status and age (Table 7).
125Table  7.  Correlation  between  tumour  IGFBP-3  protein  and  clinico- 
pathological parameters.
Number of patients (%)
Parameter All IGFBP-3 I  IGFBP-3  strongly P-value
patients (%) negative/weakly |  positive (Fisher’s
positive |  (score10-14) exact test)
(score1-9)
; I
Histology:
Ductal 12(50) 6(50) 6(50) 0.6
Lobular 2(8.3) 1(50 1(50)
Other 10(41.7) 6(60) 4(40)
Tumour size:
< 20mm 13(54) 8(62) 5(38) 0.46
> 20mm 11(46) 5(45.5) 6(54.4)
Nodal status:
0 11(46) 7(64) 4(36) 0.05
<5 8(33) 4(50) 4(50) 0.6
>5 4(21) 2(50) 2(50)
Grade:
1 3(12.5) 2(66.6) 1(33.3) 0.59
2 11(45.8) 5(45.5) 6(64.5)
3 10(41.6) 6(60) 4(40) 0.8
Vacular invasion:
Not detected 14(58) 9(64) 5(36) 0.27
positive 10(42) 4(40) 6(60)
ER/PgR negative 4(17) 1(25) 3(75) 0.2
ER/PgR positive 19(83) 11(58) 8(42)
DCIS:
No 8(33.3) 6(75) 2(25) 0.18
Yes 16(66.6) 7(44) 9(56)
<60yrs 12(50) 5(41.6) 7(58.3) 0.4
£60yrs 12(50) 7(58.3) 5(41.6)
1264.4.  Results of serum IGF-I and IGFBP-3
4.4.1.  Serum IGF-I
In  the  pre-operative group,  the  mean  patient age was 61  years and  the 
average  IGF-I  was  162ng/ml  (range  100  -   425ng/ml).  In  the  post­
operative  group,  the  mean  patient  age  was  64  years  and  the  average 
IGF-I  was  142ng/ml  (range  56  -   257ng/ml).  Within  the  post-operative 
group, 28 (80%) patients were taking tamoxifen (T) and 7 (20%) were not 
(NT). The mean age of patients in NT was 62 years and the average IGF- 
I was  153ng/ml  (range 79-257ng/ml).  In  the T group,  the  patients  had  a 
mean age of 55 years which appeared much younger than NT,  however, 
this was not statistically significant (Mann Whitney,  p=0.1) probably as a 
result of a small sample size. The average serum  IGF-I in this group was 
130ng/ml (range 59-197ng/ml)
In order to account for the age related  influence in serum  IGF-I  levels,  a 
ratio  of  the  serum  value  divided  by  the  upper  limit  of  the  age  related 
normal  range  was  calculated  (Tables  8  and  9  ).  With  this  correction, 
serum  IGF-I  levels were decreased  in  the  post-operative  patients taking 
tamoxifen  when  compared  to  pre-operative  patients  and  post-operative 
patients not taking tamoxifen (Mann Whitney, p<0.05).
127Table 8. Average serum values of IGF-I according to age.
Age (years) | Average  serum  IGF-I 
|  concentration (ng/ml)
19-29 |  125-329
30 -39 |  120-330
40-49 [136 - 369
50-59 1   108-263
60-70 |  108-229
Table 9. Serum IGF-I levels expressed as a ratio of the upper limit of 
the age related normal range.
Median  ratio  +/- 
standard deviation
Pre-operative 0.6 +/-0.18*
Post-operative NT 0.62 +/-0.14*
Post-operative T 0.52 +/-0.14
* = p<0.05 (Mann Whitney U), when compared to post-operative T.
1284.4.2. IGFBP-3
Serum  IGFBP-3  levels  increase from  late childhood to  puberty and then 
gradually fall during adult life. The levels are also higher in females than 
in males (normal range 2.6 -  5.5mg/l versus 1.5- 4.6mg/l).
In the  pre-operative group,  the  mean  patient age was 61  years and  the 
average  IGFBP-3  level  was  3mg/L  (range  1.6  -   5.5mg/L).  In  the  post­
operative  group,  the  mean  patient  age  was  64  years  and  the  average 
IGFBP-3 was  3.1mg/L  (range  1.3 -  5.3mg/L).  Within  this  post-operative 
group, 28 (80%) patients were taking tamoxifen (T) and 7 (20%) were not 
(NT).  The  average  age  of the  NT group was  62  years  and  the  average 
IGFBP-3  was  3.3mg/L  (range  1.3  5.3mg/L).  The  average  age  of the  T 
group  was  55  years  with  a  mean  IGFBP-3  of  3.2mg/L  (range  1.4  -  
5.2mg/L). Tamoxifen clearly has no effect on serum IGFBP-3 levels.
4.4.3.  IGF-I and IGFBP-3 serum levels
The IGF-I:BP-3 ratio was determined for the three groups of patients; pre­
operative, post-operative NT and post-operative T. To account for the age 
related decline of IGF-I, the IGF-I values were calculated as a ratio of the 
upper  limit of the  age-related  normal  range  (Table  10).  IGFBP-3  values 
were also calculated as the ratio of the upper limit of the normal range.
The  results  show that  the  IGF-I:BP-3  ratio  is  significantly  higher  in  the 
pre-operative  group  than  the  post-operative  T  group  (Mann  Whitney, 
p=0.05).  There  is  no  significant  difference,  however,  between  the  pre­
operative group and the post-operative group not taking Tamoxifen.
129Table  10.  Serum  IGF-I  BP-3  ratio expressed  as  a  ratio  of the  upper 
limit of the normal range.
Median  ratio  +/- 
standard deviation
Pre-operative 0.051  +/- 0.027 *
Post-operative NT 0.054 +/- 0.03 **
Post-operative T 0.04 +/-0.013
* p=0.05, when compared to post-operative T 
** p=0.09, when compared to post-operative T
1304.5 Results of viability assessment of culture breast 
explants
4.5.1. Results of MTS assay
Fig  23  demonstrates  the  mean  absorbances  of  six  experiments.  There 
was a steady increase in MTS up to 48 hours followed by a sharp decline. 
Triton-X  100 was used as a  negative control.  By 48 hours of incubation, 
there  appeared  to  be  a  drop  in  MTS  and  hence  a  reduced  cell 
proliferation.  Using the MTS proliferation assay, therefore,  it appears that 
the explant culture system is viable up to 48 hours.
4.5.2. Results of differing explant weight on MTS absorbance
The  MTS  assay was  performed  on  20 explants of differing weights.  The 
results  demonstrate  a  good  linear correlation  (Spearman  Rank,  R2=0.7, 
p=0.0001)  between explant weight and  increasing  MTS absorbance (Fig 
24).  For the purposes of future experiments, it was decided to ensure that 
all  explants  were  approximately  the  same  size  in  order  to  minimise 
variability  of  results.  1-2mg  was  taken  to  be  the  most  physiologically 
relevant size  since good  MTS  absorbance values were obtained  at this 
size  and  anything  larger  with  an  increased  surface  area  may  make 
penetration of added substrates difficult and may interfere with results.
131Figure  23.  MTS  assay  of  breast tumour  explants  at  5m,  24hr,  48hr 
and  72hr.  An  increase  in  MTS  is  seen  in  the  medium  only  wells 
compared  to  negative  control,  Triton.  This  confirms  the  viability  of 
the explants up to 24/48hr, after which point the results appear to be 
inconsistent. Values are expressed as mean ± SEM.
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Figure 24.  MTS assay comparing  absorbance with differing explant 
weight  A good  linear correlation  is  seen  between  explant weights 
and MTS absorbance.
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1334.5.3. Results of LDH assay
Figs 25 and 26 show the results of the mean of 6 LDH assays for normal 
and malignant explants as a guide to their lysed cell content. The results 
demonstrate a gradual increase in LDH release in the cultured medium of 
the normal samples after 48 hours. After 72 hours, there appears to be a 
decline  in  LDH  release  suggesting  that the  culture  system  is  no  longer 
functioning.  In  the  tumours,  LDH  release  is  stable  for  up  to  72  hours. 
Larger amounts of LDH  are released from tumour explants compared to 
normal,  probably due to the  higher content of epithelial  cells and  hence 
proportionately larger release of LDH into the medium. The large increase 
in  LDH from the samples treated with 2% triton  (a detergent which  lyses 
cell membranes), the positive control, confirm that the assay is working.
4.5.4.  Variability of the LDH assay section
4.5.4.1 Inter-assay variability
Figs  27  and  28  demonstrates  the  absorbance  between  duplicates  for 
tumour explants cultured  in  medium only and triton  (positive control).  Fig 
27  is  the  mean  of  3  experiments  at  3hr  and  Fig  28  is  the  mean  of  4 
experiments  at  48hr with  an  increase  in  LDH  seen  at  this  time  frame. 
Good concordance  is seen  between the samples.  The mean  co-efficient 
of variation was 6.6%.
4.5.4.2 Intra-assay variability
Table  11  demonstrates  the  intra-assay  variability  for the  LDH  assay  at 
5min and 4hr. The mean co-efficient of variation was 3.8%.
134Figure 25. LDH assay of normal breast tissue explants (n=6) at 5min,
24hr, 48hr, 72hr and 96hr. Values are expressed as mean ± SEM.
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Figure  26.  LDH  assay  of  breast tumour  explants  (n=6)  at 5m,  4hr,
24hr, 48hr and 72hr. Values are expressed as mean ± SEM.
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136Figure  27.  Inter-assay  variability  of  the  LDH  assay  of  duplicate 
tumour explants at 3hr. 1  and 2 on the x axis represent the duplicate 
samples taken from the same explant (n=3) for explants cultured  in 
medium  only  and  Triton.  Good  variability  is  seen  for  both 
duplicates. Values are expressed as mean ± SEM.
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137Figure  28.  Inter-assay  variability  of LDH  assay  of duplicate  tumour 
explants  at  48hr  (n=4).  Good  variability  is  seen  in  both  samples 
(standard  error  bars  are  not shown  on  medium  only  duplicates  as 
they  are  too  small,  0.004,  0.005).  Values  are  expressed  as  mean  ± 
SEM.
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138Table  11.  Intra-assay  variability  of LDH  assay.  Sample  1  and  2  are 
tumour explants assayed  in  medium  only.  Each sample  is assayed 
12 times  in  duplicate at 5min  and  3hr.  The  results are  measured  in 
absorbance at 490 nM.
I 5min 4hr
[  Well 
|  no
Sample no 1 Sample no 2
1 0.241  |  0.245 0.472 0.498
2 0.471  |  0.464 1.189 1.196
3 0.243  |  0.251 0.464 0.468
4 0.4  |  0.375 0.976 0.953
5 0.254  |  0.267 0.45 0.46
6 0.306  |  0.314 0.506 0.505
7 0.379  | 0.362 0.926 1.024
8 0.318  | 0.327 0.768 0.777
9 0.281  |  0.286 0.713 0.712
10 0.606  | 0.573 0.472 0.498
11 0.496  |  0.511 1.532 1.532
12 0.587  | 0.526 1.303 1.327
1394.5.5. Results of caspase-3 protease assay
4.5.5.1  Results of doxorubicin dose response
Using the caspase 3 colorimetric assay, a dose response for doxorubicin 
was  produced  using two differing  concentrations;  0.1  mM  and  0.3mM  in 
order to investigate the ideal concentration for this culture system. At 4hr 
there was little effect on apoptosis at 0.1 mM  (Fig 29). At 24hr,  however, 
there was a significant increase  in apoptosis seen  in tumour explants at 
both concentrations (Fig 30). 0.3mM was therefore the dose employed for 
all future explant experiments.
140Figure 29. Caspase-3 protease assay of doxorubicin dose response 
at 4hr. A minimal effect is seen in breast tumour explants cultured in 
0.1 mM and 0.3mM doxorubicin. Values are expressed as mean +SEM 
(n=3).
141Figure 30. Caspase-3 protease assay of doxorubicin dose response 
at  24hr.  Breast  tumour  explants  showing  an  increase  in  caspase 
activity  with  0.3mM  doxorubicin.  Values  are  expressed  as  mean 
+SEM (n=3).
1424.5.5.2 Breast tumour explants
Fig  31  demonstrates  a  small  increase  in  caspase-3  activity  in  breast 
tumour explants  incubated  with  IGFBP-3 when  compared  to the tumour 
incubated  in  medium  only.  This  did  not,  however,  reach  statistical 
significance.  Similarly,  a  small  increase  in  apoptosis  was  seen  with 
doxorubicin,  however, this was also not significant. A striking  increase in 
apoptosis  was  seen,  however,  with  IGFBP-3  in  combination  with 
doxorubicin  when  compared  to  medium  alone  (p=0.004)  and  IGFBP-3 
alone  (p=0.01).  In  breast  tumours  therefore,  IGFBP-3  appears  to 
markedly enhance the apoptotic effects of cytotoxic agent, doxorubicin.
4.5.5.3  Normal breast tissue explants
Fig 32 shows that in normal breast tissue explants, as with tumours, very 
little  apoptosis  was  seen  with  IGFBP-3  alone.  A  significant  increase  in 
caspase-3 activity was seen,  however,  with  doxorubicin when compared 
to  medium  only  (p=0.02)  and  IGFBP-3  alone  (p=0.04).  In  contrast  to 
tumours,  doxorubicin  in  combination  with  IGFBP-3  in  normals  did  not 
result  in  a  marked  increase  in  apoptosis.  Using  this  explant  system 
divergent effects can  therefore  be seen  in  normal  and  malignant breast 
tissue.
143Figure 31. Caspase-3 protease assay in tumour explants at 24hr. An 
increase  in  caspase-3  activity  is  seen  in  breast  tumour  explants 
(mean of six experiments). Values are expressed as mean + SEM.
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144Figure  32.  Caspase-3  protease  assay  in  normal  explants.  An 
increase  in  caspase-3  activity  is  seen  in  normal  tissue  explants 
incubated with doxorubicin at 24hr (mean of 6 experiments + SEM).
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1454.5.6. Results of validation of caspase-3 assay
4.5.6.1.  Results of immunofluorescence
The  results  of  immunofluroescence  were  difficult  to  assess  since  the 
reaction  was  too  quick  to  quantitate  apoptosis  (Fig  33). 
Immunofluorescence was therefore abandoned as a quantative validation 
of the caspase-3 protease assay and only used once in order to compare 
results using the two techniques.
146Figure 33. Immunofluorescence of tumour explants treated with  BP- 
3  and  doxorubicin  at  24hr.  Apoptotic  cells  were  visualised  within 
seconds  of  staining,  however,  were  not  seen  30s  later  (x100 
magnification).
Apoptotic cell seen within seconds  No apoptotic cells seen after 30 seconds
1474.5.6.2. Results of anti-caspase-3 immunohistochemistry
An  increase  in  apoptosis was seen  in the tumour explants cultured  with 
IGFBP-3, doxorubicin and IGFBP-3 in combination with doxorubicin at 24 
hours  (Fig  34).  The  mean  number  of  cells  undergoing  apoptosis  was 
statistically  higher  in  the  tumours  cultured  with  doxorubicin  alone  and 
doxorubicin  in combination with  IGFBP-3, when compared to the tumour 
cultured  in  medium  alone  (p<0.05).  There  was,  however,  no  statistical 
difference detected  in the number of apoptotic cells seen  in the tumours 
that  were  cultured  with  IGFBP-3  alone  and  similarly,  the  addition  of 
IGFBP-3  to  doxorubicin  seemed  to  have  no  additive  effect.  Only  2 
experiments were performed, however, due to the difficulties encountered 
in  obtained  enough  tissue  for  all  experiments.  The  results  therefore, 
reflect a trend and further samples need to be performed to confirm these 
results.
Several cells per section stained  positively with anti-caspase 3 antibody, 
however,  some  of these  cells  appeared  to  have  completely  undergone 
apoptosis  whereas  others  were  at  different  stages  in  the  apoptotic 
pathway (Fig  35).  The final  results,  therefore,  reflect the total  number of 
cells that have completely  undergone apoptosis and  are  undergoing  the 
process of apoptosis.
148Figure 34. Anti-capase 3 immunohistochemistry of tumour explants. 
Mean  number of apoptotic cells/section of tumour explant cultured 
at 24hr (mean of 2 experiments, approximately 10 sections/explant, 
magnification x200).
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149Figure 35. Positive anti-caspase 3 staining in tumour explants. Some 
cells  have  completely  undergone  apoptosis  (apoptotic  bodies)  and 
others are undergoing the process.
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1505. Discussion
5.1. IGFBP-3 expression in breast tissue
This study was performed to confirm the expression of IGFBP-3 in human 
breast  tissue.  Previous  in  vitro  studies  have  shown  that  IGFBP-3 
regulates growth of breast cancer cells (11;34;120), however, in vivo data 
is conflicting. We detected a high universal expression of IGFBP-3 mRNA 
in  normal  breast  tissue,  malignant  breast  tissue,  normal  breast  tissue 
from  healthy subjects and  recurrent breast cancers.  The  level  of mRNA 
expression  in  all these groups was found to  be very  high  and  similar to 
the expression of IGFBP-3 mRNA expressed by the liver,  its main site of 
production.  No  studies  have  been  performed  comparing  simultaneous 
IGFBP-3  levels  in  breast  tumours,  adjacent  normal  breast  tissue  and 
healthy  normal  breast  tissue  from  women  without  cancer.  One  study 
investigated the levels of IGFBP-3 mRNA in breast cancers and adjacent 
normal  tissue  using  RT-PCR  and  found  that  levels  were  higher  in  the 
cancers  (120).  Only 5  paired  samples were  analysed,  however,  making 
statistical significance difficult to assess.
The  over expression  of IGFBP-3  by aggressive  breast cancer cells  and 
samples  initially  appears  somewhat  of  a  paradox  since  IGFBP-3  is 
generally considered to be a growth inhibitor.  It is possible, therefore, that 
in fact the over expression  of IGFBP-3  is from the  nearby  normal tissue 
and stroma  in  response to the aggressiveness  of the tumour.  This  may, 
therefore,  reflect  a  local  response  of  the  body  to  try  to  limit  the 
development  of  the  breast  tumour.  There  was,  however,  no  statistical 
difference  seen  between  the  IGFBP-3  expression  of  normal  and 
malignant breast tissue or any of the  other types of breast tissue.  If the 
local  production  of  IGFBP-3  in  normal  breast  tissue  is  affected  by  the 
presence of a breast tumour, we might therefore expect to see a
151difference  in  IGFBP-3  levels  between  normal  breast tissue from  healthy 
women  and  those  with  breast  cancer.  This  finding,  however,  was  not 
reflected in the mRNA data.
5.1.1 Limitations of RT-PCR
Real-time  RT-PCR  is  now  widely  used  for  characterising  or  confirming 
gene expression patterns and comparing mRNA levels in different sample 
populations.  Recent  improvements  in  internal  standards,  references  for 
normalising  data  and  new  mathematical  models  to  analyse  data  have 
improved  its  use as a  possible clinical diagnostic tool.  Doubts still exist, 
however,  about how quantitative and  informative real-time  RT-PCR is. A 
wide  variety  of  protocols  exist  amongst  research  laboratories,  similarly 
there  is  no  universally  accepted  validation  of  normalising  data  thereby 
leading to difficulties in reproducing data.  Recent improvements have led 
to  the  development  of  standardised  templates  (257)  which  allows 
comparison between experiments and use of internal standards to reduce 
variation in template starting amounts and operator loading error (258).
One of the  major problems with this study is the in  vivo  RNA extraction 
from  whole  tissue  samples.  The  heterogeniety  of  cell  types  within  the 
sample leads to an averaging out of the expression in different cell types 
and perhaps the expression profile of a specific cell type may be masked 
or even lost.  Previous studies have shown significant differences in gene 
expression profiles of microdissected and bulk tissue samples (259;260). 
This  may  be  particularly  problematic  when  comparing  normal  and 
malignant tissue since normal tissue directly adjacent to a tumour may be 
phenotypically normal when  infact it displays an altered gene expression 
due  to  its  proximity  to  the  tumour  (261).  In  order  to  overcome  this 
problem,  we  obtained  normal  breast  as  far  away  as  possible  from  the 
main  tumour  site  (average  of  10cm)  which  was  then  confirmed  as 
microscopically normal breast tissue by the pathology department.
152Laser capture microdissection (LCD) is a novel technique that allows the 
extraction  of  a  pure  subpopulation  of  cells  from  heterogenous  in  vivo 
tissue samples (262). A brief laser pulse is directed at cells within a tissue 
section  on  a  glass  slide and  individual  cells  may  be  selected  and  gene 
expression  may  then  be  determined  at  an  RNA  and  protein  level.  The 
main  drawback  of this technique  is  that a  very  small  sample  is  yielded 
making  RNA  isolation  difficult  and  good  quality  RNA  is  essential  for 
successful  RT-PCR.  The  technique  is  also  classically  performed  using 
archival formalin-fixed paraffin-embedded tissue specimens and the RNA 
yielded  from  these  slides  may  have  undergone  extensive  degradation 
and  also  the  use  of fixatives  may  well  alter  the  results  (263;264).New 
commercial  kits have been  developed  in order to tackle these problems, 
however,  and  so  future  use  of  this  technique  for  this  study  may  well 
improve the validity of these results.
5.2.  IGFBP-3 protein expression
IGFBP-3  protein  was  detected  in  96%  of  all  samples,  thereby 
corroborating the  high  level  of expression  in  all  samples detected  using 
RT-PCR.  Unfortunately,  however,  no  statistically  significant  correlation 
was  seen  between  protein  expression  and  mRNA  of  IGFBP-3  in  these 
samples (R= -0.2, p=0.17). This may be due to sample size, however, we 
should expect to observe a trend with the sample size studied. Accurate 
quantification  of  mRNA  levels  provides  no  information  on  transcription 
levels  or mRNA stability.  Also,  mRNA data  may  not reflect the  levels  of 
protein  produced  by  the  cell  as  regulation  occurs  at  the  post- 
transcriptional  stage  (265).  RT-PCR  data  may  therefore  be  very 
uninformative about protein activity.  Previous studies have demonstrated 
a  strong  correlation  between  IGFBP-3  mRNA and  IGFBP-3 detected  by 
immunoradiometric  assay  (IRMA)  but  no  statistically  significant 
correlation was seen between IGFBP-3 mRNA and  IGFBP-3 detected by 
ligand blot or immunoblot (153). Ligand blot and immunoblot are,
153however,  only  semi-quantative  whereas  IRMA  is  more  sensitive  and 
precise  suggesting  that  IGFBP-3  levels  may  be  directly  related  to  their 
mRNA and therefore transcriptionally upregulated in breast cancers. This 
difference  in  findings  may  be  accounted  for  by the  different techniques 
used to measure IGFBP-3 mRNA and protein.
When analysing the pattern of expression of IGFBP-3 protein,  there is a 
significant increase in stromal staining. This is a novel finding and has not 
previously  been  reported  in  breast cancer.  This  is  an  interesting finding 
given the increased epithelial content of breast tumours, where we would 
perhaps expect to find an  increase in epithelial staining compared to the 
normal tissue.  In  colon  cancer,  however,  IGFBP-3  protein  was detected 
predominantly in the epithelium with less BP-3 protein being expressed in 
the  poorly differentiated  adenocarcinomas  (39).  It was suggested  in this 
case that BP-3 causes apoptosis via a p53-dependant mechanism and so 
loss  of  p53  function  may  lead  to  a  down  regulation  of  BP-3  protein 
potentially  leading  to  aberrant  cell  survival.  However,  one  study  has 
suggested  that the  DNA sequence of BP-3  is altered  in the normal  and 
malignant tissue  of patients  with  colon  cancer,  thereby the  patient  may 
have  been  predisposed  to  developing  the  cancer (266).  Further studies 
would be required to analyse protein expression in the breast tissue from 
non-cancer patients for comparison.
5.3.  BP-3 expression and clinico-pathological features
We  detected  a  significant  correlation  between  breast  tumour  tissue 
sections that stained  negative/weakly positive for  BP-3 and  lymph  node 
negativity (p=0.05).  This  again  is  in  contrast to colon  cancer where  less 
BP-3  protein  is  seen  with  more  aggressive  cancers  (267).It  is  further 
evidence that breast tumours may behave differently to colon cancer and 
supports  a  potential  role  for  IGFBP-3  in  the  development  of  invasive 
breast  disease.  It  further  adds  to  the  epidemiological  evidence  from 
Renehan et al that high serum levels of BP-3 are associated with an
154increased  risk of breast cancer (98).  It is possible that the high  levels of 
BP-3 produced  by the surrounding stroma have anti-apoptotic effects on 
adjacent epithelium thereby aiding the development of invasive cancer or 
infact, the tumour may have become resistant to the pro-apoptotic effects 
of BP-3 from the stroma.
One  previous  study  measured  IGFBP-3  using  ELISA  in  195  node 
negative  tumours  (268).  Their findings  agreed  with  our  data  in  that  all 
samples  expressed  high  levels  of  IGFBP-3.  However,  they  did  not 
correlate  BP-3  levels  in  this  group  with  patients who  were  lymph  node 
positive so it is difficult to determine whether their findings are consistent 
with  ours.  IGFBP-3  levels  were,  however,  inversely  correlated  with  age 
and ER/PgR status and found to be higher in tumours greater than 2 cm. 
Our data did  not demonstrate any such association with  hormone status 
or tumour size.  This  may  be as a  result of the  limitations of the sample 
collection.  The  majority  of  samples  were  taken  from  post-menopausal 
women  with  tumours  that  were  2cm  or greater since  it was  technically 
difficult to obtain samples from smaller specimens without compromising 
the  margins for analysis.  Also,  approximately 85%  of samples were  ER 
positive  reflecting  the  usual  hormonal  status  in  all  breast  tumours, 
however,  resulting in a small sample size of ER negative tumours in this 
study.  Our data,  however,  did  reflect a general trend towards high levels 
of  expression  of  IGFBP-3  mRNA  in  larger  tumour  over  2cm  (75%  of 
samples expressed >  1.0 x 108 copy numbers) and ER negative tumours 
(78% of samples expressed >  1.0 x 108 copy numbers). Therefore, with a 
greater  variety  of  samples,  we  may  be  able  to  demonstrate  similar 
findings. No other association was found between IGFBP-3 levels and the 
following clinico-patholgical variables; tumour grade,  histological type and 
presence of vascular invasion.
Another  study  measured  IGFBP-3  protein  levels  in  47  cancers  using 
western  ligand  blot  with  1 1 2 5 1 1   IGF-I  as  a  label  (120).  They  found  that 
IGFBP-3  levels were significantly  higher in  ER  negative tumours,  which 
are known to predict for a poorer outcome. Similarly Yu et al measured
155IGFBP-3  levels in tumour tissue cytosols from  169 breast cancers. They 
found that  IGFBP-3  levels were  inversely correlated  with  ER  status and 
positively  correlated  with  S  phase  fraction,  known  to  be  a  powerful 
predictor of prognosis  in  node  negative  cancers  (269).  In  another study 
by Figueroa et al,  IGFBP-3 was measured  by western  ligand blot (WLB) 
and  immunoblot  analysis  in  40  breast  cancers.  IGFBP-3  mRNA  was 
directly quantified  by scanning the gel with a radio-analytical system and 
results  showed  that  low  levels  of  IGFBP-3  were  expressed  but  were 
increased in ER negative tumours (270).
Shao  et  al  found  similar  results  using  in  situ  hybridization  and  image 
cytometry  (121).  In  another study of 40  breast tumours  by  Rocha  et al, 
IGFBP-3  levels  were  measured  by  ligand  blot  analysis,  immunoblot 
analysis,  immunoradiometric assay  (IRMA),  and  ribonuclease  protection 
assay.  High  levels  of  IGFBP-3  were  found  to  be  associated  with  poor 
prognostic  features  such  as  ER/PgR  negativity,  high  S  phase  and 
aneuploidy (153). Shao et al felt that the higher expression of IGFBP-3 by 
ER  negative tumours may play a  role  in the  rapid  proliferation and  poor 
prognosis of these tumours.
Two  studies  have  measured  IGFBP-3  mRNA.  One  used  in  situ 
hybridisation  and  image  cytometry  in  20  breast cancers  and  found  that 
there was some overlap  between the  ER  positive and  negative samples 
(121).  The  other  study  performed  RNase  protection  and  video 
densitometry on 40 cancers and found no correlation with ER status.
For  analysis  purposes,  our  IGFBP-3  mRNA  data  was  divided  in  two 
groups;  tumours expressing  high  levels  of  IGFBP-3  mRNA  (>  1.0 x  108 
copy numbers) and  low levels of IGFBP-3 (<1.0 x 108 copy numbers).  In 
the group expressing high levels, a significant increase in the presence of 
high grade ductal carcinoma in-situ (HG DCIS) was seen when compared 
to  the  group  expressing  lower  levels.  DCIS  is  the  precursor  to  the 
development  of  invasive  breast  cancer  and  can  predict  for  a  more 
aggressive clinical outcome. This finding has not previously been
156reported and is further evidence for a role of BP-3 in the development of 
invasive breast cancer. These findings therefore suggest that high  levels 
of  IGFBP-3  may  be  involved  early  on  in  the  process  of  breast 
tumourigenesis  and  may  predict  for  a  more  aggressive  outcome.  One 
similar study found a positive correlation between  IGF-I  and  presence of 
DCIS (102), however, nobody has looked at the association with BP-3.
Previous  studies,  therefore,  demonstrate  conflicting  evidence  for  the 
association  between  IGFBP-3  levels  and  poor  predictive  markers  for 
breast  cancer.  We  have  clarified  the  inverse  correlation  of  IGFBP-3 
expression with lymph node positivity and similarly the positive correlation 
with  DCIS.  Both of these factors predict for a more aggressive outlook in 
breast cancer.
5.4.  IGFBP-3 and survival
By the  end  of the  study,  four deaths  had  occurred  (mean  follow  up  20 
months)  and  all  four  were  from  the  group  expressing  high  levels  of 
IGFBP-3. Due to small sample size this did not, however, reach statistical 
significance.
One  study  measuring  IGFBP-2,  3,  4  and  5  protein  in  238  samples  by 
immunoblotting,  found  that  none  of  the  IGFBPs  were  independent 
prognostic  indicators  of  disease  free  survival  using  univariate  analysis 
(271).  Other  clinical  studies  have  also  found  no  significant  correlation 
between  IGFBP-3 levels and  disease recurrence and  survival  (268;272). 
Similarly,  no  relationship  was  found  between  serum  IGF-I  levels  and 
survival in a study looking at advanced breast cancer (273).
1575.5. BP-3 expression and tumours associated genes
VEGF  is  known  to  be  up-regulated  early  in  the  development of several 
cancers,  particularly colon  (274).  It is known to play an  important role  in 
tumour angiogenesis (275) and in vitro studies have shown that IGF-I up- 
regulates VEGF transcription (276). No previous studies have reported on 
any  association  between  BP-3  and  VEGF.  We  detected  no  significant 
correlation between VEGF and IGFBP-3 mRNA.
COX-2 is known to play an important role in tumorigenesis. Considerable 
evidence  suggests  that  use  of  COX-2  inhibitors  is  associated  with  a 
reduced  incidence  in  gastro-intestinal  malignancy  probably  via  their 
inhibition  of cyclo-oxygenase  (COX)  activity  and  subsequent decreased 
production  of  prostaglandins  (277).  Studies  of  NSAID  use  in  breast 
cancer are,  however,  inconsistent. A recent meta-analysis of NSAID use 
in  breast  cancer  quoted  an  18%  reduction  in  breast  cancer  risk  (278). 
COX-2  in colon cancer has also been  reported to be directly involved  in 
tumour  angiogenesis  and  therefore  may  be  associated  with  prognosis 
(279;280).  Interestingly,  we  detected  a  significant  increase  in  COX-2 
mRNA in normal breast tissue adjacent to breast cancer when compared 
to  normal  tissue  from  healthy  patients.  No  correlation  was  found, 
however,  between IGFBP-3 and COX-2 mRNA. This suggests that COX- 
2  may  play  a  role  in  breast  tumourugenesis,  however,  perhaps  not via 
induction of IGFBP-3.
5.6.  BP-3 expression and vitamin D
Vitamin  D  is  known  to  inhibit  proliferation  of breast  cancer cells  in  vitro 
and  in  vivo (197)  and  has  been  shown to  block the mitogenic effects of 
IGF-I  (281-283).  The mechanism by which this occurs is unclear.  It may 
be due to down regulation of the IGF-IR (282), an up regulation of
158inhibitory  IGFBPs  or perhaps  a  modulation  of down  stream  effectors  of 
IGF-I  signalling.  An  in  vitro  study  performed  by  Colston  et  al 
demonstrated an increased expression of IGFBP-3 in MCF-7 and Hs578t 
breast cancer cells treated with vitamin  D which were  not stimulated  by 
IGF-I (184).
The  striking  observation  from  this  data  is  the  reduced  expression  of 
laOHase  mRNA  in  healthy  tissue  from  patients  with  breast  cancer 
compared  to  that  from  patients  with  benign  disease.  This  expression 
pattern  is  similar  to  the  one  we  have  previously  reported  in  the  colon 
(284;285).  There are three  possible explanations for this finding.  First is 
that it is merely a reflection of age as the samples of normal breast from 
women without cancer were from younger women than those with cancer. 
However,  there was no correlation  between  laOHase mRNA levels and 
age  in  either  the  normal  controls  or  the  adjacent  normal  breast  tissue 
from cancers. Also, there was no statistical difference in mRNA levels in 
the  NN  samples  between  younger  (<40  years)  and  older  (>40  years) 
patients.  Second,  the  down-regulation  in  adjacent  healthy  tissue  may 
reflect a field effect of the tumour. Our results indicate that this is not the 
case  with  laOHase  mRNA  levels  approximately  constant  between 
normal  breast tissue  immediately  adjacent  and  up  to  10  cm  away from 
the  cancer.  A  similar  result was  obtained  in  normal  colonic tissue  from 
patients with  colon  cancer (unpublished  observations).  Third,  there  is  a 
general mechanism of dysregulation of the vitamin D axis in breast tissue 
of women who subsequently develop breast cancer. This could result in a 
predisposition to tumour development given the anti-proliferative and pro- 
apoptotic  effects  of  active  vitamin  D.  Previous  work  has  implicated 
aberrant  promotor  methylation  as  an  important  mechanism  for  the 
development of both  breast and  colon  cancers  and  hypermethylation  of 
the  laOHase  gene  promotor  has  recently  been  reported  in  more  than 
40%  of  primary  breast  cancers.  Our  data  imply  that  such 
hypermethylation  may  be  present  in  normal  tissue  and  account  for  the 
observed downregulation. If present, it would suggest that disruption of
159this  hypermethylation  might  offer  novel  chemopreventive  approach  to 
breast cancer.
Interestingly, we observed a positive correlation between IGFBP-3 and  1  
alpha hydroxylase mRNA levels (R=0.4,  p= 0.01).  1   alpha hydroxylase is 
the enzyme responsible for the activation of vitamin  D which is known to 
have  anti-proliferative  and  pro-apoptotic  effects  on  breast  cancer  cells 
(184). It has been shown to be expressed at high levels by the kidney and 
similarly,  we  have  demonstrated  its  expression  in  breast  cancers. 
Previous cell  line work  has  suggested  that vitamin  D  may exert  its anti­
proliferative  effects  by  up-regulation  of  IGFBP-3  (184).  Our  results 
support  this  hypothesis.  No  other  correlation  was  detected  between 
IGFBP-3  and  other  members  of the  vitamin  D  axis;  vitamin  D  receptor 
(VDR)  and  24  hydroxylase,  the  enzyme  responsible  for  breaking  down 
active vitamin D.
We also confirmed the up regulation of VDR mRNA in breast tumours as 
has previously been reported (286;287). A previous study suggested that 
vitamin  D  up  regulates  IGFBP-3  mRNA  (182)  and  so  this  positive 
correlation therefore agrees with previous data. This effect may occur via 
the  induction  of  TGF-P  which  is  known  to  be  a  potent  modulator  of 
IGFBP-3. Other studies, however, have found an enhanced expression of 
IGFBP-5  protein  with  vitamin  D  induced  cell  growth  inhibition  (288). 
Further studies need to be performed to further elucidate whether vitamin 
D  can  influence  IGFBP  expression  or  infact,  directly  modulate  down 
stream  effectors  of  IGF-I  signalling.  It  may  be  possible  to  demonstrate 
such effects using our primary explant system.
We  did  not  observe  any  association  between  either  laOHase  or  VDR 
mRNA levels and oestrogen receptor status, histological grade of tumour, 
presence of vascular invasion or lymph  node metastases.  In contrast,  in 
breast cancer cell lines expression  of laOHase has been  reported to be 
higher in well differentiated, estrogen receptor (ER) positive cells.
160In  conclusion,  these early data  confirm the  importance  of the vitamin  D 
axis  in  breast cancer and  suggest that assessment of  laOHase  mRNA 
levels in women may be useful  in  assessing  risk of future  breast cancer 
development.
5.7.  Serum IGF-I and IGFBP-3 levels
IGF-I  levels  were  significantly  lower  in  patients  taking  tamoxifen, 
however,  no effect was seen on serum  IGFBP-3 levels.  The  IGF-I:  BP-3 
ratio  was  also  found  to  be  significantly  higher  in  women  with  breast 
cancer  prior to  surgery,  thereby  agreeing  with  previous  epidemiological 
studies.  Tamoxifen  has been  shown to significantly reduce serum  levels 
of IGF-I  (65; 168;289-294)  but to  have  no effect on  IGFBP-3  (177).  One 
study,  however,  found  that  patients  taking  Tamoxifen  had  decreased 
IGFBP-3  protease activity thereby  implying  that an  increased  IGF-I  may 
be available in the circulation (65).  Circulating levels of IGF-I and  IGFBP- 
3 are,  however,  strongly affected  by nutritional  status  (295;296)  and  the 
catabolic stress that accompanies surgery (62;297). In this study no fall in 
IGF-I  was  observed  in  the group  not taking  Tamoxifen  post-operatively, 
however,  at  6  months  we  would  expect  that  IGF-I  levels  may  have 
returned to normal.  Similarly,  the stress of surgery appeared to have  no 
effect  on  the  serum  concentrations  of  IGFBP-3,  possibly  due  to  a 
decrease in protease activity.
The  mechanism  by which  Tamoxifen  alters the  IGF-I  axis  has  not been 
fully  elucidated.  It  is  thought  that  the  oestrogen  receptor  blockade  by 
Tamoxifen  interferes  with  the  production  of  growth  hormone  from  the 
pituitary, thereby lowering the amount of IGF-I  produced  by the liver and 
released  into  the  circulation.  One  study  has  also  suggested  that 
Tamoxifen may work via a pituitary -independent action of reducing IGF-I 
in  the  peripheral  tissues  usually  favoured  by  breast  cancer  metastases 
(298). It also has direct anti-oestrogen effects on breast cancer cells and
161may  well  influence  the  amount  of  IGF-I  and  IGFBP-3  produced  by  the 
cells themselves (168; 176).
Interestingly, one study has shown that breast cancers with acquired anti­
oestrogen  resistance  continue  to  express  ER  of  normal  size  and  DNA- 
binding  ability  and  suggest  that  the  failure  of  anti-oestrogens  to  arrest 
tumor  growth  may  be  a  result  of  IGF-I  mediated  signal  transduction 
pathways  and  its  interactions  with  ER  signalling  (299).  Our own  mRNA 
data has shown a significant down regulation of IGF-I  in recurrent breast 
tumours  when  compared  to  primary  tumours  (p=0.0001)  with  no 
difference seen in BP-3 levels. This down regulation may be secondary to 
the effects of Tamoxifen, or may suggest that IGF-I is in fact not a feature 
in  the development of tamoxifen  resistance.  Further studies  in this  area 
are required.
5.8.  Primary breast explant culture
Most research has focused on the role of IGFBP-3 as a modulator of 
IGF-I action. There is,  however, increasing interest into its additional IGF- 
I  independent,  pro-apoptotic  effects.  Previous  studies  investigating  the 
biological actions of BP-3  have  mostly involved  in  vitro cell  culture work
(300)  where  results  may  not  necessarily  reflect  physiological  in  vivo 
condition  or  have  used  insensitive techniques  such  as  northern  blotting 
(120).
In  order to clarify the effects of BP-3  on  breast cancer,  we developed  a 
novel,  physiologically  relevant,  explant  system  to  provide  us  with  more 
clinically  relevant  information  than  cell  line work  can  provide.  The  main 
difference in methodology involved the use of breast tissue which  retains 
its architecture, thereby avoiding the  use of cancer cell  lines which  have 
previously  undergone  many  mutations  and  may  not  be  physiologically 
relevant.  There were,  however,  a  number of potential  areas for error  in 
experimental technique. One variability factor was the time taken to
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this and mimic in vivo conditions, all samples were collected immediately 
after  surgical  excision  and  placed  into  media  warmed  to  37°C.  45  min 
was  allowed  for  tissue  transfer.  Similarly,  another  variability  factor  in 
comparing the samples  is  a difference  in weight and  composition of the 
tissue.  Normal  breast tissue  particularly,  consists  of varying  amounts  of 
fat and fibrous tissue which may influence the weight. To standardize this 
factor, all samples were cut into sizes weighing approximately 10 -  20mg. 
Every effort was made with  normal breast tissue to excise all fatty tissue 
away  first  so  that  only  glandular  breast  tissue  was  used  in  the 
experiments.  Similarly we found  a good  correlation  between absorbance 
and  weight  up  to  20mg  in  weight,  thereby  further  standardizing  this 
technique.  Ideally,  in  addition  to  standardizing  for  weight,  adjusting  for 
protein  or DNA content would  improve the standardization  of the  results 
and should be considered for future experiments.
The  LDH  and  MTS  assays and  standardization  of absorbances  allowed 
us  to  validate  our  novel  culture  technique.  Common  methods  for 
determining  cell  line  viability  depend  upon  membrane  integrity  (e.g. 
trypan  blue  exclusion),  or  incorporation  of  nucleotides  during  cell 
proliferation  (e.g.  BrdU  or 3H-thymidine).  These  methods  are  limited  by 
the  impracticality  of  processing  large  numbers  of  samples,  the 
requirement for handling  hazardous materials and the lack of penetration 
into solid  samples.  The  MTS Assay  is  a  rapid  method  of assessing  cell 
viability and is used to measure changes in cell viability or proliferation.  In 
actively  metabolising  cells,  an  increase  in  MTS  conversion  is 
spectrophotometrically  quantified.  Comparison  of  this  value  to  an 
untreated  control  provides  an  increase  in  cellular  metabolic  activity. 
Conversely,  in  cells  that  are  undergoing  apoptosis  or  necrosis,  MTS 
reduction decreases, reflecting the loss of cell viability.
Similarly  for  assessment  of  cell  death  we  used  the  LDH  assay.  Other 
widely used methods include uptake or exclusion of vital dyes such as
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(301).  Dead and viable cells are discriminated by differential staining and 
counted  using  a  light  or  fluorescence  microscope.  These  methods  are 
time consuming and do not account for dead cells which may have lysed. 
The actual rate of cell death, therefore, may actually be underestimated in 
the  long  term.  Limitations  of  this  assay  included  a  large  variation  in 
results between normal and tumour explants which may be as a result of 
the  higher epithelial/stromal  ratio  seen  in  tumours.  It  may  be,  therefore, 
be  difficult  to  directly  compare  the  results  from  normal  and  tumour 
explants.
We  found  that  IGFBP-3  caused  little  apoptosis  when  used  alone  on 
normal  and  malignant  breast  explants.  Several  studies  have  suggested 
that IGFBP-3 exerts inhibitory,  IGF-I  independent effects on cell function. 
Rajah et al (18) demonstrated that IGFBP-3 directly induced apoptosis on 
breast  cancer  cells,  however,  in  this  study  we  did  not  observe  such 
effects.  Our results agree with  Holly et al (107) who  used  Hs578T cells. 
The reason for differing results in cell line studies may be attributable to a 
difference  in  cell  culture  conditions.  Our  results  using  fresh  tissue 
explants,  however,  do  agree  with  previous  work  (107).  Greater  number 
samples,  however,  would  be  necessary  to  make  better  overall 
judgements from the data obtained.
We  observed  a  marked  enhancement  of apoptosis  when  IGFBP-3  was 
used  in conjunction with  known cytotoxic agent,  doxorubicin.  Our data  is 
consistent with other studies where IGFBP-3 induced apoptosis has been 
accentuated by various types of cell stress, such as irradiation,  ceramide 
analogues and cytotoxic agents (36;39;41 ;114). The mechanism by which 
IGFBP-3 accentuates apoptosis  in these circumstances  is  unclear.  Holly 
et  al  suggested  that  IGFBP-3  may  exert  its  IGF-I  independent  effects 
through  direct  or  indirect  interactions  with  integrin  receptors  (107).  The 
integrin  receptors  have  a  well  characterised  role  in  maintaining  cell 
survival (302) as well as mediating cell attachment. They found that focal 
adhesion  kinase  (FAK),  a  key  mediator  of  integrin  signalling,  is 
dephosphorylated  in  the  presence  of  IGFBP-3.  The  physiological
164significance  of  this  finding  remains  to  be  determined,  however,  it  is 
possible that the apoptotic effects of IGFBP-3 may occur by modulation of 
survival signals transduced via integrin receptors.
Tumour suppressor gene, p53, is a critical regulator of the transcription of 
many cellular genes that are  involved  in  mediating  cell  cycle  arrest and 
apoptosis  (303).Many studies  have demonstrated the  importance of p53 
as a tumour suppressor,  however,  little is known about the effect of loss 
p53 on human cells in the context of ECM regulatory signals.  Interactions 
between  breast  epithelial  cells  and  ECM  play  an  important  role  in 
maintaining  normal tissue  homeostasis  and  are  likely to  be disrupted  in 
breast  tumorigenesis.  IGFBP-3  was  identified  as  a  p53-inducible  gene 
and a mediator of p53-dependent apoptosis in  EB1  colon cancer cells in 
response to cellular stress .Similarly, another study reported that IGFBP- 
3  potentiation  of apoptosis  after  ionizing  radiation  in  colon  cancer cells 
was  dependent on functional  p53  (39).  Loss  of IGFBP-3 function  would 
therefore  lead  to  loss  of  sensitivity  to  growth  inhibition  during  cellular 
stress i.e irradiation and  hence resulting  in an increase in cells which fail 
to express functional IGFBP-3 protein. Williams et al therefore concluded 
in  this  study  that  IGFBP-3  secretion  may  contribute  to  colorectal 
tumorigenesis because loss of IGFBP-3 response prior to acquisition of a 
p53 mutation may result in overgrowth of an aberrant cell population.
Interestingly,  we  have  demonstrated  differential  effects  on  apoptosis  in 
normal  and  malignant  breast  tissue.  Apoptosis  induced  by  doxorubicin 
was  similar  in  both  normal  and  malignant  breast  tissue,  however,  the 
addition  of IGFBP-3  markedly enhanced  apoptosis  in  tumours,  whereas 
the reverse effect was seen in normal breast tissue.  In these samples, far 
less  apoptosis  was  observed  suggesting  that  IGFBP-3  may  have  a 
protective effect on normal breast tissue. This is a novel finding and  is in 
accordance with previous work by McCaig et al (107) who used ceramide 
to induce apoptosis on normal breast cell line,  MCF-10A. The differential 
effects may also be explained  by the difference in epithelial and  stromal 
content  of  the  tissue  types.  In  tumours  we  would  expect  to  find 
significantly  more  epithelial  cells  and  less  stromal  tissue  and  in  normal 
tissue,  it would predominantly be stroma.  IGF-I  is  known to be produced
165by stromal tissue and we have shown that BP-3 is also expressed mainly 
by stroma and so this may account for the differences in apoptosis.
We  corroborated  the  results  by  counting  apoptotic  cells  on 
immunohistochemical  slides.  It  is  possible  also  that  this  method  of 
detecting  apoptotic  cells  was  not  sensitive  enough  to  detect  the 
differences.  Some  problems  encountered  involved  identifying  the  cells 
that  were  actually  undergoing  apoptosis  as  some  appeared  to  being 
undergoing  apoptosis  whilst  others  had  completed  the  process.  It  was 
decided  to  include  cells  at  all  stages  in  the  process  for  the  final 
calculations.  More  samples  would  be  needed,  however,  to  draw further 
conclusions.
A  study  by  Holly  et  al  (107)  also  demonstrated  a  differential  effect  of 
IGFBP-3  with  tumour cells  grown  on  plastic and  fibronectin.  On  plastic, 
ceramide  induced  apoptosis  was  enhanced  by  IGFBP-3,  however, 
reduced apoptosis was observed with fibronectin. This suggests that the 
extra-cellular  matrix  (ECM)  may  play  a  role  in  the  differential  effects  of 
IGFBP-3.  The  ECM  was  obviously  intact  in  our experimental technique, 
therefore it is difficult to directly compare the two studies.  In addition, the 
use  of serum free  medium  allows  us to  believe that the different effects 
observed, are due to BP-3 itself and not any growth factors present in the 
medium.
The viability of the cultured tissue was crucial to the validity of the explant 
system.  Two  different  methods were  used  to  assess  viability;  MTS  and 
LDH  assays  which  measured  cellular  activity  and  lysis.  These  assays 
were chosen as they are simple and sensitive techniques which measure 
two  different  biological  end-points.  There  were,  however,  a  number  of 
potential areas for error in experimental technique for both assays.  Firstly, 
care was taken to minimise  pipetting error when adding the dye  in each 
well.  Secondly,  care  was  taken  during  pipetting  to  avoid  generating 
bubbles  within  each  well  as  this  interferes  with  the  fluorescence 
measurement.  Both  assays  were  light sensitive,  therefore  all  incubation
166took place  in the dark.  For the MTS assay,  incubation time  after adding 
the dye was maintained at 4 hours for all samples in order to standardize 
results  and  allow the  dye  adequate  time  to  diffuse  into  the  tissue.  The 
negative control for both assays was a tissue explant cultured in medium 
only.  For  the  MTS  assay,  an  additional  negative  control  was  used.  A 
tissue explant was frozen in liquid nitrogen and then incubated, as before, 
in medium only. Absorbance values for this frozen negative control were 
lower  than  absorbances  for  the  non-frozen  negative  control,  thereby 
further supporting the assumption  of viability of tissue explants with  high 
MTS  absorbances  up  to  48  hours.  Similarly,  with  the  LDH  assay,  a 
positive control of 2% Triton was used which causes complete membrane 
disruption.  Absorbance  values  from  these  samples  were  much  higher 
than  the  experimental  tissue  exlants,  thereby  further  supporting  assay 
viability. The 6 normal explants appeared to maintain steady LDH release 
and viability up to 72 hours after which it tails off. The 6 tumour explants, 
however, demonstrated on overall increased amount of LDH at each time 
frame  up  to  24  hours,  tailing  off  after  this  and  thereby  suggesting 
decreased viability.  There was some discrepancy in the results of tissue 
viability  recorded  by  MTS  and  LDH.  It  may  be,  therefore,  these  two 
assays cannot be compared directly.  Other media absorbances could be 
compared to this 100% membrane-disrupted value.
The  differential  effects  of  IGFBP-3  demonstrated  in  the  primary explant 
system suggest a protective role for IGFBP-3 in normal breast tissue and 
hence  rather  than  being  a  poor  prognostic  marker,  may  reflect  a 
protective  response  in  the  local  stroma  to  limit the  damage.  One  study 
has  demonstrated  that  with  time,  breast  cancer  cells  may  become 
resistant to the  inhibitory effects of IGFBP-3  (19).  Our explant system  is 
short term only and so  unable to investigate such  long term effects.  It is 
possible therefore, that with time the breast tumour becomes insensitive 
to the effects of IGFBP-3. This may account for the inconsistencies found 
between epidemiological and in vitro data.
167The  possible  protective  in  vitro  role  of  IGFBP-3  in  normal  breast tissue 
may  explain  the  high  levels  of  IGFBP-3  mRNA  detected  in  the  breast 
tissue of healthy woman  compared  to those aged  matched  women with 
breast cancer.  It would be interesting to follow up long term to see if any 
subsequently  developed  breast  cancer  and  if so,  whether the  IGFBP-3 
expression was affected.
5.9.  Clinical potential
Targeting growth  regulatory pathways  in  breast cancer has to date been 
an  extremely effective way of treating  breast cancer.  Antagonism  of the 
oestrogen  and  HER  2/neu  receptors  (304;305)  have  clearly  shown 
beneficial effects and confirmed the biological  role of the ER and  HER 2 
receptor  in  the  development  of  breast  cancer.  Similarly,  the 
demonstration that aromatase inhibitors are as effective as Tamoxifen  in 
treating  post-menopausal  breast  cancers  suggests  that  there  are  many 
ways to manipulate a growth factor pathway.
IGF-I has been shown to be mitogenic and anti-apoptotic (306).  Elevated 
levels of plasma  IGF-I are known to be associated with an increased risk 
of  breast  cancer  in  pre-menopausal  women  (96).  Oestrogen  is  well 
established  in  normal  mammary  development,  however,  is  also 
associated  with  the  development  of  breast  cancer.  Similarly,  IGF-I  is 
required for normal mammary development (83;84) and  over expression 
results in mammary hyperplasia and  neoplastic transformation (307).  It is 
possible, therefore, that IGF-I participates in the malignant transformation 
of breast tissue much in the same way that oestrogen does.
A  possible  new  anti-IGF  therapy  could  involve  inhibition  of  IGF-IR 
activation.  Several attempts have been made to block this receptor using 
antibodies with varying results of IGF-I inhibition (308;309;309). It is also
168possible that the  IGF-I  mitogenic effects  may  be  mediated  by  receptors 
other  than  the  IGF-IR.  A  more  effective  method  of  preventing  IGF-I 
mediated mitogenesis maybe to use IGFBP-3 to neutralise its effects and 
also to have its own pro-apoptotic, anti-tumour effects. Studies have used 
IGFBP-1  in  order  to  inhibit  breast  cancer  growth  in  a  xenograft  model 
(310)  and  shown  that  growth  of  MDA-231  but  not  MCF-7  xenograft 
tumours  were  inhibited.  This  conflicts  with  in  vitro  studies  where  IGF-I 
stimulates  MCF-7  breast  cancer  cells  but  not  MDA-231  or  -435  (309). 
Problems  relating to the  long  half life  of the  IGFBP-1  used  (PEG-BP-1) 
and poor tissue penetration were thought to be the cause of these results.
The  therapeutic  use  of  IGFBP-3  may  be  an  alternative  method  of 
pharmacologically  manipulating  the  IGF-I  axis.  Our  results  show  that 
IGFBP-3  is  unlikely  to  have  an  effect  when  used  on  its  own.  It  may, 
however,  be  possible  to  achieve  a  therapeutic  effect  if  used  in 
combination  with  known  cytotoxic  agents  such  as  doxorubicin  or 
paclitaxel,  particularly in ER negative tumours. There are no clinical trials 
yet established in this area.
Measuring  serum  IGF-I  and  IGFBP-3  levels  may  also  provide  a  useful 
adjunct in women at increased risk of developing breast cancer and  may 
provide useful information on prognosis should any subsequently develop 
breast cancer.  Similarly,  serum  IGFBP-3 levels may be used to measure 
the  tumours  response  to  treatment.  Other  factors,  however,  such  as 
proteases and other IGFBP-rPs contribute to the regulation of IGFBP-3 in 
the  breast and  further studies  need to be  performed to further elucidate 
their role.  IGFBP-3 certainly plays an  important role in maintaining tissue 
homeostasis,  indirectly  modulating  IGF-I  and  independently  modulating 
cell growth, however, the full complexities of the IGF system in the breast 
have  yet to  be  fully  understood.  Hopefully,  clinical  studies  may find  an 
effective treatment strategy for use in treatment of breast cancer patients.
1696. Conclusion
We  have  quantified  the  expression  of  IGFBP-3  in  breast  tissue  and 
developed a viable system for keeping  normal and  breast tissue alive for 
up to 48 hours. The establishment of this novel,  physiologically relevant, 
culture system has allowed us to study the effects of BP-3 on normal and 
malignant  breast  tissue.  It  is  the  first time  that  such  effects  have  been 
quantified  using  this  methodology.  A  larger  sample  size  is  needed, 
however,  to  confirm  consistant  patterns  between  individuals  and  to 
analyse the pathways involved in mediating BP-3’s effects in the breast.
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Four copies of this form should be obtained.
One should be given to the patient, one filed in the hospital notes, one retained by the researcher and one given
to pathology with the specimen.
Patient’s details:
Name...................................................
Hospital number.................................
D.O.B..................................................
Patient’s condition requiring treatment
Intended operation / investigation
Tissue, organs or body parts involved
Tissue  samples  will  be  taken  during  your  procedure,  and  sent  to  the  hospital  laboratories.  This  is  routine 
practice essential for diagnosis and for planning further treatment. However in some cases more tissue will be 
removed than is needed for these tests. The aim of this form is to ask whether we may keep the remainder of the 
breast tissue that has been removed, to use in our research.
In our department  we carry out  research  on  breast disease.  In your particular case,  examples  of the type of 
research  we  might  plan  include testing DNA  and  RNA  (gene testing),  growing cells  from  the sample  in  an 
incubator,  analyzing the chemicals  made  by  the cells  in  the  sample,  and  finding out  why  the  cells  behave 
abnormally. Such research improves our understanding of these diseases.
171By signing this form you will only be giving us permission to store your tissue for future research of this type. 
Any use that we want to make of it in the future will have first to be approved by our local Research Ethics 
Committee,  which  is  an  independent  panel  of experts  who  assess  all  research  projects  for  safety,  ethical 
acceptability  and  who  protect  patients’  interests.  Most  of the  work  that  we  envisage  will  have  no  direct 
implications for your personal health. This may be because the tissue cannot be identified as yours, or it may 
simple be because of the type of research involved.
However  in  some circumstances  we  may wish to use your tissue  which  we can  link back to you  and your 
clinical record. Such research may have direct consequences for you or for your family.  If it does, we would 
first ask the Research Ethics Committee and having obtained their approval for the research; we would always 
come back to you to explain the implications, and would then ask your consent to proceed. You would of course 
have the opportunity to refuse permission at that stage. If we do not believe our research will have implications 
for you  or  your  relatives,  and  the  Research  Ethics  Committee  approves  the  research  without  your  further 
consent, then we will not ask your permission.
Further details of the type of research we do are on the other side of this page, and will be explained to you by 
the doctor signing the form.
The information obtained from our research could be published in scientific journals and discussed at scientific 
and medical conferences. It would b completely anonymous. If we decided that it would be helpful to publish or 
discuss  information about your case alone,  it would still  be anonymous but we would not go ahead without 
obtaining your consent again.
There is always a possibility that tissue, which cannot be linked back to you, may  be used in  the  commercial
development of medical technology.  We would only ask for your consent to such  development  in  relation to
your tissue if for any reason it could be linked to you.
You do not have to agree to the storage of your tissue. You are free to decide not to participate.
I confirm that I have explained the nature of the tissue, organs or body parts that it is intended to remove. I have 
explained that they may be stored for use at a later date, in research as well as for diagnosis. I have explained 
this in terms which, in my judgment are suited to the understanding of the patient and/or guardian if the patient 
is a child.
Signature.....................................................................................................
Date..........................................................
Name of practitioner seeking consent
(PRINT)...........................................................................................................................
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Breast tumours are growths arising from the glands in the breast, and in the first instance the best treatment is to 
remove them surgically. You will shortly be undergoing an operation to remove your tumour, and this will be 
taken to the Pathology Department who will cut the tumour into very thin sections so that it can be examined 
under the  microscope.  This  is  an  important  part  of your  investigation  as  it  will  give  your  doctors  detailed 
information about which will help them to provide you with the best treatment. However, a lot of the tissue is 
then left over, and we store this in the Pathology Department. We are very interested as to how these tumours 
start in the first place. We believe it is probably due to a change in the DNA, the information molecule at the 
center of every cell. Our research studies examine the cells of breast tumours to see how they are different from 
normal cells, and what makes them act as tumours. To this end, we may look at different types of chemical 
within the tumour, including DNA, RNA and protein molecules, which we can compare with normal tissue. We 
may also look at the way that these tumours make hormones when they are in test tubes, and see what controls 
their hormone production and also what makes the cells divide. No information relating to you personally will 
be used, but we may look at details such as your sex, age, the size of the tumour, and the particular abnormal 
cells. If we find any changes within the tumour, we my need to re-contact you for a blood sample or we may 
take one now if blood samples are taken as part of your current treatment. This would merely be to compare the 
results  in the tumour to your blood to see whether the changes within the tumour were significant, and this 
would have no relation to your particular disease.
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Please read this form carefully. You will be given a copy.
If there is anything that you do not understand about the explanation and information you have been given, or if 
you want more information, you should ask the doctor before you sign the form.
If  you understand the explanation and agree to the proposed plan, please print your name and sign in the space 
indicated below. Please note that you will also be asked to sign a separate consent form for the operation or 
investigation itself.
1.1  understand that I am consenting for my tissue to be stored for research of a particular kind.
2. I understand that any further use of my tissue in the future for research of this kind will be approved by the 
local Research Ethics Committee.
3.  I  understand that if our research is thought likely to have any  implications for me or my family, you will 
explain them to me, and ask my specific consent before proceeding with it.
4.1 understand that if it is believed that our research will have no such implications, and if the Research Ethics 
Committee has approved the research, I will not be asked for further permission.
5 .1  understand that I will be asked to give consent for the commercial use of any tissue that can be linked back 
to me.
Signature.....................................................................................................................Date.
Name..................................................................................Relationship: Patient/Parent/Guardian/Other*
*  (please delete as necessary)
This form should be witnessed by another person independent from the doctors looking after the patient. This 
could for example be a relative or member of the nursing staff.
Witness
signature.....................................................................................................Date................
Name (PRINT)..............................................................................................Relationship.
Where  relevant,  a  translator  should  sign  below  to  confirm  they  have  interpreted  the  information  on  this 
completed form for the above patient in terms which they believe he or she can understand.
Translator
signature..................................................................................................Date..............................................................
Name  Language used............................................
Name and address of the Principal Investigator responsible for storing the patient’s material (please PRINT):
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